filipredpine's picture
Add the Redpine Biomedical QA question set
cd5ba1c verified
Raw History Blame Contribute Delete
449 kB
{"id": "steered/10.1136/openhrt-2026-003979", "track": "cardiology", "question": "What does a CT-derived fractional flow reserve at or below 0.80 mean for future major adverse cardiovascular events?", "required_claims": ["A CT-derived fractional flow reserve at or below 0.80 marks a patient at roughly four times the risk of major adverse cardiovascular events compared with a value above it", "the signal is most consistent when the outcome is restricted to death or myocardial infarction, where the studies agree almost exactly, whereas for the broader composite the expected effect varies widely from one setting to another", "that association comes almost entirely from observational studies, the one randomised setting found no such association, and study design is the single factor that significantly explains the disagreement between studies"], "certainty": "The prognostic association is strong and consistent across most of the evidence but directly contested by one part of it.", "scope": "applies to suspected or known coronary artery disease assessed by coronary CT angiography in adults undergoing CT-derived fractional flow reserve assessment, outpatient settings", "wrong_if": "it states that the size of the association differed by the software used or between Western and Asian populations", "gold": "A strong answer conveys: A CT-derived fractional flow reserve at or below 0.80 marks a patient at roughly four times the risk of major adverse cardiovascular events compared with a value above it; the signal is most consistent when the outcome is restricted to death or myocardial infarction, where the studies agree almost exactly, whereas for the broader composite the expected effect varies widely from one setting to another; that association comes almost entirely from observational studies, the one randomised setting found no such association, and study design is the single factor that significantly explains the disagreement between studies. Certainty: The prognostic association is strong and consistent across most of the evidence but directly contested by one part of it. Scope: applies to suspected or known coronary artery disease assessed by coronary CT angiography in adults undergoing CT-derived fractional flow reserve assessment, outpatient settings. An answer is wrong if it states that the size of the association differed by the software used or between Western and Asian populations.", "doi": "10.1136/openhrt-2026-003979", "access": "open"}
{"id": "steered/10.1002/clc.70369", "track": "cardiology", "question": "In patients after percutaneous coronary intervention, how does moderate-intensity statin plus ezetimibe compare with high-intensity statin monotherapy?", "required_claims": ["Substituting a moderate-intensity statin with ezetimibe for a high-intensity statin is not associated with a different overall rate of major adverse cardiovascular events, and repeat revascularisation rates are likewise similar between the two strategies", "A modest reduction in cardiovascular mortality was observed with the combination, and a modest reduction in myocardial infarction was likewise observed, but neither finding was robust and both carried wide prediction intervals", "Eight of the nine contributing studies were observational, which limits causal interpretation, and the single randomised study was too imprecise to settle anything", "Residual confounding by indication is likely, because high-intensity statins were used preferentially in higher-risk patients"], "certainty": "The equivalence is a consistent association across the available evidence, while the component advantages remain unreliable.", "scope": "applies to atherosclerotic coronary disease treated with percutaneous coronary intervention in adults after percutaneous coronary intervention requiring lipid-lowering therapy, outpatient settings", "wrong_if": "it presents the reductions in cardiovascular death or myocardial infarction with the combination as an established advantage that should decide which regimen is used", "gold": "A strong answer conveys: Substituting a moderate-intensity statin with ezetimibe for a high-intensity statin is not associated with a different overall rate of major adverse cardiovascular events, and repeat revascularisation rates are likewise similar between the two strategies; A modest reduction in cardiovascular mortality was observed with the combination, and a modest reduction in myocardial infarction was likewise observed, but neither finding was robust and both carried wide prediction intervals; Eight of the nine contributing studies were observational, which limits causal interpretation, and the single randomised study was too imprecise to settle anything; Residual confounding by indication is likely, because high-intensity statins were used preferentially in higher-risk patients. Certainty: The equivalence is a consistent association across the available evidence, while the component advantages remain unreliable. Scope: applies to atherosclerotic coronary disease treated with percutaneous coronary intervention in adults after percutaneous coronary intervention requiring lipid-lowering therapy, outpatient settings. An answer is wrong if it presents the reductions in cardiovascular death or myocardial infarction with the combination as an established advantage that should decide which regimen is used.", "doi": "10.1002/clc.70369", "access": "open"}
{"id": "steered/10.1136/bmjopen-2025-115027", "track": "cardiology", "question": "What is known about giving a fibrinolytic drug into the coronary artery when flow fails to return during primary percutaneous coronary intervention for ST-elevation myocardial infarction?", "required_claims": ["intracoronary prourokinase given when flow fails to return improved coronary flow and myocardial perfusion compared with placebo, with complete ST-segment resolution in roughly two-thirds of patients against under half", "peak creatine kinase-MB, a marker of myocardial damage, was lower with the intracoronary fibrinolytic than with placebo", "major bleeding was not increased compared with placebo", "whether that better flow translates into fewer cardiovascular events over the following year has not been tested in the reported comparison, since the available comparison followed patients for only 30 days with a surrogate flow endpoint and was too small to detect clinical events"], "certainty": "This is an early signal from a single randomised comparison rather than a settled effect on patient outcomes.", "scope": "applies to slow flow or no-reflow arising during primary percutaneous coronary intervention for ST-elevation myocardial infarction in adults with ST-elevation myocardial infarction who develop slow flow or no-reflow during percutaneous coronary intervention, inpatient settings", "wrong_if": "it presents the flow and perfusion benefit as demonstrated across the full range of acute coronary syndrome presentations rather than in ST-elevation infarction alone", "gold": "A strong answer conveys: intracoronary prourokinase given when flow fails to return improved coronary flow and myocardial perfusion compared with placebo, with complete ST-segment resolution in roughly two-thirds of patients against under half; peak creatine kinase-MB, a marker of myocardial damage, was lower with the intracoronary fibrinolytic than with placebo; major bleeding was not increased compared with placebo; whether that better flow translates into fewer cardiovascular events over the following year has not been tested in the reported comparison, since the available comparison followed patients for only 30 days with a surrogate flow endpoint and was too small to detect clinical events. Certainty: This is an early signal from a single randomised comparison rather than a settled effect on patient outcomes. Scope: applies to slow flow or no-reflow arising during primary percutaneous coronary intervention for ST-elevation myocardial infarction in adults with ST-elevation myocardial infarction who develop slow flow or no-reflow during percutaneous coronary intervention, inpatient settings. An answer is wrong if it presents the flow and perfusion benefit as demonstrated across the full range of acute coronary syndrome presentations rather than in ST-elevation infarction alone.", "doi": "10.1136/bmjopen-2025-115027", "access": "open"}
{"id": "steered/10.1111/jce.70362", "track": "cardiology", "question": "What outcomes follow left atrial appendage occlusion performed without contrast injection compared with contrast-guided implantation?", "required_claims": ["closing the left atrial appendage without any contrast injection achieves procedural success and short-term safety on a par with the contrast-guided approach (success in nearly every case either way)", "sealing of the appendage, device-related thrombus and thromboembolic events through the first year are similar whether or not contrast was used", "the two approaches were chosen by operator preference rather than assigned, at a single high-volume centre with incomplete imaging follow-up, so the evidence shows the contrast-free approach is workable rather than establishing the two as equivalent"], "certainty": "The similarity between the two approaches is a consistent observation rather than an established equivalence.", "scope": "applies to atrial fibrillation with an indication for left atrial appendage occlusion in adults undergoing percutaneous left atrial appendage occlusion, inpatient settings", "wrong_if": "it presents the two approaches as having been assigned rather than chosen by the operator, or the comparability as established rather than observed", "gold": "A strong answer conveys: closing the left atrial appendage without any contrast injection achieves procedural success and short-term safety on a par with the contrast-guided approach (success in nearly every case either way); sealing of the appendage, device-related thrombus and thromboembolic events through the first year are similar whether or not contrast was used; the two approaches were chosen by operator preference rather than assigned, at a single high-volume centre with incomplete imaging follow-up, so the evidence shows the contrast-free approach is workable rather than establishing the two as equivalent. Certainty: The similarity between the two approaches is a consistent observation rather than an established equivalence. Scope: applies to atrial fibrillation with an indication for left atrial appendage occlusion in adults undergoing percutaneous left atrial appendage occlusion, inpatient settings. An answer is wrong if it presents the two approaches as having been assigned rather than chosen by the operator, or the comparability as established rather than observed.", "doi": "10.1111/jce.70362", "access": "open"}
{"id": "steered/10.1177/10742484261456161", "track": "cardiology", "question": "How does norepinephrine compare with dopamine as initial vasoactive therapy for mortality in cardiogenic shock?", "required_claims": ["death within four weeks was about as common whether norepinephrine or dopamine was the first vasoactive agent, and the uncertainty around that comparison is wide enough to leave a real difference in either direction possible", "the need to add rescue epinephrine was also comparable between the two agents", "a signal of worse survival with dopamine when the shock did not arise from an acute coronary syndrome came from an exploratory subgroup split and is not a basis for choosing the agent on its own"], "certainty": "The absence of a detectable difference between the two agents is an observation from care as it was given, not a demonstration that the agents are equivalent.", "scope": "applies to cardiogenic shock in adults requiring an initial vasoactive agent in a coronary care setting, inpatient settings", "wrong_if": "it treats the link between epinephrine use and death as harm done by epinephrine, since that use marked resuscitation and overall illness severity rather than a drug effect", "gold": "A strong answer conveys: death within four weeks was about as common whether norepinephrine or dopamine was the first vasoactive agent, and the uncertainty around that comparison is wide enough to leave a real difference in either direction possible; the need to add rescue epinephrine was also comparable between the two agents; a signal of worse survival with dopamine when the shock did not arise from an acute coronary syndrome came from an exploratory subgroup split and is not a basis for choosing the agent on its own. Certainty: The absence of a detectable difference between the two agents is an observation from care as it was given, not a demonstration that the agents are equivalent. Scope: applies to cardiogenic shock in adults requiring an initial vasoactive agent in a coronary care setting, inpatient settings. An answer is wrong if it treats the link between epinephrine use and death as harm done by epinephrine, since that use marked resuscitation and overall illness severity rather than a drug effect.", "doi": "10.1177/10742484261456161", "access": "open"}
{"id": "steered/10.1002/clc.70377", "track": "cardiology", "question": "Which nocturnal blood pressure patterns relate to major adverse cardiovascular events during the year after anterior STEMI?", "required_claims": ["A reversed overnight pattern, in which blood pressure rises at night instead of falling, is associated with substantially more major adverse cardiovascular events over the following year than a normal nocturnal fall (a several-fold higher hazard)", "A merely blunted nocturnal fall, or an exaggerated one, is not independently associated with those events once other risk factors are accounted for", "patterns measured during the first day after the infarction may reflect the acute illness rather than the patient's habitual overnight rhythm"], "certainty": "The link is an association carrying wide uncertainty around its size, not a demonstrated cause of the events.", "scope": "applies to anterior ST-elevation myocardial infarction treated with emergency percutaneous coronary intervention in adults after emergency percutaneous coronary intervention for anterior ST-elevation myocardial infarction, inpatient settings", "wrong_if": "it presents timing antihypertensive treatment to restore the overnight fall as shown to improve outcomes", "gold": "A strong answer conveys: A reversed overnight pattern, in which blood pressure rises at night instead of falling, is associated with substantially more major adverse cardiovascular events over the following year than a normal nocturnal fall (a several-fold higher hazard); A merely blunted nocturnal fall, or an exaggerated one, is not independently associated with those events once other risk factors are accounted for; patterns measured during the first day after the infarction may reflect the acute illness rather than the patient's habitual overnight rhythm. Certainty: The link is an association carrying wide uncertainty around its size, not a demonstrated cause of the events. Scope: applies to anterior ST-elevation myocardial infarction treated with emergency percutaneous coronary intervention in adults after emergency percutaneous coronary intervention for anterior ST-elevation myocardial infarction, inpatient settings. An answer is wrong if it presents timing antihypertensive treatment to restore the overnight fall as shown to improve outcomes.", "doi": "10.1002/clc.70377", "access": "open"}
{"id": "steered/10.1111/jce.70366", "track": "cardiology", "question": "Among patients with newly diagnosed left ventricular dysfunction and a sustained arrhythmia whose rhythm is successfully controlled, what proportion turn out to have arrhythmia-induced cardiomyopathy?", "required_claims": ["among patients who maintained sinus rhythm or suppressed ectopy after rhythm control, roughly three in five met the criteria for a reversible arrhythmia-induced cardiomyopathy", "the observed proportion aligns with rates between 50% and 82% reported in previous series", "no measurable feature at presentation, cardiac magnetic resonance included, reliably identified the reversible cases in advance", "only about half of those with the reversible form recovered a normal ejection fraction"], "certainty": "This is a counted proportion carrying real uncertainty in both directions rather than a settled figure.", "scope": "applies to newly diagnosed left ventricular systolic dysfunction with a concurrent sustained arrhythmia in adults with newly diagnosed idiopathic left ventricular systolic dysfunction severe enough to warrant a wearable defibrillator, with atrial fibrillation, atrial flutter or frequent ventricular ectopy, mixed settings", "wrong_if": "it states that the defibrillator indication persisted in most patients after rhythm control", "gold": "A strong answer conveys: among patients who maintained sinus rhythm or suppressed ectopy after rhythm control, roughly three in five met the criteria for a reversible arrhythmia-induced cardiomyopathy; the observed proportion aligns with rates between 50% and 82% reported in previous series; no measurable feature at presentation, cardiac magnetic resonance included, reliably identified the reversible cases in advance; only about half of those with the reversible form recovered a normal ejection fraction. Certainty: This is a counted proportion carrying real uncertainty in both directions rather than a settled figure. Scope: applies to newly diagnosed left ventricular systolic dysfunction with a concurrent sustained arrhythmia in adults with newly diagnosed idiopathic left ventricular systolic dysfunction severe enough to warrant a wearable defibrillator, with atrial fibrillation, atrial flutter or frequent ventricular ectopy, mixed settings. An answer is wrong if it states that the defibrillator indication persisted in most patients after rhythm control.", "doi": "10.1111/jce.70366", "access": "open"}
{"id": "steered/10.1136/openhrt-2026-004054", "track": "cardiology", "question": "How does adding angina to the H₂FPEF score change identification of HFpEF in women?", "required_claims": ["counting exertional chest pain as an extra item in the score identifies more of the women who turn out to have the condition, while the score stays well calibrated", "the improvement in how well the score separates women with and without the condition is modest (a small rise in discrimination), so the change refines the score rather than transforming it", "the same addition did not help in men, and everyone assessed was over sixty and already scored at least one point, so the finding belongs to older women being screened rather than to unselected patients"], "certainty": "The improvement is an early finding taken from the same data in which the change was devised, and has not been confirmed elsewhere.", "scope": "applies to suspected heart failure with preserved ejection fraction in women older than sixty being assessed for unexplained breathlessness, primary care settings", "wrong_if": "it treats angina in these women as a marker of obstructive coronary disease, since obstructive disease does not account for the whole burden of angina in this condition", "gold": "A strong answer conveys: counting exertional chest pain as an extra item in the score identifies more of the women who turn out to have the condition, while the score stays well calibrated; the improvement in how well the score separates women with and without the condition is modest (a small rise in discrimination), so the change refines the score rather than transforming it; the same addition did not help in men, and everyone assessed was over sixty and already scored at least one point, so the finding belongs to older women being screened rather than to unselected patients. Certainty: The improvement is an early finding taken from the same data in which the change was devised, and has not been confirmed elsewhere. Scope: applies to suspected heart failure with preserved ejection fraction in women older than sixty being assessed for unexplained breathlessness, primary care settings. An answer is wrong if it treats angina in these women as a marker of obstructive coronary disease, since obstructive disease does not account for the whole burden of angina in this condition.", "doi": "10.1136/openhrt-2026-004054", "access": "open"}
{"id": "steered/10.1002/clc.70344", "track": "cardiology", "question": "How does the blood urea to creatinine ratio relate to outcomes in patients with heart failure?", "required_claims": ["a higher blood urea to creatinine ratio marks patients with heart failure who go on to die sooner, and the signal is strongest in those with preserved ejection fraction (where the gap is roughly threefold)", "a raised ratio also tracks with worse symptom class and with more early cardiovascular events, but not with acute kidney injury", "the ratio separates individual patients poorly, its added value on top of established biomarker testing is unsettled, and the certainty of the underlying evidence was graded very low"], "certainty": "The link between a higher ratio and worse outcome is a repeated association of low certainty, not an established cause.", "scope": "applies to adults with heart failure across the ejection fraction range, mixed settings", "wrong_if": "it presents the reported risk estimates as pooled figures, since heterogeneity and missing extractable data prevented statistical pooling and the findings were combined descriptively", "gold": "A strong answer conveys: a higher blood urea to creatinine ratio marks patients with heart failure who go on to die sooner, and the signal is strongest in those with preserved ejection fraction (where the gap is roughly threefold); a raised ratio also tracks with worse symptom class and with more early cardiovascular events, but not with acute kidney injury; the ratio separates individual patients poorly, its added value on top of established biomarker testing is unsettled, and the certainty of the underlying evidence was graded very low. Certainty: The link between a higher ratio and worse outcome is a repeated association of low certainty, not an established cause. Scope: applies to adults with heart failure across the ejection fraction range, mixed settings. An answer is wrong if it presents the reported risk estimates as pooled figures, since heterogeneity and missing extractable data prevented statistical pooling and the findings were combined descriptively.", "doi": "10.1002/clc.70344", "access": "open"}
{"id": "steered/10.1111/1440-1681.70142", "track": "cardiology", "question": "Which markers of hypertension-mediated organ damage warrant assessment when stratifying cardiovascular risk in hypertensive patients?", "required_claims": ["left ventricular hypertrophy predicts adverse cardiovascular outcomes over and above the hypertension itself", "risk rises continuously across the range of left ventricular mass, including below the conventional thresholds for hypertrophy", "A concentric pattern of left ventricular remodelling indicates pressure overload and is associated with poor cardiovascular prognosis", "microvascular rarefaction may persist after brachial blood pressure has been normalised, so vascular damage is partly dissociated from blood pressure control"], "certainty": "These are consistent prognostic associations rather than effects of the damage itself being demonstrated.", "scope": "applies to adults with hypertension undergoing cardiovascular risk stratification, outpatient settings", "wrong_if": "it presents regression of ventricular hypertrophy with intensive blood pressure lowering as a definitive and consistent finding", "gold": "A strong answer conveys: left ventricular hypertrophy predicts adverse cardiovascular outcomes over and above the hypertension itself; risk rises continuously across the range of left ventricular mass, including below the conventional thresholds for hypertrophy; A concentric pattern of left ventricular remodelling indicates pressure overload and is associated with poor cardiovascular prognosis; microvascular rarefaction may persist after brachial blood pressure has been normalised, so vascular damage is partly dissociated from blood pressure control. Certainty: These are consistent prognostic associations rather than effects of the damage itself being demonstrated. Scope: applies to adults with hypertension undergoing cardiovascular risk stratification, outpatient settings. An answer is wrong if it presents regression of ventricular hypertrophy with intensive blood pressure lowering as a definitive and consistent finding.", "doi": "10.1111/1440-1681.70142", "access": "paywalled"}
{"id": "steered/10.1111/ctr.70569", "track": "cardiology", "question": "What one-year survival follows heart transplantation from donation after circulatory death donors in recipients with prior cardiac surgery?", "required_claims": ["one-year survival after a circulatory-death donor heart transplant is close to nine in ten in recipients with previous conventional cardiac surgery, lower than in recipients without such surgery", "the lower survival persisted after propensity score matching on measured risk factors", "within the group with previous cardiac surgery, one-year survival was comparable whether the donor heart came after circulatory death or after brain death", "the survival penalty is concentrated in recipients whose previous operation combined coronary revascularisation with valve intervention, the subtype with the lowest one-year survival"], "certainty": "These are consistent associations rather than effects established by direct comparison.", "scope": "applies to end-stage heart failure treated by heart transplantation from a circulatory-death donor in adults with previous conventional cardiac surgery, excluding those supported by a durable ventricular assist device or with previous congenital heart surgery, inpatient settings", "wrong_if": "it presents the survival deficit as a reason to withhold circulatory-death donor hearts from recipients with previous cardiac surgery", "gold": "A strong answer conveys: one-year survival after a circulatory-death donor heart transplant is close to nine in ten in recipients with previous conventional cardiac surgery, lower than in recipients without such surgery; the lower survival persisted after propensity score matching on measured risk factors; within the group with previous cardiac surgery, one-year survival was comparable whether the donor heart came after circulatory death or after brain death; the survival penalty is concentrated in recipients whose previous operation combined coronary revascularisation with valve intervention, the subtype with the lowest one-year survival. Certainty: These are consistent associations rather than effects established by direct comparison. Scope: applies to end-stage heart failure treated by heart transplantation from a circulatory-death donor in adults with previous conventional cardiac surgery, excluding those supported by a durable ventricular assist device or with previous congenital heart surgery, inpatient settings. An answer is wrong if it presents the survival deficit as a reason to withhold circulatory-death donor hearts from recipients with previous cardiac surgery.", "doi": "10.1111/ctr.70569", "access": "open"}
{"id": "steered/10.1002/clc.70446", "track": "cardiology", "question": "What do changes in urinary albumin to creatinine ratio over time indicate about outcomes in heart failure with preserved ejection fraction?", "required_claims": ["a urinary albumin to creatinine ratio that stays high and swings about over repeated measurements marks patients whose risk of cardiovascular death, cardiac arrest or heart failure admission is raised (roughly doubled)", "a ratio that falls over time does not carry that excess risk, and its apparent link with myocardial infarction rested on few events and was left as exploratory", "knowing which pattern a patient follows adds only a small amount to risk assessment on top of the usual clinical variables"], "certainty": "The link between the albuminuria pattern and later events is a consistent association rather than an established cause.", "scope": "applies to adults with symptomatic heart failure and preserved ejection fraction undergoing repeated albuminuria measurement, outpatient settings", "wrong_if": "it recommends treating to bring the albumin to creatinine ratio down as a way of preventing these events, since the patterns were observed rather than assigned and no attempt to change the ratio was tested", "gold": "A strong answer conveys: a urinary albumin to creatinine ratio that stays high and swings about over repeated measurements marks patients whose risk of cardiovascular death, cardiac arrest or heart failure admission is raised (roughly doubled); a ratio that falls over time does not carry that excess risk, and its apparent link with myocardial infarction rested on few events and was left as exploratory; knowing which pattern a patient follows adds only a small amount to risk assessment on top of the usual clinical variables. Certainty: The link between the albuminuria pattern and later events is a consistent association rather than an established cause. Scope: applies to adults with symptomatic heart failure and preserved ejection fraction undergoing repeated albuminuria measurement, outpatient settings. An answer is wrong if it recommends treating to bring the albumin to creatinine ratio down as a way of preventing these events, since the patterns were observed rather than assigned and no attempt to change the ratio was tested.", "doi": "10.1002/clc.70446", "access": "open"}
{"id": "steered/10.1136/bmjopen-2025-108331", "track": "cardiology", "question": "In Chinese adults admitted with moderate-to-severe valvular heart disease, how does management differ between men and women?", "required_claims": ["men were significantly more likely than women to undergo coronary angiography", "among patients with atrial fibrillation or flutter, women were more likely than men to receive warfarin", "whether women are less likely to receive valve intervention is disputed: one cohort found no difference in the overall intervention rate by sex, while another reports substantially lower odds of intervention in women"], "certainty": "The treatment findings are consistently described within one cohort, while the difference in access to valve intervention is actively contested.", "scope": "applies to moderate-to-severe valvular heart disease in adults admitted to tertiary and referral cardiovascular centres in China, inpatient settings", "wrong_if": "it attributes the pattern of valve intervention by sex to a specific cause such as patient refusal", "gold": "A strong answer conveys: men were significantly more likely than women to undergo coronary angiography; among patients with atrial fibrillation or flutter, women were more likely than men to receive warfarin; whether women are less likely to receive valve intervention is disputed: one cohort found no difference in the overall intervention rate by sex, while another reports substantially lower odds of intervention in women. Certainty: The treatment findings are consistently described within one cohort, while the difference in access to valve intervention is actively contested. Scope: applies to moderate-to-severe valvular heart disease in adults admitted to tertiary and referral cardiovascular centres in China, inpatient settings. An answer is wrong if it attributes the pattern of valve intervention by sex to a specific cause such as patient refusal.", "doi": "10.1136/bmjopen-2025-108331", "access": "open"}
{"id": "steered/10.1002/clc.70312", "track": "cardiology", "question": "Which characteristics of patients receiving immune checkpoint inhibitors relate to developing myocarditis?", "required_claims": ["older age, male sex, hypertension and hyperlipidaemia all mark patients on checkpoint inhibitors as more likely to be flagged with myocarditis", "tumour type matters as well, with thymic tumours carrying the highest odds (roughly doubled) and lung cancer a smaller rise, and blocking more than one checkpoint adding further risk", "these were suspected rather than confirmed cases, picked up largely through troponin rises that arise for many other reasons"], "certainty": "These characteristics mark who is more likely to be flagged, and are associations from care as it was delivered rather than established causes.", "scope": "applies to myocarditis during immune checkpoint inhibitor therapy in adults receiving an immune checkpoint inhibitor for cancer, mixed settings", "wrong_if": "it lists diabetes among the characteristics carrying extra risk, since it did not hold up once the other characteristics were accounted for", "gold": "A strong answer conveys: older age, male sex, hypertension and hyperlipidaemia all mark patients on checkpoint inhibitors as more likely to be flagged with myocarditis; tumour type matters as well, with thymic tumours carrying the highest odds (roughly doubled) and lung cancer a smaller rise, and blocking more than one checkpoint adding further risk; these were suspected rather than confirmed cases, picked up largely through troponin rises that arise for many other reasons. Certainty: These characteristics mark who is more likely to be flagged, and are associations from care as it was delivered rather than established causes. Scope: applies to myocarditis during immune checkpoint inhibitor therapy in adults receiving an immune checkpoint inhibitor for cancer, mixed settings. An answer is wrong if it lists diabetes among the characteristics carrying extra risk, since it did not hold up once the other characteristics were accounted for.", "doi": "10.1002/clc.70312", "access": "open"}
{"id": "steered/10.1002/clc.70398", "track": "cardiology", "question": "What is known about the effect of ethanol infusion into the vein of Marshall on achieving durable mitral isthmus block?", "required_claims": ["ethanol delivered into the vein of Marshall is associated with durable bidirectional mitral isthmus block being achieved more often than with radiofrequency ablation alone", "whether the improvement in block translates into fewer arrhythmia recurrences is disputed, with a randomised trial and pooled analyses reporting less recurrence while one cohort found no significant gain in either block or arrhythmia-free survival", "ethanol infusion cannot always be delivered, with reported procedural success between roughly 84% and 92%"], "certainty": "The gain in block is consistent across the evidence, while the gain in arrhythmia outcomes is actively contested.", "scope": "applies to persistent atrial fibrillation or mitral isthmus-dependent atrial tachycardia undergoing catheter ablation in adults undergoing catheter ablation in whom mitral isthmus block is intended, inpatient settings", "wrong_if": "it presents the reduction in arrhythmia recurrence as established for paroxysmal atrial fibrillation as well as for persistent atrial fibrillation", "gold": "A strong answer conveys: ethanol delivered into the vein of Marshall is associated with durable bidirectional mitral isthmus block being achieved more often than with radiofrequency ablation alone; whether the improvement in block translates into fewer arrhythmia recurrences is disputed, with a randomised trial and pooled analyses reporting less recurrence while one cohort found no significant gain in either block or arrhythmia-free survival; ethanol infusion cannot always be delivered, with reported procedural success between roughly 84% and 92%. Certainty: The gain in block is consistent across the evidence, while the gain in arrhythmia outcomes is actively contested. Scope: applies to persistent atrial fibrillation or mitral isthmus-dependent atrial tachycardia undergoing catheter ablation in adults undergoing catheter ablation in whom mitral isthmus block is intended, inpatient settings. An answer is wrong if it presents the reduction in arrhythmia recurrence as established for paroxysmal atrial fibrillation as well as for persistent atrial fibrillation.", "doi": "10.1002/clc.70398", "access": "open"}
{"id": "steered/10.1136/heartjnl-2025-326694", "track": "cardiology", "question": "Which imaging modalities establish cardiac sarcoidosis when endomyocardial biopsy is negative or not feasible?", "required_claims": ["cardiovascular magnetic resonance is the test to reach for first, because absence of late gadolinium enhancement reduces the possibility of clinically significant disease", "magnetic resonance carries the better prognostic information for arrhythmic risk and cardiac mortality", "metabolic imaging with fluorodeoxyglucose positron emission tomography answers a different question, showing whether inflammation is currently active and whether it is responding to anti-inflammatory treatment", "neither modality alone secures the diagnosis, the highest diagnostic accuracy coming from colocalising focal metabolic uptake with enhancement or with raised native T1"], "certainty": "These are consistent associations rather than established test characteristics.", "scope": "applies to suspected cardiac sarcoidosis with negative or unobtainable endomyocardial biopsy in adults with suspected cardiac sarcoidosis, with or without known extracardiac disease, mixed settings", "wrong_if": "it states that a normal fluorodeoxyglucose positron emission tomography study excludes cardiac sarcoidosis", "gold": "A strong answer conveys: cardiovascular magnetic resonance is the test to reach for first, because absence of late gadolinium enhancement reduces the possibility of clinically significant disease; magnetic resonance carries the better prognostic information for arrhythmic risk and cardiac mortality; metabolic imaging with fluorodeoxyglucose positron emission tomography answers a different question, showing whether inflammation is currently active and whether it is responding to anti-inflammatory treatment; neither modality alone secures the diagnosis, the highest diagnostic accuracy coming from colocalising focal metabolic uptake with enhancement or with raised native T1. Certainty: These are consistent associations rather than established test characteristics. Scope: applies to suspected cardiac sarcoidosis with negative or unobtainable endomyocardial biopsy in adults with suspected cardiac sarcoidosis, with or without known extracardiac disease, mixed settings. An answer is wrong if it states that a normal fluorodeoxyglucose positron emission tomography study excludes cardiac sarcoidosis.", "doi": "10.1136/heartjnl-2025-326694", "access": "paywalled"}
{"id": "steered/10.1136/bmj-2023-078952", "track": "cardiology", "question": "How do transcatheter and surgical aortic valve replacement compare over longer follow-up in low surgical risk patients with aortic stenosis?", "required_claims": ["the early advantage of the transcatheter approach over surgery in low-risk patients does not hold: by seven years the composite of death, stroke and repeat hospital stay is no longer separated, although the early gap was roughly a halving of events", "reintervention on the valve moves the other way with longer follow-up, happening more often after the transcatheter procedure and driven mainly by regurgitation rather than by failure of the prosthesis", "how this plays out in a bicuspid valve is unsettled, with the only randomised comparison to include such patients underpowered and hinting at harm"], "certainty": "The differences between the two procedures can be read as caused by which procedure the patient was assigned to receive.", "scope": "applies to severe aortic stenosis in adults at low surgical risk undergoing aortic valve replacement, inpatient settings", "wrong_if": "it attributes the early advantage of the transcatheter approach to fewer deaths, since it was driven mainly by fewer repeat hospital stays", "gold": "A strong answer conveys: the early advantage of the transcatheter approach over surgery in low-risk patients does not hold: by seven years the composite of death, stroke and repeat hospital stay is no longer separated, although the early gap was roughly a halving of events; reintervention on the valve moves the other way with longer follow-up, happening more often after the transcatheter procedure and driven mainly by regurgitation rather than by failure of the prosthesis; how this plays out in a bicuspid valve is unsettled, with the only randomised comparison to include such patients underpowered and hinting at harm. Certainty: The differences between the two procedures can be read as caused by which procedure the patient was assigned to receive. Scope: applies to severe aortic stenosis in adults at low surgical risk undergoing aortic valve replacement, inpatient settings. An answer is wrong if it attributes the early advantage of the transcatheter approach to fewer deaths, since it was driven mainly by fewer repeat hospital stays.", "doi": "10.1136/bmj-2023-078952", "access": "paywalled"}
{"id": "steered/10.1002/cam4.71682", "track": "cardiology", "question": "How should cancer therapy related cardiac dysfunction be assessed and managed without interrupting effective cancer treatment?", "required_claims": ["cardiac risk is graded before cardiotoxic treatment begins, and biomarker and imaging surveillance is then pitched to that baseline risk rather than applied uniformly", "a fall in ejection fraction without symptoms is not on its own a reason to stop effective cancer treatment: cardioprotective medication is started and monitoring tightened while treatment continues", "when the dysfunction is symptomatic or marked the drug is held while heart failure treatment is optimised, ischaemia is looked for and ventricular function is reassessed within weeks"], "certainty": "These are expert recommendations assembled from existing guidance, not a comparison of one management pathway against another.", "scope": "applies to cancer therapy related cardiac dysfunction in adults receiving potentially cardiotoxic cancer treatment, outpatient settings", "wrong_if": "it says that adding a cardioprotective agent to reduce heart failure costs cancer control, since response, overall survival and progression-free survival were all unaffected", "gold": "A strong answer conveys: cardiac risk is graded before cardiotoxic treatment begins, and biomarker and imaging surveillance is then pitched to that baseline risk rather than applied uniformly; a fall in ejection fraction without symptoms is not on its own a reason to stop effective cancer treatment: cardioprotective medication is started and monitoring tightened while treatment continues; when the dysfunction is symptomatic or marked the drug is held while heart failure treatment is optimised, ischaemia is looked for and ventricular function is reassessed within weeks. Certainty: These are expert recommendations assembled from existing guidance, not a comparison of one management pathway against another. Scope: applies to cancer therapy related cardiac dysfunction in adults receiving potentially cardiotoxic cancer treatment, outpatient settings. An answer is wrong if it says that adding a cardioprotective agent to reduce heart failure costs cancer control, since response, overall survival and progression-free survival were all unaffected.", "doi": "10.1002/cam4.71682", "access": "open"}
{"id": "steered/10.1136/openhrt-2025-003954", "track": "cardiology", "question": "What clinical outcomes follow conduction system pacing versus right ventricular pacing in patients with atrioventricular block?", "required_claims": ["conduction system pacing is associated with preservation of left ventricular ejection fraction, with less decline than right ventricular pacing", "paced QRS complexes are markedly shorter with conduction system pacing than with right ventricular pacing", "whether that translates into fewer heart failure admissions or deaths is disputed within the randomised evidence itself: one trial found no significant difference in heart failure hospitalisation or mortality, a second reduced a composite of pacing-induced cardiomyopathy and resynchronisation upgrade without changing either endpoint individually, and a third reduced heart failure hospitalisation"], "certainty": "The advantage in ventricular function and activation is consistent, while the effect on admissions and survival is contested within the randomised evidence itself.", "scope": "applies to atrioventricular block requiring ventricular pacing in adults receiving a pacemaker for atrioventricular block, including those with preserved ventricular function, mixed settings", "wrong_if": "it presents the reduction in a composite endpoint as showing that conduction system pacing reduces mortality", "gold": "A strong answer conveys: conduction system pacing is associated with preservation of left ventricular ejection fraction, with less decline than right ventricular pacing; paced QRS complexes are markedly shorter with conduction system pacing than with right ventricular pacing; whether that translates into fewer heart failure admissions or deaths is disputed within the randomised evidence itself: one trial found no significant difference in heart failure hospitalisation or mortality, a second reduced a composite of pacing-induced cardiomyopathy and resynchronisation upgrade without changing either endpoint individually, and a third reduced heart failure hospitalisation. Certainty: The advantage in ventricular function and activation is consistent, while the effect on admissions and survival is contested within the randomised evidence itself. Scope: applies to atrioventricular block requiring ventricular pacing in adults receiving a pacemaker for atrioventricular block, including those with preserved ventricular function, mixed settings. An answer is wrong if it presents the reduction in a composite endpoint as showing that conduction system pacing reduces mortality.", "doi": "10.1136/openhrt-2025-003954", "access": "open"}
{"id": "steered/10.1136/jnis-2025-024031", "track": "neuroimmunology", "question": "What changes occur in peripheral leukocyte and lymphocyte subsets after in situ ischemic postconditioning during thrombectomy?", "required_claims": ["patients who received in situ ischemic postconditioning during thrombectomy had a higher helper-to-cytotoxic T-cell ratio than propensity-matched external controls", "the same patients had a lower proportion of natural killer cells than the matched controls", "total lymphocyte counts were numerically higher in the postconditioning group, but the difference did not reach statistical significance", "The proportion of neutrophils in the postconditioning group was lower than in matched controls"], "certainty": "These immune shifts are preliminary signals rather than confirmed effects.", "scope": "applies to acute ischemic stroke from large vessel occlusion in adults undergoing mechanical thrombectomy, inpatient settings", "wrong_if": "it reports that overall infarct volume at seventy-two hours was significantly reduced", "gold": "A strong answer conveys: patients who received in situ ischemic postconditioning during thrombectomy had a higher helper-to-cytotoxic T-cell ratio than propensity-matched external controls; the same patients had a lower proportion of natural killer cells than the matched controls; total lymphocyte counts were numerically higher in the postconditioning group, but the difference did not reach statistical significance; The proportion of neutrophils in the postconditioning group was lower than in matched controls. Certainty: These immune shifts are preliminary signals rather than confirmed effects. Scope: applies to acute ischemic stroke from large vessel occlusion in adults undergoing mechanical thrombectomy, inpatient settings. An answer is wrong if it reports that overall infarct volume at seventy-two hours was significantly reduced.", "doi": "10.1136/jnis-2025-024031", "access": "paywalled"}
{"id": "steered/10.1177/17562864261421717", "track": "neuroimmunology", "question": "How does antibody subtype relate to the response to ofatumumab in refractory generalised myasthenia gravis?", "required_claims": ["in a small retrospective early series, minimal symptom expression was reached by more of the muscle-specific-kinase patients than the acetylcholine-receptor patients, and after a shorter median time", "the unadjusted comparison of time to minimal symptom expression did not reach statistical significance", "the subtype association appeared only in a model adjusted for age at treatment and attenuated on further adjustment for autoimmune comorbidity", "the series was retrospective, uncontrolled and small, with different assays used for the two antibody types and a proactive biomarker-driven dosing intensity, so whether antibody subtype changes the response is left open"], "certainty": "This is an observation in twenty-one patients rather than a demonstrated subtype difference.", "scope": "applies to refractory generalised myasthenia gravis in adults treated with anti-CD20 therapy grouped by antibody type, specialist outpatient settings", "wrong_if": "it states that memory B-cell counts reliably predict imminent relapse and can be used as a retreatment trigger", "gold": "A strong answer conveys: in a small retrospective early series, minimal symptom expression was reached by more of the muscle-specific-kinase patients than the acetylcholine-receptor patients, and after a shorter median time; the unadjusted comparison of time to minimal symptom expression did not reach statistical significance; the subtype association appeared only in a model adjusted for age at treatment and attenuated on further adjustment for autoimmune comorbidity; the series was retrospective, uncontrolled and small, with different assays used for the two antibody types and a proactive biomarker-driven dosing intensity, so whether antibody subtype changes the response is left open. Certainty: This is an observation in twenty-one patients rather than a demonstrated subtype difference. Scope: applies to refractory generalised myasthenia gravis in adults treated with anti-CD20 therapy grouped by antibody type, specialist outpatient settings. An answer is wrong if it states that memory B-cell counts reliably predict imminent relapse and can be used as a retreatment trigger.", "doi": "10.1177/17562864261421717", "access": "open"}
{"id": "steered/10.1002/mus.70211", "track": "neuroimmunology", "question": "What comorbidity burden accumulates in the years following a myasthenia gravis diagnosis in adults?", "required_claims": ["cardiovascular conditions, above all hypertension, are the commonest coexisting illnesses already before the diagnosis is made and remain prominent afterwards", "in the years after diagnosis the burden shifts, with anaemia, osteoporosis and cataract becoming several times more common than beforehand, a pattern that runs alongside sustained corticosteroid and immunosuppressive use", "autoimmune conditions, particularly thyroid and rheumatic disease, run alongside the illness, while psychiatric conditions weigh more heavily on younger than on older patients"], "certainty": "These are consistent descriptive patterns rather than demonstrated effects of the disease or its treatment.", "scope": "applies to myasthenia gravis in adults followed from diagnosis in national health registries, population-based settings", "wrong_if": "it states that the post-diagnosis rise was shown to be caused by treatment", "gold": "A strong answer conveys: cardiovascular conditions, above all hypertension, are the commonest coexisting illnesses already before the diagnosis is made and remain prominent afterwards; in the years after diagnosis the burden shifts, with anaemia, osteoporosis and cataract becoming several times more common than beforehand, a pattern that runs alongside sustained corticosteroid and immunosuppressive use; autoimmune conditions, particularly thyroid and rheumatic disease, run alongside the illness, while psychiatric conditions weigh more heavily on younger than on older patients. Certainty: These are consistent descriptive patterns rather than demonstrated effects of the disease or its treatment. Scope: applies to myasthenia gravis in adults followed from diagnosis in national health registries, population-based settings. An answer is wrong if it states that the post-diagnosis rise was shown to be caused by treatment.", "doi": "10.1002/mus.70211", "access": "open"}
{"id": "steered/10.1136/lupus-2025-001643", "track": "neuroimmunology", "question": "What does translocator protein positron emission tomography show when lupus with neuropsychiatric involvement is compared with lupus without it?", "required_claims": ["peak tracer uptake was significantly higher in patients with neuropsychiatric involvement than in those without, while mean uptake across the region was not", "peak uptake correlated with damage index, disability scale and disease activity scores, while mean uptake showed no significant correlation with any of them", "peak uptake discriminated the two groups better than mean uptake, but that discrimination was estimated in the same small retrospective sample the models were fitted to and without dynamic modelling of binding kinetics", "the tracer marks activated microglia, astrocytes and macrophages together rather than microglia alone, so a raised signal points to a broad inflammatory reaction rather than one cell type"], "certainty": "This is an early signal in a small sample rather than a validated diagnostic test.", "scope": "applies to systemic lupus erythematosus with neuropsychiatric involvement in adults undergoing translocator protein positron emission tomography, specialist outpatient settings", "wrong_if": "it presents this imaging as a validated diagnostic test or as having replaced clinical criteria", "gold": "A strong answer conveys: peak tracer uptake was significantly higher in patients with neuropsychiatric involvement than in those without, while mean uptake across the region was not; peak uptake correlated with damage index, disability scale and disease activity scores, while mean uptake showed no significant correlation with any of them; peak uptake discriminated the two groups better than mean uptake, but that discrimination was estimated in the same small retrospective sample the models were fitted to and without dynamic modelling of binding kinetics; the tracer marks activated microglia, astrocytes and macrophages together rather than microglia alone, so a raised signal points to a broad inflammatory reaction rather than one cell type. Certainty: This is an early signal in a small sample rather than a validated diagnostic test. Scope: applies to systemic lupus erythematosus with neuropsychiatric involvement in adults undergoing translocator protein positron emission tomography, specialist outpatient settings. An answer is wrong if it presents this imaging as a validated diagnostic test or as having replaced clinical criteria.", "doi": "10.1136/lupus-2025-001643", "access": "open"}
{"id": "steered/10.1177/17562864261429570", "track": "neuroimmunology", "question": "What clinical responses follow CD19 CAR T-cell therapy in refractory myasthenia gravis and other antibody-mediated neurological autoimmune diseases?", "required_claims": ["in refractory myasthenia gravis, CD19-directed cell therapy was followed by long-term remission with stable immunoglobulin G concentrations in the two patients reported", "in a small single-arm study of RNA-engineered BCMA-directed cells, most of the treated myasthenia patients still showed improvement in activities of daily living, quantitative and composite scores at twelve months", "comparable reversals of long-standing disability have been reported in stiff-person spectrum disease and Lambert-Eaton syndrome", "refractory antisynthetase myositis and refractory chronic inflammatory demyelinating polyneuropathy have also responded, with drug-free remission and recovery of unassisted walking reported in the latter"], "certainty": "The responses are striking but early, and confirmation is still outstanding.", "scope": "applies to refractory antibody-mediated neurological autoimmune disease in adults who have failed available immunotherapies, specialist cell-therapy centre settings", "wrong_if": "it states the therapy carries no neurological toxicity", "gold": "A strong answer conveys: in refractory myasthenia gravis, CD19-directed cell therapy was followed by long-term remission with stable immunoglobulin G concentrations in the two patients reported; in a small single-arm study of RNA-engineered BCMA-directed cells, most of the treated myasthenia patients still showed improvement in activities of daily living, quantitative and composite scores at twelve months; comparable reversals of long-standing disability have been reported in stiff-person spectrum disease and Lambert-Eaton syndrome; refractory antisynthetase myositis and refractory chronic inflammatory demyelinating polyneuropathy have also responded, with drug-free remission and recovery of unassisted walking reported in the latter. Certainty: The responses are striking but early, and confirmation is still outstanding. Scope: applies to refractory antibody-mediated neurological autoimmune disease in adults who have failed available immunotherapies, specialist cell-therapy centre settings. An answer is wrong if it states the therapy carries no neurological toxicity.", "doi": "10.1177/17562864261429570", "access": "open"}
{"id": "steered/10.1177/13524585261418536", "track": "neuroimmunology", "question": "How does concomitant corticosteroid tapering proceed in patients with NMOSD starting satralizumab in routine care?", "required_claims": ["once interleukin-6 receptor blockade is started, the oral corticosteroid is the medication clinicians bring down first, and it is stopped altogether in about half of patients over two and a half years", "non-steroidal immunosuppressants come down more slowly and unevenly, with azathioprine withdrawn in most patients who were taking it but tacrolimus in fewer than half", "reduction follows clinician judgement rather than a standard schedule, and relapse has occurred after corticosteroid withdrawal, so the taper is monitored rather than assumed safe"], "certainty": "This describes observed practice and its outcomes rather than a tested tapering strategy.", "scope": "applies to aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder in patients starting interleukin-6 receptor blockade in routine care, outpatient settings", "wrong_if": "it says discontinuations of the biologic were driven by inadequate effect rather than tolerability", "gold": "A strong answer conveys: once interleukin-6 receptor blockade is started, the oral corticosteroid is the medication clinicians bring down first, and it is stopped altogether in about half of patients over two and a half years; non-steroidal immunosuppressants come down more slowly and unevenly, with azathioprine withdrawn in most patients who were taking it but tacrolimus in fewer than half; reduction follows clinician judgement rather than a standard schedule, and relapse has occurred after corticosteroid withdrawal, so the taper is monitored rather than assumed safe. Certainty: This describes observed practice and its outcomes rather than a tested tapering strategy. Scope: applies to aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder in patients starting interleukin-6 receptor blockade in routine care, outpatient settings. An answer is wrong if it says discontinuations of the biologic were driven by inadequate effect rather than tolerability.", "doi": "10.1177/13524585261418536", "access": "open"}
{"id": "steered/10.1177/13524585251409581", "track": "neuroimmunology", "question": "What patient characteristics mark AQP4-IgG NMOSD patients at risk of severe or opportunistic infections during immunosuppression?", "required_claims": ["severe or opportunistic infection reaches a substantial minority of patients on long-term immunosuppression and accounts for about a third of deaths", "older age at onset, longer time with the disease, a coexisting autoimmune condition and diabetes each mark higher infection risk once the other factors are accounted for", "a first severe infection is not a single event: recurrence is common among survivors and carries higher mortality than the first episode, which is what makes continuing an unchanged regimen a decision to weigh"], "certainty": "These are associations that identify higher-risk patients rather than established causes.", "scope": "applies to aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder on long-term immunosuppression in adults followed for at least a year, specialist outpatient settings", "wrong_if": "it presents the number of immunosuppressants or total treatment duration as an independent predictor", "gold": "A strong answer conveys: severe or opportunistic infection reaches a substantial minority of patients on long-term immunosuppression and accounts for about a third of deaths; older age at onset, longer time with the disease, a coexisting autoimmune condition and diabetes each mark higher infection risk once the other factors are accounted for; a first severe infection is not a single event: recurrence is common among survivors and carries higher mortality than the first episode, which is what makes continuing an unchanged regimen a decision to weigh. Certainty: These are associations that identify higher-risk patients rather than established causes. Scope: applies to aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder on long-term immunosuppression in adults followed for at least a year, specialist outpatient settings. An answer is wrong if it presents the number of immunosuppressants or total treatment duration as an independent predictor.", "doi": "10.1177/13524585251409581", "access": "paywalled"}
{"id": "steered/10.1177/17562864261433329", "track": "neuroimmunology", "question": "How do serum NfL and GFAP concentrations behave during attacks and remission in NMOSD and MOGAD?", "required_claims": ["in aquaporin-4 antibody disease both the axonal and the astrocyte marker rise during attacks and settle again in remission, with z-score cut-offs proposed to separate the two states", "in myelin oligodendrocyte glycoprotein antibody disease the axonal marker is raised, highest during attacks, fluctuating over the following three months and usually normalising within six", "astrocyte-marker data in that disease are inconsistent, some series finding levels stable across relapse and remission without correlation to disability and others finding them raised during relapse and correlated with disability", "neither marker rises between attacks, arguing against attack-independent axonal or glial injury"], "certainty": "The attack-related rise is well supported, while the astrocyte marker in myelin oligodendrocyte glycoprotein antibody disease remains genuinely disputed.", "scope": "applies to aquaporin-4 antibody neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in patients sampled during attacks and in remission, specialist neurology settings", "wrong_if": "it states that the astrocyte marker runs higher in myelin oligodendrocyte glycoprotein antibody disease than in aquaporin-4 antibody disease", "gold": "A strong answer conveys: in aquaporin-4 antibody disease both the axonal and the astrocyte marker rise during attacks and settle again in remission, with z-score cut-offs proposed to separate the two states; in myelin oligodendrocyte glycoprotein antibody disease the axonal marker is raised, highest during attacks, fluctuating over the following three months and usually normalising within six; astrocyte-marker data in that disease are inconsistent, some series finding levels stable across relapse and remission without correlation to disability and others finding them raised during relapse and correlated with disability; neither marker rises between attacks, arguing against attack-independent axonal or glial injury. Certainty: The attack-related rise is well supported, while the astrocyte marker in myelin oligodendrocyte glycoprotein antibody disease remains genuinely disputed. Scope: applies to aquaporin-4 antibody neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in patients sampled during attacks and in remission, specialist neurology settings. An answer is wrong if it states that the astrocyte marker runs higher in myelin oligodendrocyte glycoprotein antibody disease than in aquaporin-4 antibody disease.", "doi": "10.1177/17562864261433329", "access": "open"}
{"id": "steered/10.1177/08830738251356122", "track": "neuroimmunology", "question": "What outcomes follow therapeutic plasma exchange combined with methylprednisolone in children with severe autoimmune encephalitis?", "required_claims": ["most children still carry substantial functional limitation when they leave hospital, after a median stay of well over a month", "only a minority still carry substantial functional limitation at follow-up of a year or more, so recovery unfolds over months rather than weeks", "starting the exchange within the first four weeks went with a higher rate of improvement at discharge, which is the clearest available signal on timing", "whether adding corticosteroid to the exchange improves on exchange alone is unsettled, since the combination had the highest improvement rate descriptively while the formal comparison across regimens found no difference"], "certainty": "These are early uncontrolled observations, and the regimen question is left open by the material itself.", "scope": "applies to severe autoimmune encephalitis in children treated with plasma exchange during the acute admission, inpatient settings", "wrong_if": "it presents the combination of methylprednisolone with exchange as demonstrated superior to exchange alone", "gold": "A strong answer conveys: most children still carry substantial functional limitation when they leave hospital, after a median stay of well over a month; only a minority still carry substantial functional limitation at follow-up of a year or more, so recovery unfolds over months rather than weeks; starting the exchange within the first four weeks went with a higher rate of improvement at discharge, which is the clearest available signal on timing; whether adding corticosteroid to the exchange improves on exchange alone is unsettled, since the combination had the highest improvement rate descriptively while the formal comparison across regimens found no difference. Certainty: These are early uncontrolled observations, and the regimen question is left open by the material itself. Scope: applies to severe autoimmune encephalitis in children treated with plasma exchange during the acute admission, inpatient settings. An answer is wrong if it presents the combination of methylprednisolone with exchange as demonstrated superior to exchange alone.", "doi": "10.1177/08830738251356122", "access": "paywalled"}
{"id": "steered/10.1177/20552173251406973", "track": "neuroimmunology", "question": "What burden do repeated NMOSD relapses place on patient disability, quality of life, and caregivers?", "required_claims": ["bladder and bowel control problems were more common in patients who had relapsed than in those who had not, and became more common with additional relapses", "impact on daily living was high throughout, with over half of patients affected in their ability to work or drive, and significantly more of those with a relapse history not in full-time work and limited in home maintenance", "patients who had relapsed required more caregiver support than those who had not, most often from their partner", "patient-rated quality of life did not track the physical burden, running counter to trial data in which a single relapse worsens quality of life"], "certainty": "The burden findings are associations, and the quality-of-life result is in genuine tension with other evidence.", "scope": "applies to aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder in adults under neurologist care with or without relapses since the initial attack, outpatient settings", "wrong_if": "it states that relapses caused the disability and burden, since the design is cross-sectional and supports associations only", "gold": "A strong answer conveys: bladder and bowel control problems were more common in patients who had relapsed than in those who had not, and became more common with additional relapses; impact on daily living was high throughout, with over half of patients affected in their ability to work or drive, and significantly more of those with a relapse history not in full-time work and limited in home maintenance; patients who had relapsed required more caregiver support than those who had not, most often from their partner; patient-rated quality of life did not track the physical burden, running counter to trial data in which a single relapse worsens quality of life. Certainty: The burden findings are associations, and the quality-of-life result is in genuine tension with other evidence. Scope: applies to aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder in adults under neurologist care with or without relapses since the initial attack, outpatient settings. An answer is wrong if it states that relapses caused the disability and burden, since the design is cross-sectional and supports associations only.", "doi": "10.1177/20552173251406973", "access": "open"}
{"id": "steered/10.1177/13524585251370884", "track": "neuroimmunology", "question": "How do peripheral immune cells reach the CNS compartment and sustain tissue injury in multiple sclerosis?", "required_claims": ["Peripheral immune cells reach the central nervous system by more than one route: across the blood-brain barrier, across the blood-cerebrospinal-fluid barrier at the choroid plexus, and directly through dura-associated meningeal channels", "Cells and immune mediators accumulating in meningeal and perivascular niches are implicated in the subpial demyelination and periventricular tissue damage characteristic of the disease, with the interface regions mattering as well as the parenchyma", "High-dose ablative therapy directed at the systemic immune system stops clinical relapses and acute lesion formation, establishing that systemic components underlie them, while the same therapies do not halt the progressive phase once it is established, which indicates that additional mechanisms are involved", "Earlier restriction of systemic immune access to the central nervous system is associated with a lower likelihood of later progression, on long-term extension and observational evidence rather than a head-to-head comparison"], "certainty": "This is a well-supported account of the mechanism, with the treatment-timing element an association rather than a demonstrated comparative effect.", "scope": "applies to multiple sclerosis in patients across relapsing and progressive disease, specialist neurology settings", "wrong_if": "it claims the animal model mechanisms translate uniformly to patients", "gold": "A strong answer conveys: Peripheral immune cells reach the central nervous system by more than one route: across the blood-brain barrier, across the blood-cerebrospinal-fluid barrier at the choroid plexus, and directly through dura-associated meningeal channels; Cells and immune mediators accumulating in meningeal and perivascular niches are implicated in the subpial demyelination and periventricular tissue damage characteristic of the disease, with the interface regions mattering as well as the parenchyma; High-dose ablative therapy directed at the systemic immune system stops clinical relapses and acute lesion formation, establishing that systemic components underlie them, while the same therapies do not halt the progressive phase once it is established, which indicates that additional mechanisms are involved; Earlier restriction of systemic immune access to the central nervous system is associated with a lower likelihood of later progression, on long-term extension and observational evidence rather than a head-to-head comparison. Certainty: This is a well-supported account of the mechanism, with the treatment-timing element an association rather than a demonstrated comparative effect. Scope: applies to multiple sclerosis in patients across relapsing and progressive disease, specialist neurology settings. An answer is wrong if it claims the animal model mechanisms translate uniformly to patients.", "doi": "10.1177/13524585251370884", "access": "open"}
{"id": "steered/10.1177/00368504251390710", "track": "neuroimmunology", "question": "Which glial activation biomarkers in CSF or serum track astrocyte and microglial involvement in multiple sclerosis?", "required_claims": ["Astrocyte involvement is tracked by glial fibrillary acidic protein and by S100 calcium-binding protein B, which is raised in both cerebrospinal fluid and serum at relapsing-remitting diagnosis and is concentrated in reactive astrocytes within active lesions", "Microglial and macrophage activation is tracked by soluble triggering receptor expressed on myeloid cells 2, which is raised in cerebrospinal fluid in this disease", "The astrocyte and myeloid markers correlate positively in cerebrospinal fluid, indicating that the two cell types activate in concert", "None of these markers is specific to glia or to the central nervous system, between-person variability is wide, and results across studied markers have been inconsistent, so combinations of markers with imaging rather than any single measure are what is being pursued"], "certainty": "The marker-to-cell-type mapping is reasonably supported but their clinical value remains unproven.", "scope": "applies to multiple sclerosis in patients sampled in cerebrospinal fluid and serum, specialist neurology settings", "wrong_if": "it presents these markers as validated for routine clinical use", "gold": "A strong answer conveys: Astrocyte involvement is tracked by glial fibrillary acidic protein and by S100 calcium-binding protein B, which is raised in both cerebrospinal fluid and serum at relapsing-remitting diagnosis and is concentrated in reactive astrocytes within active lesions; Microglial and macrophage activation is tracked by soluble triggering receptor expressed on myeloid cells 2, which is raised in cerebrospinal fluid in this disease; The astrocyte and myeloid markers correlate positively in cerebrospinal fluid, indicating that the two cell types activate in concert; None of these markers is specific to glia or to the central nervous system, between-person variability is wide, and results across studied markers have been inconsistent, so combinations of markers with imaging rather than any single measure are what is being pursued. Certainty: The marker-to-cell-type mapping is reasonably supported but their clinical value remains unproven. Scope: applies to multiple sclerosis in patients sampled in cerebrospinal fluid and serum, specialist neurology settings. An answer is wrong if it presents these markers as validated for routine clinical use.", "doi": "10.1177/00368504251390710", "access": "open"}
{"id": "steered/10.1002/mus.28450", "track": "neuroimmunology", "question": "What clinical and serological profile do adults with myasthenia gravis show in multi-country observational registry cohorts?", "required_claims": ["The enrolled population is predominantly older adults with a slight female majority and, at enrolment, a median disease duration of several years", "Acetylcholine receptor antibodies are much the commonest serological group, with muscle-specific kinase antibodies a small minority, and a substantial minority present with purely ocular disease at diagnosis", "Most enrolled patients are on immunotherapy, only a small minority need three or more concurrent immunotherapies, and a minority have undergone thymectomy", "Composite severity scores are lower at the most recent visit than at the first across serostatus groups, an observation in a treated cohort with no untreated comparator"], "certainty": "This is a description of an enrolled population rather than a tested relationship.", "scope": "applies to myasthenia gravis in adults enrolled in multi-country observational registries, specialist outpatient settings", "wrong_if": "it states that muscle-specific kinase antibody positive patients had markedly worse recorded outcomes than acetylcholine receptor antibody positive patients", "gold": "A strong answer conveys: The enrolled population is predominantly older adults with a slight female majority and, at enrolment, a median disease duration of several years; Acetylcholine receptor antibodies are much the commonest serological group, with muscle-specific kinase antibodies a small minority, and a substantial minority present with purely ocular disease at diagnosis; Most enrolled patients are on immunotherapy, only a small minority need three or more concurrent immunotherapies, and a minority have undergone thymectomy; Composite severity scores are lower at the most recent visit than at the first across serostatus groups, an observation in a treated cohort with no untreated comparator. Certainty: This is a description of an enrolled population rather than a tested relationship. Scope: applies to myasthenia gravis in adults enrolled in multi-country observational registries, specialist outpatient settings. An answer is wrong if it states that muscle-specific kinase antibody positive patients had markedly worse recorded outcomes than acetylcholine receptor antibody positive patients.", "doi": "10.1002/mus.28450", "access": "open"}
{"id": "steered/10.1177/08830738251396175", "track": "neuroimmunology", "question": "Which clinical features at admission shape short-term prognosis in children with autoimmune encephalitis?", "required_claims": ["poor short-term outcome is marked at admission by an abnormal brain scan, impaired consciousness, autonomic involvement, fever and a preceding infection, each carrying roughly three- to fourfold higher odds after adjustment", "status epilepticus and a raised cerebrospinal fluid cell count separate the outcome groups on their own but do not hold up once the other admission features are accounted for", "combining the admission features discriminates better than any single one, though at a level that still leaves substantial misclassification and has not been tested in a separate sample"], "certainty": "These are associations with outcome rather than established causes, and the accuracy figure is apparent rather than validated.", "scope": "applies to autoimmune encephalitis in children admitted with acute disease, inpatient settings", "wrong_if": "it reports a difference in age or sex between the outcome groups", "gold": "A strong answer conveys: poor short-term outcome is marked at admission by an abnormal brain scan, impaired consciousness, autonomic involvement, fever and a preceding infection, each carrying roughly three- to fourfold higher odds after adjustment; status epilepticus and a raised cerebrospinal fluid cell count separate the outcome groups on their own but do not hold up once the other admission features are accounted for; combining the admission features discriminates better than any single one, though at a level that still leaves substantial misclassification and has not been tested in a separate sample. Certainty: These are associations with outcome rather than established causes, and the accuracy figure is apparent rather than validated. Scope: applies to autoimmune encephalitis in children admitted with acute disease, inpatient settings. An answer is wrong if it reports a difference in age or sex between the outcome groups.", "doi": "10.1177/08830738251396175", "access": "paywalled"}
{"id": "steered/10.1002/mus.70171", "track": "neuroimmunology", "question": "Which clinical and antibody features distinguish corticosteroid-refractory juvenile myasthenia gravis from corticosteroid-responsive disease?", "required_claims": ["acetylcholine receptor antibody positivity marks children less likely to be controlled by corticosteroids alone", "isolated ptosis, and ocular-only disease more broadly, marks children more likely to respond to corticosteroids", "most corticosteroid-refractory children respond once a nonsteroidal immunosuppressant is added, but the chance of response falls sharply once the first two agents have failed"], "certainty": "These are associations between baseline features and response group rather than demonstrated determinants.", "scope": "applies to juvenile myasthenia gravis in children diagnosed before adolescence, specialist outpatient settings", "wrong_if": "it credits thymectomy with any of the improvement", "gold": "A strong answer conveys: acetylcholine receptor antibody positivity marks children less likely to be controlled by corticosteroids alone; isolated ptosis, and ocular-only disease more broadly, marks children more likely to respond to corticosteroids; most corticosteroid-refractory children respond once a nonsteroidal immunosuppressant is added, but the chance of response falls sharply once the first two agents have failed. Certainty: These are associations between baseline features and response group rather than demonstrated determinants. Scope: applies to juvenile myasthenia gravis in children diagnosed before adolescence, specialist outpatient settings. An answer is wrong if it credits thymectomy with any of the improvement.", "doi": "10.1002/mus.70171", "access": "paywalled"}
{"id": "steered/10.1177/0271678x261419964", "track": "neuroimmunology", "question": "Which in vitro models capture microbiota effects on blood-brain barrier integrity for gut-brain axis research?", "required_claims": ["barrier integrity is read out as electrical resistance across the cell layer and as leakage of fluorescent tracers, with falling resistance signalling a leakier barrier", "complexity is added in steps, from two-dimensional transwell cultures to three-dimensional hydrogel and spheroid constructs that form tighter junctions, and on to multi-organ microfluidic chips linking a microbial compartment to gut, barrier and neural compartments", "each step trades physiological realism for experimental control, direct microbe-to-vessel contact only becomes relevant where the gut barrier is severely compromised, and animal work is still required for behavioural and whole-system outcomes"], "certainty": "This describes established laboratory practice and the recognised limits of each model class.", "scope": "applies to microbiota-gut-brain axis effects on blood-brain barrier integrity in cultured brain endothelial cells with pericytes, astrocytes and neural cells, co-cultured with microbial compartments, in vitro laboratory settings", "wrong_if": "it claims these findings transfer directly to the human barrier without in vivo work", "gold": "A strong answer conveys: barrier integrity is read out as electrical resistance across the cell layer and as leakage of fluorescent tracers, with falling resistance signalling a leakier barrier; complexity is added in steps, from two-dimensional transwell cultures to three-dimensional hydrogel and spheroid constructs that form tighter junctions, and on to multi-organ microfluidic chips linking a microbial compartment to gut, barrier and neural compartments; each step trades physiological realism for experimental control, direct microbe-to-vessel contact only becomes relevant where the gut barrier is severely compromised, and animal work is still required for behavioural and whole-system outcomes. Certainty: This describes established laboratory practice and the recognised limits of each model class. Scope: applies to microbiota-gut-brain axis effects on blood-brain barrier integrity in cultured brain endothelial cells with pericytes, astrocytes and neural cells, co-cultured with microbial compartments, in vitro laboratory settings. An answer is wrong if it claims these findings transfer directly to the human barrier without in vivo work.", "doi": "10.1177/0271678x261419964", "access": "open"}
{"id": "steered/10.1002/advs.202519049", "track": "neuroimmunology", "question": "Which second-line immunotherapies are used for refractory autoimmune encephalitis when antibody results remain pending in the ICU?", "required_claims": ["when clinical suspicion is high and infection has been reasonably excluded, immunotherapy is started promptly rather than held back while antibody results are awaited", "rituximab is the preferred second-line agent for suspected cell-surface-antibody and antibody-negative disease", "cyclophosphamide is favoured where a paraneoplastic, intracellular antibody is the concern, and in other refractory disease", "interleukin-6 receptor blockade and proteasome inhibition are reached for beyond rituximab in refractory disease but remain under trial evaluation rather than established"], "certainty": "This reflects settled practice for the sequencing question and unsettled evidence for the newer agents.", "scope": "applies to autoimmune encephalitis in critically ill adults with suspected or refractory disease, intensive care settings", "wrong_if": "it states that a negative antibody panel excludes autoimmune encephalitis", "gold": "A strong answer conveys: when clinical suspicion is high and infection has been reasonably excluded, immunotherapy is started promptly rather than held back while antibody results are awaited; rituximab is the preferred second-line agent for suspected cell-surface-antibody and antibody-negative disease; cyclophosphamide is favoured where a paraneoplastic, intracellular antibody is the concern, and in other refractory disease; interleukin-6 receptor blockade and proteasome inhibition are reached for beyond rituximab in refractory disease but remain under trial evaluation rather than established. Certainty: This reflects settled practice for the sequencing question and unsettled evidence for the newer agents. Scope: applies to autoimmune encephalitis in critically ill adults with suspected or refractory disease, intensive care settings. An answer is wrong if it states that a negative antibody panel excludes autoimmune encephalitis.", "doi": "10.1002/advs.202519049", "access": "open"}
{"id": "steered/10.1177/15230864251401591", "track": "neuroimmunology", "question": "In model systems of ischemic stroke, how do microglial phenotype shifts and cytokine release interact during the acute phase?", "required_claims": ["in the acute phase after the vessel occludes, microglia activate rapidly and polarise toward a proinflammatory phenotype", "those activated microglia release proinflammatory cytokines into the injured tissue, tumour necrosis factor alpha and interleukin-1 beta among them", "those cytokines signal through nuclear factor kappa B, which they activate and which in turn drives more of their own production, locking the response into a self-amplifying loop", "the same mediators promote apoptosis of vascular endothelial cells and disrupt the blood-brain barrier, so the cytokine response widens the injury rather than only reflecting it"], "certainty": "This is mechanistic evidence from model systems, consistent in direction but not established in patients.", "scope": "applies to acute ischaemic stroke in rodent models of cerebral ischaemia-reperfusion and cultured microglia and endothelial cells, preclinical settings", "wrong_if": null, "gold": "A strong answer conveys: in the acute phase after the vessel occludes, microglia activate rapidly and polarise toward a proinflammatory phenotype; those activated microglia release proinflammatory cytokines into the injured tissue, tumour necrosis factor alpha and interleukin-1 beta among them; those cytokines signal through nuclear factor kappa B, which they activate and which in turn drives more of their own production, locking the response into a self-amplifying loop; the same mediators promote apoptosis of vascular endothelial cells and disrupt the blood-brain barrier, so the cytokine response widens the injury rather than only reflecting it. Certainty: This is mechanistic evidence from model systems, consistent in direction but not established in patients. Scope: applies to acute ischaemic stroke in rodent models of cerebral ischaemia-reperfusion and cultured microglia and endothelial cells, preclinical settings.", "doi": "10.1177/15230864251401591", "access": "paywalled"}
{"id": "steered/10.1002/advs.202520313", "track": "neuroimmunology", "question": "What determines clinical outcome in children with NMDA receptor antibody encephalitis?", "required_claims": ["cerebrospinal fluid antibody titre is the measure that tracks outcome most closely, going with length of hospital stay and with disability from presentation through the first year", "initial brain imaging is usually unremarkable and about half of first EEGs are normal, so there is no imaging signature of the disease and normal early studies do not indicate a milder course", "no outcome difference was detected between the treatments given or by how quickly they were started, but nearly all children received the same combination, so the comparison could not be made"], "certainty": "These are things that go together in records reviewed after the fact, not effects of anything on outcome.", "scope": "applies to children and adolescents diagnosed with NMDA receptor antibody encephalitis, mixed settings", "wrong_if": "it presents cerebrospinal fluid antibody titre as an established test for setting treatment intensity in an individual child", "gold": "A strong answer conveys: cerebrospinal fluid antibody titre is the measure that tracks outcome most closely, going with length of hospital stay and with disability from presentation through the first year; initial brain imaging is usually unremarkable and about half of first EEGs are normal, so there is no imaging signature of the disease and normal early studies do not indicate a milder course; no outcome difference was detected between the treatments given or by how quickly they were started, but nearly all children received the same combination, so the comparison could not be made. Certainty: These are things that go together in records reviewed after the fact, not effects of anything on outcome. Scope: applies to children and adolescents diagnosed with NMDA receptor antibody encephalitis, mixed settings. An answer is wrong if it presents cerebrospinal fluid antibody titre as an established test for setting treatment intensity in an individual child.", "doi": "10.1002/advs.202520313", "access": "open"}
{"id": "steered/10.1136/jitc-2026-015176", "track": "neuroimmunology", "question": "What is the long-term neurological course after immune checkpoint inhibitor-related neurological adverse events?", "required_claims": ["recovery is only partial: about half of patients improve neurologically by three months, and among those still alive at one year roughly four in ten are left with neurological sequelae", "further neurological improvement after the first year is rare and effectively stops after the second, so the deficit present at one year is largely the deficit that remains", "recurrence of the neurological event affects a minority of patients, roughly one in seven, and typically occurs within the first year rather than later", "sequelae at one year are more likely in patients with paraneoplastic phenotypes and in those who relapse, while a myositis phenotype goes with better recovery"], "certainty": "These are outcomes counted as they occurred and phenotypes compared after the fact, not effects of any assigned treatment.", "scope": "applies to neurological immune-related adverse events of immune checkpoint inhibitors in adults treated with checkpoint inhibitors for cancer who develop moderate or severe neurological adverse events, mixed settings", "wrong_if": "it presents rechallenge with the checkpoint inhibitor as established to be safe after one of these events", "gold": "A strong answer conveys: recovery is only partial: about half of patients improve neurologically by three months, and among those still alive at one year roughly four in ten are left with neurological sequelae; further neurological improvement after the first year is rare and effectively stops after the second, so the deficit present at one year is largely the deficit that remains; recurrence of the neurological event affects a minority of patients, roughly one in seven, and typically occurs within the first year rather than later; sequelae at one year are more likely in patients with paraneoplastic phenotypes and in those who relapse, while a myositis phenotype goes with better recovery. Certainty: These are outcomes counted as they occurred and phenotypes compared after the fact, not effects of any assigned treatment. Scope: applies to neurological immune-related adverse events of immune checkpoint inhibitors in adults treated with checkpoint inhibitors for cancer who develop moderate or severe neurological adverse events, mixed settings. An answer is wrong if it presents rechallenge with the checkpoint inhibitor as established to be safe after one of these events.", "doi": "10.1136/jitc-2026-015176", "access": "open"}
{"id": "steered/10.1002/clc.70225", "track": "cardiology", "question": "How does loop diuretic therapy relate to mortality in patients with severe aortic stenosis undergoing valve replacement?", "required_claims": ["Loop diuretic use before valve replacement is associated with roughly twice the long-term mortality of patients not taking one", "This mortality signal is not explained by more severe stenosis, which is comparable in treated and untreated patients", "Patients on a loop diuretic reach valve replacement with greater congestion and higher filling pressures", "The excess mortality is best interpreted as marking an advanced disease stage rather than an established effect of the drug"], "certainty": "The evidence supports a consistent association rather than a causal effect, and the small number of deaths together with the older, more comorbid and higher-surgical-risk profile of treated patients weakens it further.", "scope": "applies to severe aortic stenosis treated with aortic valve replacement in adults, inpatient settings", "wrong_if": "it advises weaning, withholding or stopping loop diuretic therapy around valve replacement as a way to reduce mortality", "gold": "A strong answer conveys: Loop diuretic use before valve replacement is associated with roughly twice the long-term mortality of patients not taking one; This mortality signal is not explained by more severe stenosis, which is comparable in treated and untreated patients; Patients on a loop diuretic reach valve replacement with greater congestion and higher filling pressures; The excess mortality is best interpreted as marking an advanced disease stage rather than an established effect of the drug. Certainty: The evidence supports a consistent association rather than a causal effect, and the small number of deaths together with the older, more comorbid and higher-surgical-risk profile of treated patients weakens it further. Scope: applies to severe aortic stenosis treated with aortic valve replacement in adults, inpatient settings. An answer is wrong if it advises weaning, withholding or stopping loop diuretic therapy around valve replacement as a way to reduce mortality.", "doi": "10.1002/clc.70225", "access": "open"}
{"id": "steered/10.1007/s00134-025-08112-8", "track": "cardiology", "question": "What is known about echocardiographic assessment of the left atrium when choosing rhythm control in critically ill patients with atrial fibrillation?", "required_claims": ["Left atrial size, measured as the left atrial volume index, is a central echocardiographic input to the rhythm-versus-rate decision, with a non-dilated left atrium favouring an attempt at rhythm control", "A dilated left atrium is associated with longstanding or recurrent atrial fibrillation and steers management towards rate control", "Higher left atrial ejection fraction and a higher mitral A wave velocity-time integral measured some hours after cardioversion tracked maintenance of sinus rhythm and fewer recurrences in a single cited septic shock study, a preliminary observation rather than a general rule", "Tachycardia limits the mitral A wave velocity-time integral because it fuses the early and late mitral inflow waves"], "certainty": "These are preliminary observations from a small selected group and should not be read as general facts.", "scope": "applies to new-onset or unknown-duration atrial fibrillation complicating critical illness in adults, inpatient settings", "wrong_if": "it states that selecting patients for rhythm control on the basis of left atrial size or function has been shown to improve survival", "gold": "A strong answer conveys: Left atrial size, measured as the left atrial volume index, is a central echocardiographic input to the rhythm-versus-rate decision, with a non-dilated left atrium favouring an attempt at rhythm control; A dilated left atrium is associated with longstanding or recurrent atrial fibrillation and steers management towards rate control; Higher left atrial ejection fraction and a higher mitral A wave velocity-time integral measured some hours after cardioversion tracked maintenance of sinus rhythm and fewer recurrences in a single cited septic shock study, a preliminary observation rather than a general rule; Tachycardia limits the mitral A wave velocity-time integral because it fuses the early and late mitral inflow waves. Certainty: These are preliminary observations from a small selected group and should not be read as general facts. Scope: applies to new-onset or unknown-duration atrial fibrillation complicating critical illness in adults, inpatient settings. An answer is wrong if it states that selecting patients for rhythm control on the basis of left atrial size or function has been shown to improve survival.", "doi": "10.1007/s00134-025-08112-8", "access": "open"}
{"id": "steered/10.1177/15385744251387547", "track": "cardiology", "question": "What is known about bleeding risk with antithrombotic regimens after carotid stenting in patients with atrial fibrillation?", "required_claims": ["Major bleeding within the first three months did not differ significantly between dual antiplatelet therapy, single antiplatelet plus oral anticoagulation, and triple therapy", "Major bleeding was numerically least frequent with dual antiplatelet therapy alone and most frequent with triple therapy, a non-significant trend", "Bleeding events were too few and the sample too small to detect real differences, so no regimen can be identified as the safest"], "certainty": "The evidence is weak and preliminary, with far too few bleeding events to exclude real differences between the regimens.", "scope": "applies to atherosclerotic carotid stenosis treated with carotid artery stenting with concurrent non-valvular atrial fibrillation in adults, outpatient settings", "wrong_if": "it recommends dual antiplatelet therapy alone as the preferred regimen or advises withholding oral anticoagulation because bleeding was numerically lowest", "gold": "A strong answer conveys: Major bleeding within the first three months did not differ significantly between dual antiplatelet therapy, single antiplatelet plus oral anticoagulation, and triple therapy; Major bleeding was numerically least frequent with dual antiplatelet therapy alone and most frequent with triple therapy, a non-significant trend; Bleeding events were too few and the sample too small to detect real differences, so no regimen can be identified as the safest. Certainty: The evidence is weak and preliminary, with far too few bleeding events to exclude real differences between the regimens. Scope: applies to atherosclerotic carotid stenosis treated with carotid artery stenting with concurrent non-valvular atrial fibrillation in adults, outpatient settings. An answer is wrong if it recommends dual antiplatelet therapy alone as the preferred regimen or advises withholding oral anticoagulation because bleeding was numerically lowest.", "doi": "10.1177/15385744251387547", "access": "paywalled"}
{"id": "steered/10.1007/s00392-025-02702-8", "track": "cardiology", "question": "What is known about outcomes after tricuspid transcatheter edge-to-edge repair in the very elderly?", "required_claims": ["The very elderly, the oldest patients treated, reach two-year survival after tricuspid edge-to-edge repair comparable to that of the youngest, so older age at intervention is not associated with worse survival", "Survival free from heart failure hospitalisation is similar irrespective of age at intervention, including in patients with massive or torrential regurgitation at baseline", "Reduction of tricuspid regurgitation is durable in elderly and very elderly patients", "Improvement in functional class is of similar degree in older patients as in younger ones"], "certainty": "The evidence is an observed comparison across age groups in routine practice with no untreated comparison group, so comparable outcomes with advancing age are a consistent pattern rather than proven equivalence or a demonstrated benefit of the procedure.", "scope": "applies to significant tricuspid regurgitation treated with transcatheter edge-to-edge repair in older adults, including the very elderly, outpatient settings", "wrong_if": "it states that age can be disregarded in selection so that the procedure should be offered to any very elderly patient irrespective of comorbidity, symptoms, anatomy and expected life expectancy", "gold": "A strong answer conveys: The very elderly, the oldest patients treated, reach two-year survival after tricuspid edge-to-edge repair comparable to that of the youngest, so older age at intervention is not associated with worse survival; Survival free from heart failure hospitalisation is similar irrespective of age at intervention, including in patients with massive or torrential regurgitation at baseline; Reduction of tricuspid regurgitation is durable in elderly and very elderly patients; Improvement in functional class is of similar degree in older patients as in younger ones. Certainty: The evidence is an observed comparison across age groups in routine practice with no untreated comparison group, so comparable outcomes with advancing age are a consistent pattern rather than proven equivalence or a demonstrated benefit of the procedure. Scope: applies to significant tricuspid regurgitation treated with transcatheter edge-to-edge repair in older adults, including the very elderly, outpatient settings. An answer is wrong if it states that age can be disregarded in selection so that the procedure should be offered to any very elderly patient irrespective of comorbidity, symptoms, anatomy and expected life expectancy.", "doi": "10.1007/s00392-025-02702-8", "access": "open"}
{"id": "steered/10.1002/clc.70247", "track": "cardiology", "question": "How does the Naples Prognostic Score relate to mortality in acute coronary syndrome patients undergoing PCI?", "required_claims": ["A high Naples Prognostic Score is associated with higher all-cause mortality after percutaneous coronary intervention for acute coronary syndrome, on the order of a two-fold difference between high and low score groups (pooled risk ratio about 0.42 for low versus high)", "Pooled comparisons of high versus low score groups show no significant difference in death during the index hospital admission", "The in-hospital mortality comparison is far less stable than the all-cause mortality result, with heterogeneity between datasets so high that the estimate shifts according to which studies are included"], "certainty": "The association with all-cause mortality is consistent and quantified but reflects observed differences between patient groups rather than the effect of any assigned treatment, while the in-hospital mortality estimate is too heterogeneous to be relied upon.", "scope": "applies to acute coronary syndrome treated with percutaneous coronary intervention in adults, inpatient settings", "wrong_if": "it states that treating the nutritional or inflammatory components of the score lowers the score and thereby reduces death", "gold": "A strong answer conveys: A high Naples Prognostic Score is associated with higher all-cause mortality after percutaneous coronary intervention for acute coronary syndrome, on the order of a two-fold difference between high and low score groups (pooled risk ratio about 0.42 for low versus high); Pooled comparisons of high versus low score groups show no significant difference in death during the index hospital admission; The in-hospital mortality comparison is far less stable than the all-cause mortality result, with heterogeneity between datasets so high that the estimate shifts according to which studies are included. Certainty: The association with all-cause mortality is consistent and quantified but reflects observed differences between patient groups rather than the effect of any assigned treatment, while the in-hospital mortality estimate is too heterogeneous to be relied upon. Scope: applies to acute coronary syndrome treated with percutaneous coronary intervention in adults, inpatient settings. An answer is wrong if it states that treating the nutritional or inflammatory components of the score lowers the score and thereby reduces death.", "doi": "10.1002/clc.70247", "access": "open"}
{"id": "steered/10.1111/jce.70139", "track": "cardiology", "question": "Which clinical and procedural factors identify patients at risk of permanent pacemaker implantation after valve-in-valve TAVR?", "required_claims": ["Pre-procedural bifascicular block is associated with higher odds of permanent pacemaker implantation after valve-in-valve transcatheter aortic valve replacement", "Greater septal implantation depth of the transcatheter valve is associated with higher odds of permanent pacemaker implantation", "New left or right bundle branch block appearing after the procedure is associated with higher odds of pacemaker implantation before discharge", "Aortic regurgitation as the mechanism of bioprosthetic valve failure is associated with lower odds of pacemaker implantation than other failure mechanisms"], "certainty": "The findings show associations rather than proven causes, and because pacemaker events were few the estimates are imprecise.", "scope": "applies to degenerated bioprosthetic aortic valve treated with valve-in-valve transcatheter replacement in adults, inpatient settings", "wrong_if": "it presents the choice of transcatheter valve type as an established predictor of, or a way to prevent, pacemaker need after valve-in-valve replacement", "gold": "A strong answer conveys: Pre-procedural bifascicular block is associated with higher odds of permanent pacemaker implantation after valve-in-valve transcatheter aortic valve replacement; Greater septal implantation depth of the transcatheter valve is associated with higher odds of permanent pacemaker implantation; New left or right bundle branch block appearing after the procedure is associated with higher odds of pacemaker implantation before discharge; Aortic regurgitation as the mechanism of bioprosthetic valve failure is associated with lower odds of pacemaker implantation than other failure mechanisms. Certainty: The findings show associations rather than proven causes, and because pacemaker events were few the estimates are imprecise. Scope: applies to degenerated bioprosthetic aortic valve treated with valve-in-valve transcatheter replacement in adults, inpatient settings. An answer is wrong if it presents the choice of transcatheter valve type as an established predictor of, or a way to prevent, pacemaker need after valve-in-valve replacement.", "doi": "10.1111/jce.70139", "access": "paywalled"}
{"id": "steered/10.1007/s11357-025-02026-5", "track": "cardiology", "question": "How do multimorbidity, frailty and polypharmacy relate to death or major adverse cardiovascular events in atrial fibrillation?", "required_claims": ["Multimorbidity, frailty and polypharmacy are each associated with a higher risk of the composite of all-cause death and major adverse cardiovascular events after adjustment for confounders", "Crude rates of the composite outcome rise stepwise across patients fulfilling zero, one, two or three of these complexity domains", "The graded relationship between the number of complexity domains and the outcomes persisted in multivariable models adjusted for confounders"], "certainty": "The required claims rest on associations that hold consistently across each complexity domain and strengthen as the number of domains rises within a large analysed population, so they support correlation rather than established cause and effect.", "scope": "applies to atrial fibrillation in adults, mixed settings", "wrong_if": "it asserts that reducing the number of medications or reversing frailty has been shown to lower the risk of death or major adverse cardiovascular events", "gold": "A strong answer conveys: Multimorbidity, frailty and polypharmacy are each associated with a higher risk of the composite of all-cause death and major adverse cardiovascular events after adjustment for confounders; Crude rates of the composite outcome rise stepwise across patients fulfilling zero, one, two or three of these complexity domains; The graded relationship between the number of complexity domains and the outcomes persisted in multivariable models adjusted for confounders. Certainty: The required claims rest on associations that hold consistently across each complexity domain and strengthen as the number of domains rises within a large analysed population, so they support correlation rather than established cause and effect. Scope: applies to atrial fibrillation in adults, mixed settings. An answer is wrong if it asserts that reducing the number of medications or reversing frailty has been shown to lower the risk of death or major adverse cardiovascular events.", "doi": "10.1007/s11357-025-02026-5", "access": "open"}
{"id": "steered/10.1007/s00392-025-02755-9", "track": "cardiology", "question": "How does TAVI with PCI compare with SAVR plus CABG for mortality in aortic stenosis with coronary disease?", "required_claims": ["All-cause mortality through three years is similar after combined transcatheter valve implantation with percutaneous revascularization and after combined surgical valve replacement with bypass grafting, with no statistically significant difference in matched comparisons", "Deaths are nonetheless numerically fewer with the combined surgical strategy by three years, so a late survival disadvantage of the percutaneous strategy cannot be excluded", "In pooled randomised trials of valve treatment alone, an early survival advantage of the transcatheter approach was lost and reversed to favour surgery after twenty-four months", "Coronary disease was more complex in the surgically treated patients, and this complexity difference remained after propensity matching"], "certainty": "Because the mortality comparison draws on groups balanced by matching rather than by chance allocation, and the reference dataset supplies no significance testing itself, the evidence indicates outcomes are comparable rather than demonstrating true equivalence, while signals for later survival remain inconsistent.", "scope": "applies to severe aortic stenosis with concomitant coronary artery disease in elderly adults, inpatient settings", "wrong_if": "it states that the percutaneous strategy has been shown to give equivalent survival in patients with left main or complex multivessel coronary disease", "gold": "A strong answer conveys: All-cause mortality through three years is similar after combined transcatheter valve implantation with percutaneous revascularization and after combined surgical valve replacement with bypass grafting, with no statistically significant difference in matched comparisons; Deaths are nonetheless numerically fewer with the combined surgical strategy by three years, so a late survival disadvantage of the percutaneous strategy cannot be excluded; In pooled randomised trials of valve treatment alone, an early survival advantage of the transcatheter approach was lost and reversed to favour surgery after twenty-four months; Coronary disease was more complex in the surgically treated patients, and this complexity difference remained after propensity matching. Certainty: Because the mortality comparison draws on groups balanced by matching rather than by chance allocation, and the reference dataset supplies no significance testing itself, the evidence indicates outcomes are comparable rather than demonstrating true equivalence, while signals for later survival remain inconsistent. Scope: applies to severe aortic stenosis with concomitant coronary artery disease in elderly adults, inpatient settings. An answer is wrong if it states that the percutaneous strategy has been shown to give equivalent survival in patients with left main or complex multivessel coronary disease.", "doi": "10.1007/s00392-025-02755-9", "access": "open"}
{"id": "steered/10.1111/jce.70075", "track": "cardiology", "question": "How does catheter ablation compare with antiarrhythmic drug therapy plus a defibrillator for outcomes in ischemic ventricular tachycardia?", "required_claims": ["Compared with antiarrhythmic drug therapy plus a defibrillator, catheter ablation of ventricular tachycardia does not reduce all-cause mortality", "Compared with antiarrhythmic drug therapy plus a defibrillator, ablation does not reduce ventricular tachycardia or fibrillation recurrence", "Ablation showed no significant advantage over antiarrhythmic drug therapy plus a defibrillator for appropriate shocks, ventricular tachycardia storm or cardiovascular hospitalisation"], "certainty": "Evidence combined across multiple high-quality controlled comparisons with random allocation shows no difference between ablation and drug therapy plus a defibrillator, but these null findings indicate an absence of demonstrated benefit rather than established equivalence.", "scope": "applies to ventricular tachycardia in ischemic heart disease with an implantable defibrillator in adults, predominantly older men, mixed settings", "wrong_if": "it treats the absence of a mortality difference as proven equivalence between ablation and antiarrhythmic drug therapy, or as settled survival evidence that requires no further data", "gold": "A strong answer conveys: Compared with antiarrhythmic drug therapy plus a defibrillator, catheter ablation of ventricular tachycardia does not reduce all-cause mortality; Compared with antiarrhythmic drug therapy plus a defibrillator, ablation does not reduce ventricular tachycardia or fibrillation recurrence; Ablation showed no significant advantage over antiarrhythmic drug therapy plus a defibrillator for appropriate shocks, ventricular tachycardia storm or cardiovascular hospitalisation. Certainty: Evidence combined across multiple high-quality controlled comparisons with random allocation shows no difference between ablation and drug therapy plus a defibrillator, but these null findings indicate an absence of demonstrated benefit rather than established equivalence. Scope: applies to ventricular tachycardia in ischemic heart disease with an implantable defibrillator in adults, predominantly older men, mixed settings. An answer is wrong if it treats the absence of a mortality difference as proven equivalence between ablation and antiarrhythmic drug therapy, or as settled survival evidence that requires no further data.", "doi": "10.1111/jce.70075", "access": "paywalled"}
{"id": "steered/10.1177/08850666251405856", "track": "cardiology", "question": "How does pulmonary artery catheter use relate to in-hospital mortality among ICU patients with cardiogenic shock?", "required_claims": ["In propensity-matched and inverse-probability-weighted analyses of intensive care data, and in pooled observational reports, pulmonary artery catheter use was associated with lower in-hospital mortality, whereas randomised trials in critically ill patients did not demonstrate a mortality benefit, so the direction of any survival effect remains unsettled", "Because catheter placement was chosen by treating clinicians rather than assigned, and residual confounding from unmeasured variables persists in retrospective data, the lower mortality seen alongside catheter use cannot be read as a treatment effect", "In a pooled analysis the survival association with catheter use was present in shock from acute decompensated heart failure but not in shock secondary to acute coronary syndrome", "Any greater survival benefit where mechanical circulatory support is being contemplated is at most a preliminary and imprecise signal, not an established subgroup effect"], "certainty": "The survival signal rests on statistically adjusted comparisons of care as it happened to be delivered and has not been confirmed by evidence in which treatment was allocated by chance, so it remains unsettled rather than established.", "scope": "applies to cardiogenic shock in adults aged 18 years and older receiving critical care, inpatient settings", "wrong_if": "it concludes that pulmonary artery catheters offer no benefit and should be withheld in cardiogenic shock caused by acute coronary syndrome", "gold": "A strong answer conveys: In propensity-matched and inverse-probability-weighted analyses of intensive care data, and in pooled observational reports, pulmonary artery catheter use was associated with lower in-hospital mortality, whereas randomised trials in critically ill patients did not demonstrate a mortality benefit, so the direction of any survival effect remains unsettled; Because catheter placement was chosen by treating clinicians rather than assigned, and residual confounding from unmeasured variables persists in retrospective data, the lower mortality seen alongside catheter use cannot be read as a treatment effect; In a pooled analysis the survival association with catheter use was present in shock from acute decompensated heart failure but not in shock secondary to acute coronary syndrome; Any greater survival benefit where mechanical circulatory support is being contemplated is at most a preliminary and imprecise signal, not an established subgroup effect. Certainty: The survival signal rests on statistically adjusted comparisons of care as it happened to be delivered and has not been confirmed by evidence in which treatment was allocated by chance, so it remains unsettled rather than established. Scope: applies to cardiogenic shock in adults aged 18 years and older receiving critical care, inpatient settings. An answer is wrong if it concludes that pulmonary artery catheters offer no benefit and should be withheld in cardiogenic shock caused by acute coronary syndrome.", "doi": "10.1177/08850666251405856", "access": "paywalled"}
{"id": "steered/10.1002/mus.70121", "track": "neuroimmunology", "question": "Which clinical features characterize anti-neurofascin antibody-associated neuropathies across acute and chronic presentations?", "required_claims": ["Chronic presentations commonly show sensorimotor weakness, sensory ataxia, tremor and a fluctuating course", "Acute presentations are typically motor-predominant, severe at onset and progress rapidly to nadir", "The phenotype spans acute, chronic and recurrent acute presentations rather than a single stereotyped syndrome", "Positivity for both nodal and paranodal neurofascin isoforms (pan-neurofascin) marks a more severe and treatment-resistant course"], "certainty": "The supporting evidence is preliminary: it comes from a small number of patients described without a comparison group at a single site, so these patterns should be treated as tentative rather than confirmed.", "scope": "applies to anti-neurofascin antibody-associated neuropathy in adults and adolescents, mixed settings", "wrong_if": "it asserts that each individual nodal or paranodal antibody specificity maps to a distinct, predictable clinical syndrome", "gold": "A strong answer conveys: Chronic presentations commonly show sensorimotor weakness, sensory ataxia, tremor and a fluctuating course; Acute presentations are typically motor-predominant, severe at onset and progress rapidly to nadir; The phenotype spans acute, chronic and recurrent acute presentations rather than a single stereotyped syndrome; Positivity for both nodal and paranodal neurofascin isoforms (pan-neurofascin) marks a more severe and treatment-resistant course. Certainty: The supporting evidence is preliminary: it comes from a small number of patients described without a comparison group at a single site, so these patterns should be treated as tentative rather than confirmed. Scope: applies to anti-neurofascin antibody-associated neuropathy in adults and adolescents, mixed settings. An answer is wrong if it asserts that each individual nodal or paranodal antibody specificity maps to a distinct, predictable clinical syndrome.", "doi": "10.1002/mus.70121", "access": "paywalled"}
{"id": "steered/10.1136/jnnp-2025-337039", "track": "neuroimmunology", "question": "Which laboratory biomarkers relate to relapse risk in patients with MOG antibody-associated disease?", "required_claims": ["Persistent MOG-IgG seropositivity on repeat serum sampling is associated with a relapsing rather than monophasic disease course, with roughly threefold higher odds", "A relapsing course is associated with a much lower likelihood of seroreverting to MOG-IgG negative status, so sustained loss of the antibody tracks with a monophasic course", "Serum MOG-IgG titre category and cerebrospinal fluid white cell count are supported mainly as markers of an active attack rather than as predictors of long-term course", "The link between antibody measures and relapse risk rests on non-experimental data of variable quality with considerable between-study heterogeneity, giving moderate certainty at best"], "certainty": "These are moderate-strength associations rather than demonstrated causes of relapse, and the supporting data are inconsistent enough to keep the size of the effect approximate.", "scope": "applies to MOG antibody-associated disease in adults and children, outpatient settings", "wrong_if": "it advises starting, continuing or stopping long-term immunotherapy on the basis of antibody serostatus or titre alone", "gold": "A strong answer conveys: Persistent MOG-IgG seropositivity on repeat serum sampling is associated with a relapsing rather than monophasic disease course, with roughly threefold higher odds; A relapsing course is associated with a much lower likelihood of seroreverting to MOG-IgG negative status, so sustained loss of the antibody tracks with a monophasic course; Serum MOG-IgG titre category and cerebrospinal fluid white cell count are supported mainly as markers of an active attack rather than as predictors of long-term course; The link between antibody measures and relapse risk rests on non-experimental data of variable quality with considerable between-study heterogeneity, giving moderate certainty at best. Certainty: These are moderate-strength associations rather than demonstrated causes of relapse, and the supporting data are inconsistent enough to keep the size of the effect approximate. Scope: applies to MOG antibody-associated disease in adults and children, outpatient settings. An answer is wrong if it advises starting, continuing or stopping long-term immunotherapy on the basis of antibody serostatus or titre alone.", "doi": "10.1136/jnnp-2025-337039", "access": "open"}
{"id": "steered/10.1177/08830738251367460", "track": "neuroimmunology", "question": "What is known about interferon beta-1a treatment of multiple sclerosis in children and adolescents?", "required_claims": ["Reports of children and adolescents treated with injectable interferon beta-1a describe reduced relapse rates during treatment", "Registry experience with these formulations suggests treated children may experience outcomes similar to those seen in adult populations", "The pegylated formulation was given to far fewer children, and for a shorter median duration, than the intramuscular formulation"], "certainty": "The underlying evidence is uncontrolled and lacks comparison groups, so the findings are best read as provisional signals rather than as an established treatment effect.", "scope": "applies to multiple sclerosis treated with interferon beta-1a formulations in children and adolescents, outpatient settings", "wrong_if": "it presents interferon beta-1a as the preferred first-line disease-modifying therapy for children and adolescents with multiple sclerosis generally, or as an approved paediatric option", "gold": "A strong answer conveys: Reports of children and adolescents treated with injectable interferon beta-1a describe reduced relapse rates during treatment; Registry experience with these formulations suggests treated children may experience outcomes similar to those seen in adult populations; The pegylated formulation was given to far fewer children, and for a shorter median duration, than the intramuscular formulation. Certainty: The underlying evidence is uncontrolled and lacks comparison groups, so the findings are best read as provisional signals rather than as an established treatment effect. Scope: applies to multiple sclerosis treated with interferon beta-1a formulations in children and adolescents, outpatient settings. An answer is wrong if it presents interferon beta-1a as the preferred first-line disease-modifying therapy for children and adolescents with multiple sclerosis generally, or as an approved paediatric option.", "doi": "10.1177/08830738251367460", "access": "open"}
{"id": "steered/10.1177/17562864251387930", "track": "neuroimmunology", "question": "What is known about anti-CD19 CAR T-cell therapy in stiff-person syndrome spectrum disorder?", "required_claims": ["In the first reported treated patient with refractory stiff-person syndrome, anti-CD19 CAR T-cell therapy was followed by increased mobility and reduced symptomatic medication use", "Deep CD19-directed depletion of B-cells and plasmablasts is the proposed rationale, most directly in glycine receptor antibody disease where the antibodies are regarded as directly pathogenic", "Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome remain the principal safety concerns of this therapy", "A multicentre phase II trial is currently investigating the safety and efficacy of anti-CD19 CAR T-cell therapy in this disorder, with safety as its primary focus"], "certainty": "The clinical evidence rests on a single reported treated patient with no comparison group, so benefit is suggested rather than demonstrated.", "scope": "applies to stiff-person syndrome spectrum disorder in adults, inpatient settings", "wrong_if": "it recommends anti-CD19 CAR T-cell therapy as initial immunotherapy for newly diagnosed disease in place of established first-line treatment", "gold": "A strong answer conveys: In the first reported treated patient with refractory stiff-person syndrome, anti-CD19 CAR T-cell therapy was followed by increased mobility and reduced symptomatic medication use; Deep CD19-directed depletion of B-cells and plasmablasts is the proposed rationale, most directly in glycine receptor antibody disease where the antibodies are regarded as directly pathogenic; Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome remain the principal safety concerns of this therapy; A multicentre phase II trial is currently investigating the safety and efficacy of anti-CD19 CAR T-cell therapy in this disorder, with safety as its primary focus. Certainty: The clinical evidence rests on a single reported treated patient with no comparison group, so benefit is suggested rather than demonstrated. Scope: applies to stiff-person syndrome spectrum disorder in adults, inpatient settings. An answer is wrong if it recommends anti-CD19 CAR T-cell therapy as initial immunotherapy for newly diagnosed disease in place of established first-line treatment.", "doi": "10.1177/17562864251387930", "access": "open"}
{"id": "steered/10.1136/bmjno-2025-001252", "track": "neuroimmunology", "question": "What distinguishes tumefactive demyelinating lesions with MOG or NMDAR antibodies from those without such antibodies?", "required_claims": ["MOG antibody-positive patients showed a more inflammatory cerebrospinal fluid profile, with higher white cell counts, than antibody-negative patients", "MOG antibody-positive lesions more often shrank or disappeared on repeat MRI than antibody-negative lesions", "NMDAR antibody-positive patients showed higher systemic inflammatory markers than NMDAR antibody-negative patients, possibly reflecting a preceding infection", "Comparison of MOG antibody-positive with antibody-negative tumefactive lesions identified no unique clinical or MRI characteristic separating them"], "certainty": "These are preliminary signals from very small antibody-defined subgroups rather than established discriminators.", "scope": "applies to tumefactive demyelinating lesions stratified by MOG and NMDAR antibody status in adults, inpatient settings", "wrong_if": "it asserts that NMDAR antibody positivity here indicates an underlying teratoma that must be resected", "gold": "A strong answer conveys: MOG antibody-positive patients showed a more inflammatory cerebrospinal fluid profile, with higher white cell counts, than antibody-negative patients; MOG antibody-positive lesions more often shrank or disappeared on repeat MRI than antibody-negative lesions; NMDAR antibody-positive patients showed higher systemic inflammatory markers than NMDAR antibody-negative patients, possibly reflecting a preceding infection; Comparison of MOG antibody-positive with antibody-negative tumefactive lesions identified no unique clinical or MRI characteristic separating them. Certainty: These are preliminary signals from very small antibody-defined subgroups rather than established discriminators. Scope: applies to tumefactive demyelinating lesions stratified by MOG and NMDAR antibody status in adults, inpatient settings. An answer is wrong if it asserts that NMDAR antibody positivity here indicates an underlying teratoma that must be resected.", "doi": "10.1136/bmjno-2025-001252", "access": "open"}
{"id": "steered/10.1177/13524585261424125", "track": "neuroimmunology", "question": "What do visual evoked potentials contribute to the paraclinical workup of suspected optic neuritis under the 2022 ICON criteria?", "required_claims": ["Visual evoked potentials detected optic nerve involvement in suspected optic neuritis with high overall diagnostic accuracy in the reported series", "Adding visual evoked potentials as a further paraclinical test to the 2022 ICON criteria improved the sensitivity of the criteria in the reported series", "An abnormal visual evoked potential is not specific to optic neuritis, since a compressive lesion displacing the optic nerve produced a compatible alteration, so a clear alternative diagnosis from the rest of the workup takes precedence"], "certainty": "The accuracy estimates remain provisional, derived from a small patient sample scored against an expert reference diagnosis and not yet reproduced independently.", "scope": "applies to suspected optic neuritis assessed under the 2022 ICON criteria in adults, mixed settings", "wrong_if": "it states that a normal visual evoked potential rules out optic neuritis or removes the need for further assessment", "gold": "A strong answer conveys: Visual evoked potentials detected optic nerve involvement in suspected optic neuritis with high overall diagnostic accuracy in the reported series; Adding visual evoked potentials as a further paraclinical test to the 2022 ICON criteria improved the sensitivity of the criteria in the reported series; An abnormal visual evoked potential is not specific to optic neuritis, since a compressive lesion displacing the optic nerve produced a compatible alteration, so a clear alternative diagnosis from the rest of the workup takes precedence. Certainty: The accuracy estimates remain provisional, derived from a small patient sample scored against an expert reference diagnosis and not yet reproduced independently. Scope: applies to suspected optic neuritis assessed under the 2022 ICON criteria in adults, mixed settings. An answer is wrong if it states that a normal visual evoked potential rules out optic neuritis or removes the need for further assessment.", "doi": "10.1177/13524585261424125", "access": "open"}
{"id": "steered/10.1007/s00109-025-02616-y", "track": "neuroimmunology", "question": "What is known about candidate bacterial antigens targeted by intrathecally produced cerebrospinal fluid antibodies in demyelinating disease?", "required_claims": ["The candidate antigens are whole lysates of twenty bacteria, not defined proteins, the panel drawn from organisms that earlier brain-tissue sequencing had named as multiple sclerosis candidates, and against that panel spinal fluid IgG from some subjects with demyelinating disease reacted with commensal gut and genital-tract organisms, clustering most strongly against Bacteroides, Lactobacillus, Akkermansia and Alistipes", "Antibody index values above the positivity threshold against at least one bacterial lysate, the signal taken as evidence of intrathecal production, occurred in only a minority of demyelinating subjects (four of sixteen)", "Acknowledged cross-reactivity of samples across the different bacterial lysates, together with values that could not be confirmed by retesting, means these organisms are candidate rather than established antigens of the intrathecal response"], "certainty": "The evidence comes from very few subjects with no formal comparison between the disease groups, so these are preliminary observations rather than established antigen targets.", "scope": "applies to multiple sclerosis and other demyelinating diseases in adults with paired spinal fluid and serum samples, mixed settings", "wrong_if": "it presents bacterial antibody index testing as able to distinguish demyelinating disease from other neurologic conditions", "gold": "A strong answer conveys: The candidate antigens are whole lysates of twenty bacteria, not defined proteins, the panel drawn from organisms that earlier brain-tissue sequencing had named as multiple sclerosis candidates, and against that panel spinal fluid IgG from some subjects with demyelinating disease reacted with commensal gut and genital-tract organisms, clustering most strongly against Bacteroides, Lactobacillus, Akkermansia and Alistipes; Antibody index values above the positivity threshold against at least one bacterial lysate, the signal taken as evidence of intrathecal production, occurred in only a minority of demyelinating subjects (four of sixteen); Acknowledged cross-reactivity of samples across the different bacterial lysates, together with values that could not be confirmed by retesting, means these organisms are candidate rather than established antigens of the intrathecal response. Certainty: The evidence comes from very few subjects with no formal comparison between the disease groups, so these are preliminary observations rather than established antigen targets. Scope: applies to multiple sclerosis and other demyelinating diseases in adults with paired spinal fluid and serum samples, mixed settings. An answer is wrong if it presents bacterial antibody index testing as able to distinguish demyelinating disease from other neurologic conditions.", "doi": "10.1007/s00109-025-02616-y", "access": "open"}
{"id": "steered/10.1007/s40120-026-00906-2", "track": "neuroimmunology", "question": "What is known about clinical outcomes with lorazepam or immunoglobulin therapy compared with no therapy in DSRD?", "required_claims": ["Immunoglobulin therapy is associated with greater improvement than no therapy across the assessed motor, catatonia, global severity and neuropsychiatric measures", "Lorazepam is associated with greater improvement than no therapy on most, but not all, of the assessed outcome measures", "Immunoglobulin therapy is associated with greater improvement than lorazepam on catatonia and neuropsychiatric measures, but not on every outcome assessed", "Lorazepam is associated with earlier motor and catatonia improvement, while its neuropsychiatric improvement appears only at the later assessment"], "certainty": "The evidence is moderately strong and consistent across the assessed outcome measures but supports association rather than a proven treatment effect, and the timing pattern within the lorazepam arm is a weaker within-group observation.", "scope": "applies to DSRD in children and young adults, outpatient settings", "wrong_if": "it states that these data establish how long immunoglobulin therapy should be continued or when it can be safely withdrawn", "gold": "A strong answer conveys: Immunoglobulin therapy is associated with greater improvement than no therapy across the assessed motor, catatonia, global severity and neuropsychiatric measures; Lorazepam is associated with greater improvement than no therapy on most, but not all, of the assessed outcome measures; Immunoglobulin therapy is associated with greater improvement than lorazepam on catatonia and neuropsychiatric measures, but not on every outcome assessed; Lorazepam is associated with earlier motor and catatonia improvement, while its neuropsychiatric improvement appears only at the later assessment. Certainty: The evidence is moderately strong and consistent across the assessed outcome measures but supports association rather than a proven treatment effect, and the timing pattern within the lorazepam arm is a weaker within-group observation. Scope: applies to DSRD in children and young adults, outpatient settings. An answer is wrong if it states that these data establish how long immunoglobulin therapy should be continued or when it can be safely withdrawn.", "doi": "10.1007/s40120-026-00906-2", "access": "open"}
{"id": "steered/10.1177/17562864251377559", "track": "neuroimmunology", "question": "What is known about anti-Yo antibody-positive neurological disorders in patients receiving immune checkpoint inhibitor therapy?", "required_claims": ["In the few reported patients the associated tumours differed from the ovarian serous and breast cancers classically linked to anti-Yo antibodies, including ovarian clear cell carcinoma, uterine cancer and a lung tumour", "Rapidly progressive cerebellar syndrome was among the neurological presentations described", "Atypical, non-cerebellar syndromes were also observed in these patients", "Disability was severe at diagnosis and no reported patient improved after checkpoint inhibitor withdrawal and immunosuppressive treatment"], "certainty": "The evidence comes from a handful of individually described patients without a comparison group, so these are preliminary observations rather than established patterns.", "scope": "applies to immune checkpoint inhibitor-related neurological disorders with anti-Yo antibodies in adults with solid tumours, mixed settings", "wrong_if": "it states that checkpoint inhibitor treatment can be safely continued or resumed once these neurological symptoms have appeared", "gold": "A strong answer conveys: In the few reported patients the associated tumours differed from the ovarian serous and breast cancers classically linked to anti-Yo antibodies, including ovarian clear cell carcinoma, uterine cancer and a lung tumour; Rapidly progressive cerebellar syndrome was among the neurological presentations described; Atypical, non-cerebellar syndromes were also observed in these patients; Disability was severe at diagnosis and no reported patient improved after checkpoint inhibitor withdrawal and immunosuppressive treatment. Certainty: The evidence comes from a handful of individually described patients without a comparison group, so these are preliminary observations rather than established patterns. Scope: applies to immune checkpoint inhibitor-related neurological disorders with anti-Yo antibodies in adults with solid tumours, mixed settings. An answer is wrong if it states that checkpoint inhibitor treatment can be safely continued or resumed once these neurological symptoms have appeared.", "doi": "10.1177/17562864251377559", "access": "open"}
{"id": "steered/10.1177/13524585261425076", "track": "neuroimmunology", "question": "What is known about the safety of starting ravulizumab in AQP4-antibody-positive NMOSD after prior rituximab treatment?", "required_claims": ["Treatment-emergent and serious adverse event burden during ravulizumab was similar in rituximab-exposed and rituximab-naive patients, with no signal of added risk from prior rituximab", "Most adverse events in both subgroups were mild or moderate, with severe events affecting only a minority of patients", "Deaths and adverse-event withdrawals were rare, the single death occurring in a rituximab-exposed patient and no rituximab-exposed patient withdrawing because of an adverse event", "Patients whose first ravulizumab dose fell on the day of or within two weeks of the first meningococcal vaccination received antibiotic prophylaxis until two weeks after that vaccination"], "certainty": "Event counts are small and come from an uncontrolled, non-comparative safety summary, so comparable safety is a tentative observation rather than established equivalence.", "scope": "applies to AQP4-antibody-positive NMOSD with prior rituximab treatment in adults, outpatient settings", "wrong_if": "it claims that prior rituximab exposure lowers adverse-event risk during ravulizumab", "gold": "A strong answer conveys: Treatment-emergent and serious adverse event burden during ravulizumab was similar in rituximab-exposed and rituximab-naive patients, with no signal of added risk from prior rituximab; Most adverse events in both subgroups were mild or moderate, with severe events affecting only a minority of patients; Deaths and adverse-event withdrawals were rare, the single death occurring in a rituximab-exposed patient and no rituximab-exposed patient withdrawing because of an adverse event; Patients whose first ravulizumab dose fell on the day of or within two weeks of the first meningococcal vaccination received antibiotic prophylaxis until two weeks after that vaccination. Certainty: Event counts are small and come from an uncontrolled, non-comparative safety summary, so comparable safety is a tentative observation rather than established equivalence. Scope: applies to AQP4-antibody-positive NMOSD with prior rituximab treatment in adults, outpatient settings. An answer is wrong if it claims that prior rituximab exposure lowers adverse-event risk during ravulizumab.", "doi": "10.1177/13524585261425076", "access": "open"}
{"id": "steered/10.1111/jce.70170", "track": "cardiology", "question": "How do periprocedural complications after transvenous lead extraction of cardiac implantable electronic devices differ between men and women?", "required_claims": ["Women undergoing transvenous lead extraction have modestly higher odds of cardiac and pulmonary complications than men, including pericardial effusion, tamponade, pneumothorax and hemothorax", "In-hospital mortality did not differ significantly between women and men, whereas a prior single-centre series reported female sex as a predictor of post-procedural death, so the mortality comparison remains disputed", "Vascular complications are more frequent in men than in women, and the sex-specific risk is of modest magnitude"], "certainty": "The evidence supports a consistent association between sex and complication rates rather than a demonstrated cause, and the mortality comparison is unsettled across reports.", "scope": "applies to cardiac implantable electronic device-related indications requiring transvenous lead extraction in adults, inpatient settings", "wrong_if": "it presents female sex as a demonstrated cause of extraction complications or recommends deferring, restricting or otherwise altering extraction in women on this basis", "gold": "A strong answer conveys: Women undergoing transvenous lead extraction have modestly higher odds of cardiac and pulmonary complications than men, including pericardial effusion, tamponade, pneumothorax and hemothorax; In-hospital mortality did not differ significantly between women and men, whereas a prior single-centre series reported female sex as a predictor of post-procedural death, so the mortality comparison remains disputed; Vascular complications are more frequent in men than in women, and the sex-specific risk is of modest magnitude. Certainty: The evidence supports a consistent association between sex and complication rates rather than a demonstrated cause, and the mortality comparison is unsettled across reports. Scope: applies to cardiac implantable electronic device-related indications requiring transvenous lead extraction in adults, inpatient settings. An answer is wrong if it presents female sex as a demonstrated cause of extraction complications or recommends deferring, restricting or otherwise altering extraction in women on this basis.", "doi": "10.1111/jce.70170", "access": "paywalled"}
{"id": "steered/10.1177/27683605251392469", "track": "cardiology", "question": "What outcomes follow Baduanjin exercise added to cardiac rehabilitation in patients with chronic heart failure?", "required_claims": ["Adding Baduanjin exercise to conventional heart-failure medication is associated with higher left ventricular ejection fraction, longer six-minute walk distance and better quality of life than conventional medication with other exercise methods", "Depression scores were also lower with added Baduanjin exercise, a preliminary observation rather than an established effect", "Readmission rates did not differ significantly between the added-Baduanjin and control groups, and the pooled estimate was too imprecise to rule out a benefit", "Almost all contributing trials came from a single country, which may limit how far these outcomes generalize"], "certainty": "Confidence in the pooled outcomes is low to moderate, constrained by serious to very serious inconsistency across the contributing evidence and by allocation concealment and blinding that were largely unreported, so the findings are best read as suggestive rather than established.", "scope": "applies to chronic heart failure in adults, outpatient settings", "wrong_if": "it presents Baduanjin as an established substitute for conventional exercise-based cardiac rehabilitation or recommends replacing standard exercise training on this basis", "gold": "A strong answer conveys: Adding Baduanjin exercise to conventional heart-failure medication is associated with higher left ventricular ejection fraction, longer six-minute walk distance and better quality of life than conventional medication with other exercise methods; Depression scores were also lower with added Baduanjin exercise, a preliminary observation rather than an established effect; Readmission rates did not differ significantly between the added-Baduanjin and control groups, and the pooled estimate was too imprecise to rule out a benefit; Almost all contributing trials came from a single country, which may limit how far these outcomes generalize. Certainty: Confidence in the pooled outcomes is low to moderate, constrained by serious to very serious inconsistency across the contributing evidence and by allocation concealment and blinding that were largely unreported, so the findings are best read as suggestive rather than established. Scope: applies to chronic heart failure in adults, outpatient settings. An answer is wrong if it presents Baduanjin as an established substitute for conventional exercise-based cardiac rehabilitation or recommends replacing standard exercise training on this basis.", "doi": "10.1177/27683605251392469", "access": "paywalled"}
{"id": "steered/10.1136/heartjnl-2025-326197", "track": "cardiology", "question": "What does coronary inflammation measured on routine CT angiography add to risk assessment in non-obstructive coronary artery disease?", "required_claims": ["Higher coronary inflammation measured as perivascular fat attenuation on routine coronary CT angiography is associated with a higher rate of later cardiovascular events, including in patients whose arteries show only non-obstructive disease", "Adding the perivascular attenuation measure to conventional assessment improved identification of high-risk individuals beyond calcium scoring or a standard clinical risk equation", "The measure reports inflammatory biological activity in the vessel wall and surrounding fat, information that anatomical quantification of plaque extent alone does not provide"], "certainty": "The added value rests on observed associations between the imaging measure and later events rather than on any demonstrated causal or treatment effect.", "scope": "applies to non-obstructive coronary artery disease on coronary CT angiography in adults having clinically indicated coronary imaging, outpatient settings", "wrong_if": "it presents a low coronary inflammation value as established grounds for withholding, stopping or de-escalating preventive therapy in patients who otherwise meet treatment criteria", "gold": "A strong answer conveys: Higher coronary inflammation measured as perivascular fat attenuation on routine coronary CT angiography is associated with a higher rate of later cardiovascular events, including in patients whose arteries show only non-obstructive disease; Adding the perivascular attenuation measure to conventional assessment improved identification of high-risk individuals beyond calcium scoring or a standard clinical risk equation; The measure reports inflammatory biological activity in the vessel wall and surrounding fat, information that anatomical quantification of plaque extent alone does not provide. Certainty: The added value rests on observed associations between the imaging measure and later events rather than on any demonstrated causal or treatment effect. Scope: applies to non-obstructive coronary artery disease on coronary CT angiography in adults having clinically indicated coronary imaging, outpatient settings. An answer is wrong if it presents a low coronary inflammation value as established grounds for withholding, stopping or de-escalating preventive therapy in patients who otherwise meet treatment criteria.", "doi": "10.1136/heartjnl-2025-326197", "access": "paywalled"}
{"id": "steered/10.1177/10872914261473689", "track": "cardiology", "question": "How do outcomes after acute coronary syndrome in people with HIV compare with those without HIV?", "required_claims": ["One-year mortality after acute coronary syndrome did not differ appreciably between people with and without HIV", "New cardiovascular events after acute coronary syndrome, mainly repeat revascularization and recurrent acute coronary syndrome, were numerically more frequent in people with HIV", "The hazard comparison for these new cardiovascular events was imprecise and remained compatible with no difference between groups", "Pooled results from earlier comparisons point to a modestly higher risk of major adverse cardiac events in people with HIV"], "certainty": "The evidence is weak and imprecise: too few people with HIV were compared for the comparable outcomes to establish equivalence, and the imprecise event comparison sits alongside pooled results suggesting a small excess.", "scope": "applies to acute coronary syndrome in adults with and without HIV, mixed settings", "wrong_if": "it treats the comparable one-year outcomes as established equivalence and concludes that people with HIV need no additional cardiovascular surveillance or secondary prevention after acute coronary syndrome", "gold": "A strong answer conveys: One-year mortality after acute coronary syndrome did not differ appreciably between people with and without HIV; New cardiovascular events after acute coronary syndrome, mainly repeat revascularization and recurrent acute coronary syndrome, were numerically more frequent in people with HIV; The hazard comparison for these new cardiovascular events was imprecise and remained compatible with no difference between groups; Pooled results from earlier comparisons point to a modestly higher risk of major adverse cardiac events in people with HIV. Certainty: The evidence is weak and imprecise: too few people with HIV were compared for the comparable outcomes to establish equivalence, and the imprecise event comparison sits alongside pooled results suggesting a small excess. Scope: applies to acute coronary syndrome in adults with and without HIV, mixed settings. An answer is wrong if it treats the comparable one-year outcomes as established equivalence and concludes that people with HIV need no additional cardiovascular surveillance or secondary prevention after acute coronary syndrome.", "doi": "10.1177/10872914261473689", "access": "paywalled"}
{"id": "steered/10.1136/heartjnl-2025-326186", "track": "cardiology", "question": "Which hypertension subtypes are appropriate candidates for renal denervation in current practice?", "required_claims": ["Guidelines recommend renal denervation as an adjunct therapy for adults with uncontrolled or resistant hypertension in whom other means have failed or given insufficient blood pressure control", "Candidate selection, including the patient's own preference, is settled through a shared decision-making process before the procedure", "Against a sham procedure, denervation lowers systolic blood pressure modestly, on the order of 3 to 7 mm Hg, in patients whether or not they continue antihypertensive drugs", "Candidacy is not confined to drug-resistant patients, since modest reductions were also seen in treated essential and treatment-naive hypertension, with benefit less consistent at lower drug burden"], "certainty": "The blood pressure effect rests on blinded sham-controlled comparisons of modest size, while candidacy and the selection process reflect guideline consensus rather than a tested effect.", "scope": "applies to uncontrolled or resistant hypertension in adults, outpatient settings", "wrong_if": "it presents long-term durability of the blood pressure reduction as established by controlled comparison, or recommends the procedure primarily on the strength of a permanent effect", "gold": "A strong answer conveys: Guidelines recommend renal denervation as an adjunct therapy for adults with uncontrolled or resistant hypertension in whom other means have failed or given insufficient blood pressure control; Candidate selection, including the patient's own preference, is settled through a shared decision-making process before the procedure; Against a sham procedure, denervation lowers systolic blood pressure modestly, on the order of 3 to 7 mm Hg, in patients whether or not they continue antihypertensive drugs; Candidacy is not confined to drug-resistant patients, since modest reductions were also seen in treated essential and treatment-naive hypertension, with benefit less consistent at lower drug burden. Certainty: The blood pressure effect rests on blinded sham-controlled comparisons of modest size, while candidacy and the selection process reflect guideline consensus rather than a tested effect. Scope: applies to uncontrolled or resistant hypertension in adults, outpatient settings. An answer is wrong if it presents long-term durability of the blood pressure reduction as established by controlled comparison, or recommends the procedure primarily on the strength of a permanent effect.", "doi": "10.1136/heartjnl-2025-326186", "access": "paywalled"}
{"id": "steered/10.1177/20480040261445493", "track": "cardiology", "question": "What survival outcomes follow post-cardiotomy venoarterial extracorporeal membrane oxygenation for failure to wean from cardiopulmonary bypass?", "required_claims": ["About half of adults supported for failure to wean from cardiopulmonary bypass survived to hospital discharge, with in-hospital death in the remainder", "This survival level was in keeping with the roughly 30% to 50% survival reported in earlier postcardiotomy extracorporeal support series", "Among survivors, discharge directly home was the minority outcome, most needing rehabilitation or other continuing care, a preliminary observation from a small single-institution series"], "certainty": "Evidence strength is low, resting on uncontrolled proportions from a small, narrowly sourced group of patients, so the findings describe outcomes rather than demonstrate benefit.", "scope": "applies to postcardiotomy cardiogenic shock with failure to wean from cardiopulmonary bypass in adults, inpatient settings", "wrong_if": "it presents this experience as demonstrating that extracorporeal support improves survival compared with alternative circulatory support strategies", "gold": "A strong answer conveys: About half of adults supported for failure to wean from cardiopulmonary bypass survived to hospital discharge, with in-hospital death in the remainder; This survival level was in keeping with the roughly 30% to 50% survival reported in earlier postcardiotomy extracorporeal support series; Among survivors, discharge directly home was the minority outcome, most needing rehabilitation or other continuing care, a preliminary observation from a small single-institution series. Certainty: Evidence strength is low, resting on uncontrolled proportions from a small, narrowly sourced group of patients, so the findings describe outcomes rather than demonstrate benefit. Scope: applies to postcardiotomy cardiogenic shock with failure to wean from cardiopulmonary bypass in adults, inpatient settings. An answer is wrong if it presents this experience as demonstrating that extracorporeal support improves survival compared with alternative circulatory support strategies.", "doi": "10.1177/20480040261445493", "access": "paywalled"}
{"id": "steered/10.1007/s00392-025-02784-4", "track": "cardiology", "question": "What key clinical outcomes follow finerenone therapy in patients with heart failure and left ventricular ejection fraction above 40%?", "required_claims": ["Finerenone added to standard therapy reduces the composite of cardiovascular death and worsening heart failure events (heart failure hospitalisation or emergency visits) in heart failure with ejection fraction above 40%", "The size of that composite effect is modest: about a 16% relative risk reduction, with an absolute risk reduction of only a few percentage points", "All heart failure hospitalisations were also reduced, by about 18%, as a secondary endpoint", "Cardiovascular mortality taken on its own fell by about 7% and this difference was not statistically significant versus placebo"], "certainty": "The direction of benefit on the composite endpoint and on heart failure hospitalisations rests on a single large placebo-controlled comparison in which treatment was allocated by chance, with estimates relayed without confidence intervals, while the cardiovascular mortality component on its own did not reach statistical significance.", "scope": "applies to heart failure with mildly reduced or preserved ejection fraction (ejection fraction above 40%) in adults on standard background therapy, mixed settings", "wrong_if": "it presents finerenone as an established therapy for heart failure with reduced ejection fraction, or as demonstrated across the whole ejection fraction range", "gold": "A strong answer conveys: Finerenone added to standard therapy reduces the composite of cardiovascular death and worsening heart failure events (heart failure hospitalisation or emergency visits) in heart failure with ejection fraction above 40%; The size of that composite effect is modest: about a 16% relative risk reduction, with an absolute risk reduction of only a few percentage points; All heart failure hospitalisations were also reduced, by about 18%, as a secondary endpoint; Cardiovascular mortality taken on its own fell by about 7% and this difference was not statistically significant versus placebo. Certainty: The direction of benefit on the composite endpoint and on heart failure hospitalisations rests on a single large placebo-controlled comparison in which treatment was allocated by chance, with estimates relayed without confidence intervals, while the cardiovascular mortality component on its own did not reach statistical significance. Scope: applies to heart failure with mildly reduced or preserved ejection fraction (ejection fraction above 40%) in adults on standard background therapy, mixed settings. An answer is wrong if it presents finerenone as an established therapy for heart failure with reduced ejection fraction, or as demonstrated across the whole ejection fraction range.", "doi": "10.1007/s00392-025-02784-4", "access": "open"}
{"id": "steered/10.1007/s12181-026-00807-6", "track": "cardiology", "question": "Which pharmacological therapies are currently recommended for patients with heart failure with preserved ejection fraction?", "required_claims": ["Sodium-glucose cotransporter 2 inhibition with empagliflozin or dapagliflozin reduces the composite of worsening heart failure and cardiovascular death, a benefit carried by about 21-27% fewer heart failure hospitalisations", "Finerenone reduces the composite of total heart failure events and cardiovascular death in patients with ejection fraction of at least 40%", "Weekly semaglutide improves the symptom-oriented endpoints of quality of life and body weight in obese patients with preserved ejection fraction", "Spironolactone, candesartan and sacubitril/valsartan did not meet their primary endpoints in preserved ejection fraction"], "certainty": "Both the benefit and the non-benefit claims rest on comparisons in which treatment was allocated by chance rather than chosen, although the sodium-glucose cotransporter 2 inhibitor evidence came from participants spanning preserved together with mildly reduced ejection fraction, leaving the share attributable to preserved ejection fraction alone less securely established.", "scope": "applies to heart failure with preserved ejection fraction in adults, outpatient settings", "wrong_if": "it presents a reduction in death rates with these drug classes as demonstrated in preserved ejection fraction, or recommends them on that basis", "gold": "A strong answer conveys: Sodium-glucose cotransporter 2 inhibition with empagliflozin or dapagliflozin reduces the composite of worsening heart failure and cardiovascular death, a benefit carried by about 21-27% fewer heart failure hospitalisations; Finerenone reduces the composite of total heart failure events and cardiovascular death in patients with ejection fraction of at least 40%; Weekly semaglutide improves the symptom-oriented endpoints of quality of life and body weight in obese patients with preserved ejection fraction; Spironolactone, candesartan and sacubitril/valsartan did not meet their primary endpoints in preserved ejection fraction. Certainty: Both the benefit and the non-benefit claims rest on comparisons in which treatment was allocated by chance rather than chosen, although the sodium-glucose cotransporter 2 inhibitor evidence came from participants spanning preserved together with mildly reduced ejection fraction, leaving the share attributable to preserved ejection fraction alone less securely established. Scope: applies to heart failure with preserved ejection fraction in adults, outpatient settings. An answer is wrong if it presents a reduction in death rates with these drug classes as demonstrated in preserved ejection fraction, or recommends them on that basis.", "doi": "10.1007/s12181-026-00807-6", "access": "open"}
{"id": "steered/10.1177/02841851261418633", "track": "cardiology", "question": "Which cardiovascular magnetic resonance parameters identify acute myocarditis in patients with clinically suspected disease?", "required_claims": ["Global native T1, global T2 and extracellular volume fraction are each higher in acute myocarditis than in healthy comparison subjects", "Extracellular volume fraction separated myocarditis from healthy comparison subjects more sharply than native T1 or T2 alone", "The updated two-out-of-two Lake Louise criteria, pairing a T2-based and a T1-based marker, discriminated myocarditis as well as extracellular volume did"], "certainty": "Support remains preliminary: the group differences look consistent, but the accuracy estimates come from a small sample gathered at a single hospital on one scanner, with thresholds fitted on the same participants in whom they were then evaluated.", "scope": "applies to clinically suspected acute myocarditis in adults, inpatient settings", "wrong_if": "it presents left ventricular ejection fraction or chamber volumes as established markers for identifying acute myocarditis, or recommends relying on them to make or exclude the diagnosis", "gold": "A strong answer conveys: Global native T1, global T2 and extracellular volume fraction are each higher in acute myocarditis than in healthy comparison subjects; Extracellular volume fraction separated myocarditis from healthy comparison subjects more sharply than native T1 or T2 alone; The updated two-out-of-two Lake Louise criteria, pairing a T2-based and a T1-based marker, discriminated myocarditis as well as extracellular volume did. Certainty: Support remains preliminary: the group differences look consistent, but the accuracy estimates come from a small sample gathered at a single hospital on one scanner, with thresholds fitted on the same participants in whom they were then evaluated. Scope: applies to clinically suspected acute myocarditis in adults, inpatient settings. An answer is wrong if it presents left ventricular ejection fraction or chamber volumes as established markers for identifying acute myocarditis, or recommends relying on them to make or exclude the diagnosis.", "doi": "10.1177/02841851261418633", "access": "paywalled"}
{"id": "steered/10.1136/bmjdh-2026-000053", "track": "cardiology", "question": "What is known about the clinical value of AI-derived coronary artery calcium scores for cardiovascular risk prognostication?", "required_claims": ["AI-derived coronary artery calcium from chest CT is consistently associated with all-cause mortality, cardiovascular mortality, major adverse cardiovascular events and obstructive coronary artery disease across varied patient groups and imaging indications", "Early prospective and implementation-focused experience links automated calcium reporting embedded in clinical workflows with greater engagement in preventive care", "Most included studies report time and labour savings from automated calcium scoring compared with manual Agatston scoring"], "certainty": "The evidence supports consistent associations with death and cardiovascular events rather than demonstrated benefit, while the workflow engagement and efficiency signals rest on early, methodologically varied, and largely low-strength sources.", "scope": "applies to cardiovascular risk prognostication using AI-derived coronary artery calcium in adults undergoing non-gated chest CT for cardiovascular and non-cardiovascular indications, mixed settings", "wrong_if": "it presents automated coronary artery calcium scoring as an established, cost-effective component of preventive cardiology that should be switched on as standard of care for every chest CT", "gold": "A strong answer conveys: AI-derived coronary artery calcium from chest CT is consistently associated with all-cause mortality, cardiovascular mortality, major adverse cardiovascular events and obstructive coronary artery disease across varied patient groups and imaging indications; Early prospective and implementation-focused experience links automated calcium reporting embedded in clinical workflows with greater engagement in preventive care; Most included studies report time and labour savings from automated calcium scoring compared with manual Agatston scoring. Certainty: The evidence supports consistent associations with death and cardiovascular events rather than demonstrated benefit, while the workflow engagement and efficiency signals rest on early, methodologically varied, and largely low-strength sources. Scope: applies to cardiovascular risk prognostication using AI-derived coronary artery calcium in adults undergoing non-gated chest CT for cardiovascular and non-cardiovascular indications, mixed settings. An answer is wrong if it presents automated coronary artery calcium scoring as an established, cost-effective component of preventive cardiology that should be switched on as standard of care for every chest CT.", "doi": "10.1136/bmjdh-2026-000053", "access": "open"}
{"id": "steered/10.1007/s10554-026-03658-0", "track": "cardiology", "question": "Which exercise stress parameters stratify risk of major adverse cardiovascular events after a normal exercise SPECT myocardial perfusion study?", "required_claims": ["A stress rate pressure product at peak exercise below the conventional threshold of about 25,000 is associated with more cardiac events, independently of the other exercise parameters tested", "A low Duke treadmill score is likewise associated with more cardiac events after a normal exercise perfusion study", "Neither failure to reach 85% of the age-predicted maximum heart rate nor a low metabolic equivalent level reached independent significance in the same model, a preliminary observation from few events rather than evidence that these parameters carry no prognostic information"], "certainty": "The risk gradients are moderate-strength observed associations from a single large clinical sample with few events, and the non-significant parameters are underpowered nulls rather than established negatives.", "scope": "applies to known or suspected coronary artery disease with a normal exercise SPECT myocardial perfusion study in adults able to complete a treadmill or bicycle protocol, outpatient settings", "wrong_if": "it presents ischemic exercise ECG changes accompanying a normal perfusion study as an established marker of higher event risk or recommends further testing on that basis", "gold": "A strong answer conveys: A stress rate pressure product at peak exercise below the conventional threshold of about 25,000 is associated with more cardiac events, independently of the other exercise parameters tested; A low Duke treadmill score is likewise associated with more cardiac events after a normal exercise perfusion study; Neither failure to reach 85% of the age-predicted maximum heart rate nor a low metabolic equivalent level reached independent significance in the same model, a preliminary observation from few events rather than evidence that these parameters carry no prognostic information. Certainty: The risk gradients are moderate-strength observed associations from a single large clinical sample with few events, and the non-significant parameters are underpowered nulls rather than established negatives. Scope: applies to known or suspected coronary artery disease with a normal exercise SPECT myocardial perfusion study in adults able to complete a treadmill or bicycle protocol, outpatient settings. An answer is wrong if it presents ischemic exercise ECG changes accompanying a normal perfusion study as an established marker of higher event risk or recommends further testing on that basis.", "doi": "10.1007/s10554-026-03658-0", "access": "open"}
{"id": "steered/10.1002/clc.70329", "track": "cardiology", "question": "In which clinical scenarios do ESC guidelines position cardiovascular magnetic resonance as a first-line diagnostic test?", "required_claims": ["Cardiovascular magnetic resonance is positioned as a first-line, adjudicatory test in scenarios of high diagnostic uncertainty, including myocardial infarction with non-obstructive coronary arteries, suspected cardiomyopathy, sports participation after myocarditis and complex valvular disease", "In chronic coronary syndromes stress perfusion cardiovascular magnetic resonance sits among the frontline functional tests, both for suspected obstructive coronary disease and for angina or ischaemia without obstructive coronary arteries", "This positioning reflects a shift from a last-resort problem-solving modality to a frequently recommended investigation, recommendations commonly being Class I or IIa at Level B or C"], "certainty": "This describes where guidance places the test rather than showing patient benefit; several of these recommendations rest on Level C evidence and no patient outcomes were compared between imaging strategies.", "scope": "applies to cardiovascular disease requiring diagnostic cardiac imaging in adults, mixed settings", "wrong_if": "it presents magnetic resonance-guided pathways as demonstrated to improve patient outcomes such as mortality or repeat admissions", "gold": "A strong answer conveys: Cardiovascular magnetic resonance is positioned as a first-line, adjudicatory test in scenarios of high diagnostic uncertainty, including myocardial infarction with non-obstructive coronary arteries, suspected cardiomyopathy, sports participation after myocarditis and complex valvular disease; In chronic coronary syndromes stress perfusion cardiovascular magnetic resonance sits among the frontline functional tests, both for suspected obstructive coronary disease and for angina or ischaemia without obstructive coronary arteries; This positioning reflects a shift from a last-resort problem-solving modality to a frequently recommended investigation, recommendations commonly being Class I or IIa at Level B or C. Certainty: This describes where guidance places the test rather than showing patient benefit; several of these recommendations rest on Level C evidence and no patient outcomes were compared between imaging strategies. Scope: applies to cardiovascular disease requiring diagnostic cardiac imaging in adults, mixed settings. An answer is wrong if it presents magnetic resonance-guided pathways as demonstrated to improve patient outcomes such as mortality or repeat admissions.", "doi": "10.1002/clc.70329", "access": "open"}
{"id": "steered/10.1136/heartjnl-2025-327108", "track": "cardiology", "question": "How well does photon-counting CT detect obstructive coronary stenosis compared with invasive angiography?", "required_claims": ["Against invasive angiography at a threshold of more than 50% diameter stenosis, pooled sensitivity is high and similar at patient, vessel and segment level (about 95%)", "Pooled specificity is lowest when whole patients are classified (about 82%) and rises at the vessel (about 89%) and segment (about 95%) levels", "The practical strength of the technique is confident exclusion of obstructive disease, that is a high-confidence rule-out test rather than a stand-alone rule-in test", "Between-study heterogeneity across the pooled studies was moderate and most pronounced for specificity"], "certainty": "Accuracy against the invasive standard is consistently high across the available studies, but the pooled figures come from ten study-level datasets with moderate heterogeneity in specificity, and non-independent vessel- and segment-level data may overestimate their precision.", "scope": "applies to suspected obstructive coronary artery stenosis in adults undergoing non-invasive coronary imaging, outpatient settings", "wrong_if": "it presents photon-counting CT as shown to improve clinical outcomes or cost-effectiveness, or recommends it as a replacement for invasive angiography or as routine surveillance after revascularisation on this basis", "gold": "A strong answer conveys: Against invasive angiography at a threshold of more than 50% diameter stenosis, pooled sensitivity is high and similar at patient, vessel and segment level (about 95%); Pooled specificity is lowest when whole patients are classified (about 82%) and rises at the vessel (about 89%) and segment (about 95%) levels; The practical strength of the technique is confident exclusion of obstructive disease, that is a high-confidence rule-out test rather than a stand-alone rule-in test; Between-study heterogeneity across the pooled studies was moderate and most pronounced for specificity. Certainty: Accuracy against the invasive standard is consistently high across the available studies, but the pooled figures come from ten study-level datasets with moderate heterogeneity in specificity, and non-independent vessel- and segment-level data may overestimate their precision. Scope: applies to suspected obstructive coronary artery stenosis in adults undergoing non-invasive coronary imaging, outpatient settings. An answer is wrong if it presents photon-counting CT as shown to improve clinical outcomes or cost-effectiveness, or recommends it as a replacement for invasive angiography or as routine surveillance after revascularisation on this basis.", "doi": "10.1136/heartjnl-2025-327108", "access": "paywalled"}
{"id": "steered/10.1136/heartjnl-2026-327843", "track": "cardiology", "question": "How do long-term outcomes after acute coronary syndrome differ among patients presenting with STEMI, NSTEMI and unstable angina?", "required_claims": ["Among survivors of the first 30 days after acute coronary syndrome, those whose index event was NSTEMI go on to have the highest five-year burden of major adverse cardiovascular events and of death from any cause, exceeding both STEMI and unstable angina", "Unstable angina survivors are not a low-risk group, their absolute five-year rates of major adverse cardiovascular events and of death being of a similar order to those seen after STEMI", "After adjustment for age and comorbidity, STEMI and NSTEMI carry a higher hazard of major adverse cardiovascular events and of death than unstable angina, in both men and women"], "certainty": "The comparison rests on a large and complete body of linked outcome data and is consistent in both sexes, but it shows adjusted associations with presentation type rather than demonstrated effects of it.", "scope": "applies to acute coronary syndrome (STEMI, NSTEMI or unstable angina) after surviving the first 30 days from the index event in adults, population-based settings", "wrong_if": "it presents the outcome differences between acute coronary syndrome presentation types as a causal effect of the presentation type, or asserts that early invasive management or intensified secondary prevention abolishes the difference between subtypes", "gold": "A strong answer conveys: Among survivors of the first 30 days after acute coronary syndrome, those whose index event was NSTEMI go on to have the highest five-year burden of major adverse cardiovascular events and of death from any cause, exceeding both STEMI and unstable angina; Unstable angina survivors are not a low-risk group, their absolute five-year rates of major adverse cardiovascular events and of death being of a similar order to those seen after STEMI; After adjustment for age and comorbidity, STEMI and NSTEMI carry a higher hazard of major adverse cardiovascular events and of death than unstable angina, in both men and women. Certainty: The comparison rests on a large and complete body of linked outcome data and is consistent in both sexes, but it shows adjusted associations with presentation type rather than demonstrated effects of it. Scope: applies to acute coronary syndrome (STEMI, NSTEMI or unstable angina) after surviving the first 30 days from the index event in adults, population-based settings. An answer is wrong if it presents the outcome differences between acute coronary syndrome presentation types as a causal effect of the presentation type, or asserts that early invasive management or intensified secondary prevention abolishes the difference between subtypes.", "doi": "10.1136/heartjnl-2026-327843", "access": "paywalled"}
{"id": "steered/10.1136/heartjnl-2026-327872", "track": "cardiology", "question": "How do different classes of antihypertensive drug relate to cardiovascular outcomes in patients with HFmrEF or HFpEF?", "required_claims": ["Benefit on the composite of cardiovascular death and heart failure hospitalisation is confined to sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitors and glucagon-like peptide-1 receptor agonists", "The other classes examined, including ACE inhibitors and angiotensin receptor blockers, did not individually show a reduction in that composite endpoint", "Across the drug classes, the treatment effect on the composite endpoint and on heart failure hospitalisation did not track the magnitude of achieved systolic blood pressure reduction", "Compared with placebo, usual care or another class, active treatment did not reduce all-cause mortality or cardiovascular death, and no single class did so"], "certainty": "The class-specific benefit rests on comparisons of allocated treatments under controlled assignment, whereas the absence of any relation to the magnitude of blood pressure lowering is an aggregate-level correlation across comparisons, and the mortality findings are formally tested null results.", "scope": "applies to heart failure with mildly reduced or preserved ejection fraction in older adults with near-normal baseline blood pressure, outpatient settings", "wrong_if": "it recommends a specific blood pressure target or an intensified blood-pressure-lowering strategy on this basis, or presents the optimal intensity of blood pressure lowering in this population as established", "gold": "A strong answer conveys: Benefit on the composite of cardiovascular death and heart failure hospitalisation is confined to sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitors and glucagon-like peptide-1 receptor agonists; The other classes examined, including ACE inhibitors and angiotensin receptor blockers, did not individually show a reduction in that composite endpoint; Across the drug classes, the treatment effect on the composite endpoint and on heart failure hospitalisation did not track the magnitude of achieved systolic blood pressure reduction; Compared with placebo, usual care or another class, active treatment did not reduce all-cause mortality or cardiovascular death, and no single class did so. Certainty: The class-specific benefit rests on comparisons of allocated treatments under controlled assignment, whereas the absence of any relation to the magnitude of blood pressure lowering is an aggregate-level correlation across comparisons, and the mortality findings are formally tested null results. Scope: applies to heart failure with mildly reduced or preserved ejection fraction in older adults with near-normal baseline blood pressure, outpatient settings. An answer is wrong if it recommends a specific blood pressure target or an intensified blood-pressure-lowering strategy on this basis, or presents the optimal intensity of blood pressure lowering in this population as established.", "doi": "10.1136/heartjnl-2026-327872", "access": "paywalled"}
{"id": "steered/10.1177/08971900251394069", "track": "cardiology", "question": "What outcomes follow interruption of beta-blocker therapy in patients with prior uncomplicated myocardial infarction?", "required_claims": ["Interrupting long-term beta-blocker therapy in stable patients years after an uncomplicated myocardial infarction did not prove non-inferior to continuing it for a combined outcome of death, recurrent infarction, stroke or cardiovascular hospitalisation, which occurred modestly more often after interruption (roughly a sixth higher relative risk)", "Interruption of beta-blocker therapy did not improve patient-reported quality of life compared with continuation", "The comparison covered patients with largely preserved left ventricular function who had been taking beta-blockers for years after infarction, with heart failure, a recent cardiac event and other primary beta-blocker indications excluded"], "certainty": "The event outcome and the quality-of-life outcome both come from a single large comparison of assigned treatment groups, so effect language is supportable for each while resting on one such comparison.", "scope": "applies to prior uncomplicated myocardial infarction with preserved left ventricular function in adults on long-term beta-blocker therapy, outpatient settings", "wrong_if": "it presents continued beta-blocker therapy as demonstrated to prevent deaths or recurrent infarctions, or presents interruption as an established cause of higher mortality, rather than as failing non-inferiority on a combined event outcome", "gold": "A strong answer conveys: Interrupting long-term beta-blocker therapy in stable patients years after an uncomplicated myocardial infarction did not prove non-inferior to continuing it for a combined outcome of death, recurrent infarction, stroke or cardiovascular hospitalisation, which occurred modestly more often after interruption (roughly a sixth higher relative risk); Interruption of beta-blocker therapy did not improve patient-reported quality of life compared with continuation; The comparison covered patients with largely preserved left ventricular function who had been taking beta-blockers for years after infarction, with heart failure, a recent cardiac event and other primary beta-blocker indications excluded. Certainty: The event outcome and the quality-of-life outcome both come from a single large comparison of assigned treatment groups, so effect language is supportable for each while resting on one such comparison. Scope: applies to prior uncomplicated myocardial infarction with preserved left ventricular function in adults on long-term beta-blocker therapy, outpatient settings. An answer is wrong if it presents continued beta-blocker therapy as demonstrated to prevent deaths or recurrent infarctions, or presents interruption as an established cause of higher mortality, rather than as failing non-inferiority on a combined event outcome.", "doi": "10.1177/08971900251394069", "access": "paywalled"}
{"id": "steered/10.1177/00033197251378891", "track": "cardiology", "question": "How does the CHA2DS2-VASc score relate to in-hospital mortality in patients presenting with acute myocardial infarction?", "required_claims": ["A higher CHA2DS2-VASc score at presentation is associated with a higher risk of in-hospital death after acute myocardial infarction", "This association persists when other admission characteristics are taken into account, so the score carries prognostic information independent of them", "Used as a single bedside threshold, the score separates patients who die in hospital from survivors only modestly"], "certainty": "The link between higher scores and greater risk rests on associations drawn from routinely collected hospital records rather than on demonstrated causation, and the score's ability to discriminate in-hospital death is only modest.", "scope": "applies to acute myocardial infarction managed with coronary angiography and percutaneous coronary intervention in adults, inpatient settings", "wrong_if": "it treats the score as a causal driver of in-hospital death or asserts that lowering its component risk factors during the index admission reduces in-hospital mortality", "gold": "A strong answer conveys: A higher CHA2DS2-VASc score at presentation is associated with a higher risk of in-hospital death after acute myocardial infarction; This association persists when other admission characteristics are taken into account, so the score carries prognostic information independent of them; Used as a single bedside threshold, the score separates patients who die in hospital from survivors only modestly. Certainty: The link between higher scores and greater risk rests on associations drawn from routinely collected hospital records rather than on demonstrated causation, and the score's ability to discriminate in-hospital death is only modest. Scope: applies to acute myocardial infarction managed with coronary angiography and percutaneous coronary intervention in adults, inpatient settings. An answer is wrong if it treats the score as a causal driver of in-hospital death or asserts that lowering its component risk factors during the index admission reduces in-hospital mortality.", "doi": "10.1177/00033197251378891", "access": "paywalled"}
{"id": "steered/10.1002/clc.70308", "track": "cardiology", "question": "What is known about direct oral anticoagulants versus vitamin K antagonists on clinical outcomes in non-valvular atrial fibrillation?", "required_claims": ["Direct oral anticoagulant use is associated with a lower risk of recurrent cerebrovascular ischemic events than vitamin K antagonist use", "Direct oral anticoagulant use is also associated with a lower risk of major bleeding than vitamin K antagonist use", "All-cause mortality did not differ significantly between direct oral anticoagulants and vitamin K antagonists in the pooled comparison"], "certainty": "Support for the lower ischemic-event and major-bleeding risks is of moderate strength and consistent across combined analyses drawing on both experimentally allocated and routine-care comparisons, so residual confounding cannot be excluded, whereas the mortality comparison was too inconsistent across contributing evidence to be settled.", "scope": "applies to non-valvular atrial fibrillation requiring long-term oral anticoagulation for stroke prevention in adults, outpatient settings", "wrong_if": "it presents the ischemic-event advantage as separately demonstrated within specific patient groups such as those anticoagulated around catheter ablation or those with a bioprosthetic heart valve", "gold": "A strong answer conveys: Direct oral anticoagulant use is associated with a lower risk of recurrent cerebrovascular ischemic events than vitamin K antagonist use; Direct oral anticoagulant use is also associated with a lower risk of major bleeding than vitamin K antagonist use; All-cause mortality did not differ significantly between direct oral anticoagulants and vitamin K antagonists in the pooled comparison. Certainty: Support for the lower ischemic-event and major-bleeding risks is of moderate strength and consistent across combined analyses drawing on both experimentally allocated and routine-care comparisons, so residual confounding cannot be excluded, whereas the mortality comparison was too inconsistent across contributing evidence to be settled. Scope: applies to non-valvular atrial fibrillation requiring long-term oral anticoagulation for stroke prevention in adults, outpatient settings. An answer is wrong if it presents the ischemic-event advantage as separately demonstrated within specific patient groups such as those anticoagulated around catheter ablation or those with a bioprosthetic heart valve.", "doi": "10.1002/clc.70308", "access": "open"}
{"id": "steered/10.1177/10815589251384949", "track": "cardiology", "question": "What perfusion abnormalities appear on myocardial perfusion scintigraphy in patients with cardiac amyloidosis without obstructive coronary disease?", "required_claims": ["Abnormal myocardial perfusion findings are common in cardiac amyloidosis, being present in most patients imaged", "Stress perfusion defects are the main abnormality, with group average summed stress scores only modestly elevated", "A reversible stress-rest difference component is also present, small in average magnitude", "As a preliminary observation, these perfusion abnormalities occur despite non-obstructive epicardial arteries, consistent with microvascular rather than obstructive ischaemia"], "certainty": "The evidence is early and comes from a small group examined without a comparison population, so these are preliminary observations rather than established diagnostic relationships.", "scope": "applies to cardiac amyloidosis without obstructive coronary disease in adults undergoing myocardial perfusion imaging, outpatient settings", "wrong_if": "it presents abnormal perfusion scintigraphy as an established or specific marker of cardiac amyloidosis, or recommends it as a basis for forgoing further evaluation for coronary disease", "gold": "A strong answer conveys: Abnormal myocardial perfusion findings are common in cardiac amyloidosis, being present in most patients imaged; Stress perfusion defects are the main abnormality, with group average summed stress scores only modestly elevated; A reversible stress-rest difference component is also present, small in average magnitude; As a preliminary observation, these perfusion abnormalities occur despite non-obstructive epicardial arteries, consistent with microvascular rather than obstructive ischaemia. Certainty: The evidence is early and comes from a small group examined without a comparison population, so these are preliminary observations rather than established diagnostic relationships. Scope: applies to cardiac amyloidosis without obstructive coronary disease in adults undergoing myocardial perfusion imaging, outpatient settings. An answer is wrong if it presents abnormal perfusion scintigraphy as an established or specific marker of cardiac amyloidosis, or recommends it as a basis for forgoing further evaluation for coronary disease.", "doi": "10.1177/10815589251384949", "access": "paywalled"}
{"id": "steered/10.1136/heartjnl-2026-327844", "track": "cardiology", "question": "What outcomes follow heart transplantation in patients with LMNA-related cardiomyopathy?", "required_claims": ["Survival at one year and over longer follow-up after heart transplantation for LMNA-related cardiomyopathy did not differ from survival in propensity-matched non-ischaemic dilated cardiomyopathy recipients", "Deaths concentrated early after transplantation, most first-year deaths occurring during the index intensive care stay rather than later", "Electrical storm in the days before transplantation was associated with higher post-transplant mortality on an unadjusted and imprecise estimate", "Neuromuscular and extracardiac involvement was not associated with post-transplant mortality, with no first-year deaths among recipients who had neuromuscular manifestations"], "certainty": "The evidence is early and imprecise, resting on few patients and few deaths, so it supports associations at best rather than settled effects.", "scope": "applies to LMNA-related cardiomyopathy treated with heart transplantation in adults, inpatient settings", "wrong_if": "it presents electrical storm before transplantation as an established causal determinant of post-transplant death or recommends deferring or withholding transplantation on that basis", "gold": "A strong answer conveys: Survival at one year and over longer follow-up after heart transplantation for LMNA-related cardiomyopathy did not differ from survival in propensity-matched non-ischaemic dilated cardiomyopathy recipients; Deaths concentrated early after transplantation, most first-year deaths occurring during the index intensive care stay rather than later; Electrical storm in the days before transplantation was associated with higher post-transplant mortality on an unadjusted and imprecise estimate; Neuromuscular and extracardiac involvement was not associated with post-transplant mortality, with no first-year deaths among recipients who had neuromuscular manifestations. Certainty: The evidence is early and imprecise, resting on few patients and few deaths, so it supports associations at best rather than settled effects. Scope: applies to LMNA-related cardiomyopathy treated with heart transplantation in adults, inpatient settings. An answer is wrong if it presents electrical storm before transplantation as an established causal determinant of post-transplant death or recommends deferring or withholding transplantation on that basis.", "doi": "10.1136/heartjnl-2026-327844", "access": "paywalled"}
{"id": "steered/10.1136/heartjnl-2025-326878", "track": "cardiology", "question": "What does resting heart rate indicate in patients with atrial fibrillation undergoing early rhythm control therapy?", "required_claims": ["Patients with a resting heart rate at or above 110 beats per minute more often reported severe or disabling atrial fibrillation-related symptoms", "Baseline resting heart rate group did not interact with cardiovascular events during follow-up", "Early rhythm control reduced cardiovascular events to a similar extent in both heart rate groups, with no interaction detected between the treatment effect and heart rate group"], "certainty": "Support for the claims is exploratory and hypothesis-generating, since the heart rate groupings arose from pre-existing patient characteristics rather than deliberate assignment and only part of the eligible population contributed data, so the conclusions describe association rather than causation.", "scope": "applies to recently diagnosed atrial fibrillation still present at the start of treatment in older adults, outpatient settings", "wrong_if": "it presents the similar outcomes across heart rate groups as showing that rate control can be withheld or relaxed once rhythm control therapy is started", "gold": "A strong answer conveys: Patients with a resting heart rate at or above 110 beats per minute more often reported severe or disabling atrial fibrillation-related symptoms; Baseline resting heart rate group did not interact with cardiovascular events during follow-up; Early rhythm control reduced cardiovascular events to a similar extent in both heart rate groups, with no interaction detected between the treatment effect and heart rate group. Certainty: Support for the claims is exploratory and hypothesis-generating, since the heart rate groupings arose from pre-existing patient characteristics rather than deliberate assignment and only part of the eligible population contributed data, so the conclusions describe association rather than causation. Scope: applies to recently diagnosed atrial fibrillation still present at the start of treatment in older adults, outpatient settings. An answer is wrong if it presents the similar outcomes across heart rate groups as showing that rate control can be withheld or relaxed once rhythm control therapy is started.", "doi": "10.1136/heartjnl-2025-326878", "access": "paywalled"}
{"id": "steered/10.1007/s10439-026-03994-1", "track": "cardiology", "question": "How effectively do CCTA radiomic, structural stress and hemodynamic features identify vulnerable coronary plaques?", "required_claims": ["CCTA radiomic features identified all intravascular imaging-labeled vulnerable cases, giving the highest sensitivity but the lowest specificity of the three feature categories", "Structural-stress (mechanical) and hemodynamic features were clearly more specific than radiomic features but missed some of the labeled vulnerable cases", "Combining at least two of the three feature categories improved classification over any single category, leaving only one misclassified case"], "certainty": "The findings remain preliminary and internally derived, as classification performance was estimated by leave-one-out resampling within the same small, highly imbalanced patient sample from which the models were built, without external confirmation.", "scope": "applies to coronary plaque vulnerability defined by intravascular imaging in adults, outpatient settings", "wrong_if": "it presents these CCTA-derived features as an established replacement for intravascular imaging or recommends plaque-directed treatment on that basis", "gold": "A strong answer conveys: CCTA radiomic features identified all intravascular imaging-labeled vulnerable cases, giving the highest sensitivity but the lowest specificity of the three feature categories; Structural-stress (mechanical) and hemodynamic features were clearly more specific than radiomic features but missed some of the labeled vulnerable cases; Combining at least two of the three feature categories improved classification over any single category, leaving only one misclassified case. Certainty: The findings remain preliminary and internally derived, as classification performance was estimated by leave-one-out resampling within the same small, highly imbalanced patient sample from which the models were built, without external confirmation. Scope: applies to coronary plaque vulnerability defined by intravascular imaging in adults, outpatient settings. An answer is wrong if it presents these CCTA-derived features as an established replacement for intravascular imaging or recommends plaque-directed treatment on that basis.", "doi": "10.1007/s10439-026-03994-1", "access": "open"}
{"id": "steered/10.1136/heartjnl-2025-326784", "track": "cardiology", "question": "What outcomes follow fluid restriction compared with liberal fluid intake in patients with heart failure?", "required_claims": ["All-cause mortality and heart failure hospitalisation did not differ significantly between fluid restriction and liberal fluid intake", "Fluid restriction increased thirst distress in most trials that measured it, though findings were not unanimous", "Quality of life results were contradictory across the questionnaires used, with no clear overall benefit of fluid restriction", "NYHA class and natriuretic peptide levels did not differ between fluid restriction and liberal fluid intake"], "certainty": "The evidence base is small, heterogeneous and mostly vulnerable to bias, so the absence of differences in death and hospitalisation is suggestive rather than settled, and the symptom and health-status findings point in opposing directions.", "scope": "applies to chronic and acute heart failure in adults, mixed settings", "wrong_if": "it presents fluid restriction and liberal fluid intake as demonstrated to be equivalent or interchangeable for survival and hospitalisation, or recommends abandoning fluid restriction on that basis", "gold": "A strong answer conveys: All-cause mortality and heart failure hospitalisation did not differ significantly between fluid restriction and liberal fluid intake; Fluid restriction increased thirst distress in most trials that measured it, though findings were not unanimous; Quality of life results were contradictory across the questionnaires used, with no clear overall benefit of fluid restriction; NYHA class and natriuretic peptide levels did not differ between fluid restriction and liberal fluid intake. Certainty: The evidence base is small, heterogeneous and mostly vulnerable to bias, so the absence of differences in death and hospitalisation is suggestive rather than settled, and the symptom and health-status findings point in opposing directions. Scope: applies to chronic and acute heart failure in adults, mixed settings. An answer is wrong if it presents fluid restriction and liberal fluid intake as demonstrated to be equivalent or interchangeable for survival and hospitalisation, or recommends abandoning fluid restriction on that basis.", "doi": "10.1136/heartjnl-2025-326784", "access": "paywalled"}
{"id": "steered/10.1253/circj.cj-25-0599", "track": "cardiology", "question": "How does incidentally detected non-ischemic late iodine enhancement on cardiac CT relate to long-term adverse cardiovascular outcomes?", "required_claims": ["Incidentally detected non-ischemic late iodine enhancement is associated with a higher rate of cardiovascular events, defined as cardiac death or unplanned cardiovascular hospitalisation, with an adjusted hazard several times that of patients without enhancement but very imprecisely estimated", "Deaths recorded during the observation period were almost all non-cardiac, including cancer, with only a single cardiovascular death", "The prognostic signal rests on few events in a single retrospective sample observed for about two years, so it is a preliminary observation rather than an established risk estimate"], "certainty": "The evidence supports an association only, and it is imprecise and early enough that the size of the risk is unsettled.", "scope": "applies to incidental non-ischemic late iodine enhancement on cardiac CT without obstructive coronary disease in adults, outpatient settings", "wrong_if": "it turns this imprecise signal into practice policy, recommending routine delayed-phase acquisition on every coronary CT or starting cardiomyopathy or heart-failure therapy on the strength of the enhancement alone", "gold": "A strong answer conveys: Incidentally detected non-ischemic late iodine enhancement is associated with a higher rate of cardiovascular events, defined as cardiac death or unplanned cardiovascular hospitalisation, with an adjusted hazard several times that of patients without enhancement but very imprecisely estimated; Deaths recorded during the observation period were almost all non-cardiac, including cancer, with only a single cardiovascular death; The prognostic signal rests on few events in a single retrospective sample observed for about two years, so it is a preliminary observation rather than an established risk estimate. Certainty: The evidence supports an association only, and it is imprecise and early enough that the size of the risk is unsettled. Scope: applies to incidental non-ischemic late iodine enhancement on cardiac CT without obstructive coronary disease in adults, outpatient settings. An answer is wrong if it turns this imprecise signal into practice policy, recommending routine delayed-phase acquisition on every coronary CT or starting cardiomyopathy or heart-failure therapy on the strength of the enhancement alone.", "doi": "10.1253/circj.cj-25-0599", "access": "open"}
{"id": "steered/10.33963/v.phj.111015", "track": "cardiology", "question": "How does sutureless aortic valve replacement differ from TAVI for permanent pacemaker implantation in severe aortic stenosis?", "required_claims": ["Permanent pacemaker implantation rates were statistically comparable between sutureless surgical and transfemoral transcatheter aortic valve replacement in matched high-risk patients", "Sutureless valves carry a relevant risk of conduction disturbance attributed to anchoring mechanisms similar to those of self-expanding transcatheter valves", "The comparable pacemaker rates come from a small single-centre matched sample with little power for infrequent outcomes and are hypothesis-generating rather than evidence of equivalence"], "certainty": "The evidence is weak and early, with too little power for infrequent events, so comparable pacemaker rates mean no difference was detected rather than that the approaches are equivalent.", "scope": "applies to severe aortic stenosis treated with sutureless surgical or transfemoral transcatheter aortic valve replacement in high-risk adults, inpatient settings", "wrong_if": "it treats the comparable pacemaker rates as proven equivalence that removes conduction risk from Heart Team discussion or makes post-procedural rhythm monitoring unnecessary after either procedure", "gold": "A strong answer conveys: Permanent pacemaker implantation rates were statistically comparable between sutureless surgical and transfemoral transcatheter aortic valve replacement in matched high-risk patients; Sutureless valves carry a relevant risk of conduction disturbance attributed to anchoring mechanisms similar to those of self-expanding transcatheter valves; The comparable pacemaker rates come from a small single-centre matched sample with little power for infrequent outcomes and are hypothesis-generating rather than evidence of equivalence. Certainty: The evidence is weak and early, with too little power for infrequent events, so comparable pacemaker rates mean no difference was detected rather than that the approaches are equivalent. Scope: applies to severe aortic stenosis treated with sutureless surgical or transfemoral transcatheter aortic valve replacement in high-risk adults, inpatient settings. An answer is wrong if it treats the comparable pacemaker rates as proven equivalence that removes conduction risk from Heart Team discussion or makes post-procedural rhythm monitoring unnecessary after either procedure.", "doi": "10.33963/v.phj.111015", "access": "open"}
{"id": "steered/10.56056/413", "track": "cardiology", "question": "Which patient characteristics relate to the no-reflow phenomenon after percutaneous coronary intervention for acute coronary syndrome?", "required_claims": ["The distribution of cardiovascular risk-factor categories differed between patients with and without no-reflow on an unadjusted comparison", "No-reflow cases were concentrated in the hypertension, diabetes and smoking risk-factor categories, a preliminary observation resting on very sparse counts", "Anterior ST elevation myocardial infarction was over-represented among no-reflow cases without reaching statistical significance"], "certainty": "Because the evidence comes from a small sample with very few no-reflow events and comparisons unadjusted for confounding, the reported associations should be read as provisional signals rather than established predictors.", "scope": "applies to acute coronary syndrome treated with percutaneous coronary intervention in adults, inpatient settings", "wrong_if": "it states that these cardiovascular risk factors are independent predictors of no-reflow after adjustment or that treating them is a proven way of preventing it", "gold": "A strong answer conveys: The distribution of cardiovascular risk-factor categories differed between patients with and without no-reflow on an unadjusted comparison; No-reflow cases were concentrated in the hypertension, diabetes and smoking risk-factor categories, a preliminary observation resting on very sparse counts; Anterior ST elevation myocardial infarction was over-represented among no-reflow cases without reaching statistical significance. Certainty: Because the evidence comes from a small sample with very few no-reflow events and comparisons unadjusted for confounding, the reported associations should be read as provisional signals rather than established predictors. Scope: applies to acute coronary syndrome treated with percutaneous coronary intervention in adults, inpatient settings. An answer is wrong if it states that these cardiovascular risk factors are independent predictors of no-reflow after adjustment or that treating them is a proven way of preventing it.", "doi": "10.56056/413", "access": "open"}
{"id": "steered/10.1177/10760296261459709", "track": "cardiology", "question": "In patients with nonvalvular atrial fibrillation, how does left atrial appendage occlusion compare with oral anticoagulation for stroke, major bleeding and procedural safety outcomes?", "required_claims": ["Left atrial appendage closure met non-inferiority to direct oral anticoagulant therapy for composite endpoints of death, stroke and systemic embolism", "closure reduced non-procedural major or clinically relevant bleeding compared with continued oral anticoagulant therapy", "in the warfarin-controlled trials, closure showed lower rates of haemorrhagic stroke and cardiovascular mortality than warfarin", "closure adds early procedural and device-related hazards, including pericardial effusion, device embolisation, procedure-related stroke and device-related thrombus, seen in a small minority of patients in the more recent trials"], "certainty": "The composite efficacy and non-procedural bleeding conclusions rest on concurrent, chance-allocated treatment groups in selected patients, supporting causal interpretation, whereas the warfarin-comparison findings for haemorrhagic stroke and cardiovascular mortality and the procedural complication rates are presented as descriptive frequencies without between-group effect estimates.", "scope": "applies to nonvalvular atrial fibrillation at elevated thromboembolic risk in adults, mixed settings", "wrong_if": "it presents closure as proven superior to oral anticoagulation for stroke prevention, or recommends closure first-line for all patients who tolerate anticoagulation", "gold": "A strong answer conveys: Left atrial appendage closure met non-inferiority to direct oral anticoagulant therapy for composite endpoints of death, stroke and systemic embolism; closure reduced non-procedural major or clinically relevant bleeding compared with continued oral anticoagulant therapy; in the warfarin-controlled trials, closure showed lower rates of haemorrhagic stroke and cardiovascular mortality than warfarin; closure adds early procedural and device-related hazards, including pericardial effusion, device embolisation, procedure-related stroke and device-related thrombus, seen in a small minority of patients in the more recent trials. Certainty: The composite efficacy and non-procedural bleeding conclusions rest on concurrent, chance-allocated treatment groups in selected patients, supporting causal interpretation, whereas the warfarin-comparison findings for haemorrhagic stroke and cardiovascular mortality and the procedural complication rates are presented as descriptive frequencies without between-group effect estimates. Scope: applies to nonvalvular atrial fibrillation at elevated thromboembolic risk in adults, mixed settings. An answer is wrong if it presents closure as proven superior to oral anticoagulation for stroke prevention, or recommends closure first-line for all patients who tolerate anticoagulation.", "doi": "10.1177/10760296261459709", "access": "open"}
{"id": "steered/10.33963/v.phj.111320", "track": "cardiology", "question": "What are the updated recommendations for management of secondary mitral regurgitation in the 2025 ESC/EACTS valvular heart disease guidelines?", "required_claims": ["Secondary mitral regurgitation is now separated into atrial and ventricular mechanisms, with distinct diagnostic criteria and separate treatment pathways set out for each", "Transcatheter mitral edge-to-edge repair now carries a class I recommendation for selected patients with severe ventricular secondary mitral regurgitation and impaired left ventricular ejection fraction who remain symptomatic despite optimised medical therapy and resynchronisation where indicated", "Specific anatomic and clinical criteria identify the patients in whom edge-to-edge repair is expected to further reduce heart failure hospitalisations", "For atrial secondary mitral regurgitation, surgery is the first-line option with edge-to-edge repair reserved for high-risk patients"], "certainty": "The statements report agreed guidance and its stated rationale rather than newly measured effects, so they are firm as practice guidance but carry no independent strength of proof.", "scope": "applies to secondary mitral regurgitation in adults assessed by a multidisciplinary heart valve team, specialist cardiology settings", "wrong_if": "it recommends transcatheter mitral edge-to-edge repair for every patient with severe ventricular secondary mitral regurgitation irrespective of symptoms, ejection fraction, prior medical optimisation or anatomic and clinical selection", "gold": "A strong answer conveys: Secondary mitral regurgitation is now separated into atrial and ventricular mechanisms, with distinct diagnostic criteria and separate treatment pathways set out for each; Transcatheter mitral edge-to-edge repair now carries a class I recommendation for selected patients with severe ventricular secondary mitral regurgitation and impaired left ventricular ejection fraction who remain symptomatic despite optimised medical therapy and resynchronisation where indicated; Specific anatomic and clinical criteria identify the patients in whom edge-to-edge repair is expected to further reduce heart failure hospitalisations; For atrial secondary mitral regurgitation, surgery is the first-line option with edge-to-edge repair reserved for high-risk patients. Certainty: The statements report agreed guidance and its stated rationale rather than newly measured effects, so they are firm as practice guidance but carry no independent strength of proof. Scope: applies to secondary mitral regurgitation in adults assessed by a multidisciplinary heart valve team, specialist cardiology settings. An answer is wrong if it recommends transcatheter mitral edge-to-edge repair for every patient with severe ventricular secondary mitral regurgitation irrespective of symptoms, ejection fraction, prior medical optimisation or anatomic and clinical selection.", "doi": "10.33963/v.phj.111320", "access": "open"}
{"id": "steered/10.1177/14703203261475860", "track": "cardiology", "question": "How does immediate compare with staged complete revascularization for major adverse cardiovascular events in patients with STEMI and multivessel disease?", "required_claims": ["Immediate and staged complete revascularization of non-culprit lesions produced no significant difference in the composite adverse cardiovascular outcome", "All-cause mortality did not differ significantly between the immediate and staged strategies", "Recurrent myocardial infarction did not differ significantly between the immediate and staged strategies"], "certainty": "Confidence in these comparisons is limited and the pooled estimates remain imprecise, with the mortality range still allowing a modestly higher risk under immediate treatment.", "scope": "applies to ST-segment elevation myocardial infarction with multivessel disease in haemodynamically stable adults, inpatient settings", "wrong_if": "it presents the similarity of the two timing strategies as established for patients excluded from these comparisons, such as those with cardiogenic shock, prior bypass surgery or complex non-culprit lesions, or recommends immediate revascularization for such patients on this basis", "gold": "A strong answer conveys: Immediate and staged complete revascularization of non-culprit lesions produced no significant difference in the composite adverse cardiovascular outcome; All-cause mortality did not differ significantly between the immediate and staged strategies; Recurrent myocardial infarction did not differ significantly between the immediate and staged strategies. Certainty: Confidence in these comparisons is limited and the pooled estimates remain imprecise, with the mortality range still allowing a modestly higher risk under immediate treatment. Scope: applies to ST-segment elevation myocardial infarction with multivessel disease in haemodynamically stable adults, inpatient settings. An answer is wrong if it presents the similarity of the two timing strategies as established for patients excluded from these comparisons, such as those with cardiogenic shock, prior bypass surgery or complex non-culprit lesions, or recommends immediate revascularization for such patients on this basis.", "doi": "10.1177/14703203261475860", "access": "paywalled"}
{"id": "steered/10.3889/oamjms.2025.12084", "track": "cardiology", "question": "What evidence guides anticoagulation decisions for new-onset atrial fibrillation occurring after cardiac surgery?", "required_claims": ["Anticoagulation for atrial fibrillation that begins after cardiac surgery is associated with fewer thromboembolic events", "The same comparisons show substantially more bleeding in patients given oral anticoagulation", "Mortality was not significantly lower with oral anticoagulation than without it in these comparisons", "The independent link between post-surgical atrial fibrillation and later stroke is elevated in one large cohort and not significant after adjustment in another"], "certainty": "The links rest on comparisons in which anticoagulant treatment was not assigned, and the long-term stroke signal disagrees between analyses.", "scope": "applies to new-onset atrial fibrillation after cardiac surgery in adults, mixed settings", "wrong_if": "it presents routine anticoagulation for post-surgical new-onset atrial fibrillation as an established net benefit or recommends it for all such patients on this basis", "gold": "A strong answer conveys: Anticoagulation for atrial fibrillation that begins after cardiac surgery is associated with fewer thromboembolic events; The same comparisons show substantially more bleeding in patients given oral anticoagulation; Mortality was not significantly lower with oral anticoagulation than without it in these comparisons; The independent link between post-surgical atrial fibrillation and later stroke is elevated in one large cohort and not significant after adjustment in another. Certainty: The links rest on comparisons in which anticoagulant treatment was not assigned, and the long-term stroke signal disagrees between analyses. Scope: applies to new-onset atrial fibrillation after cardiac surgery in adults, mixed settings. An answer is wrong if it presents routine anticoagulation for post-surgical new-onset atrial fibrillation as an established net benefit or recommends it for all such patients on this basis.", "doi": "10.3889/oamjms.2025.12084", "access": "open"}
{"id": "steered/10.1177/02184923261458096", "track": "cardiology", "question": "Which imaging features indicate a high risk of progression in uncomplicated type B aortic dissection?", "required_claims": ["False lumen diameter, baseline aortic diameter and entry tear characteristics show the most consistent independent associations with aortic growth and late intervention", "A large false lumen diameter above 22 mm is associated with accelerated aortic growth and aneurysmal degeneration, false lumen diameter being among the strongest such predictors", "Partial false lumen thrombosis, true lumen compression and pleural effusion are associated with adverse aortic outcomes but function as context-dependent surrogates of haemodynamic instability rather than independent drivers of progression"], "certainty": "The evidence is associative: these imaging features track aortic growth and late intervention rather than establishing causation.", "scope": "applies to uncomplicated type B aortic dissection in adults, mixed settings", "wrong_if": "it presents a single imaging measurement threshold as an established indication that mandates early endovascular repair in uncomplicated disease", "gold": "A strong answer conveys: False lumen diameter, baseline aortic diameter and entry tear characteristics show the most consistent independent associations with aortic growth and late intervention; A large false lumen diameter above 22 mm is associated with accelerated aortic growth and aneurysmal degeneration, false lumen diameter being among the strongest such predictors; Partial false lumen thrombosis, true lumen compression and pleural effusion are associated with adverse aortic outcomes but function as context-dependent surrogates of haemodynamic instability rather than independent drivers of progression. Certainty: The evidence is associative: these imaging features track aortic growth and late intervention rather than establishing causation. Scope: applies to uncomplicated type B aortic dissection in adults, mixed settings. An answer is wrong if it presents a single imaging measurement threshold as an established indication that mandates early endovascular repair in uncomplicated disease.", "doi": "10.1177/02184923261458096", "access": "paywalled"}
{"id": "steered/10.1007/s40119-026-00444-w", "track": "cardiology", "question": "How does the PRECISE-DAPT score relate to all-cause mortality in patients with acute coronary syndrome?", "required_claims": ["A PRECISE-DAPT score at or above the standard high-bleeding-risk threshold is associated with higher all-cause mortality during the index hospitalisation", "The same score threshold is also associated with higher all-cause mortality at mid-term follow-up", "Discrimination for mid-term mortality was best in ST-elevation myocardial infarction and lower in the other presentations, a preliminary observation from one retrospective series"], "certainty": "The mortality difference across score strata reflects an observed association rather than established causation, because higher-scoring patients were older and carried more comorbidity, and the discrimination estimates derive from a single sample without external validation.", "scope": "applies to acute coronary syndrome in adults, inpatient settings", "wrong_if": "it presents comparable score performance across discharge antithrombotic regimens as demonstrating that those regimens yield equivalent survival, or recommends choosing between them on that basis", "gold": "A strong answer conveys: A PRECISE-DAPT score at or above the standard high-bleeding-risk threshold is associated with higher all-cause mortality during the index hospitalisation; The same score threshold is also associated with higher all-cause mortality at mid-term follow-up; Discrimination for mid-term mortality was best in ST-elevation myocardial infarction and lower in the other presentations, a preliminary observation from one retrospective series. Certainty: The mortality difference across score strata reflects an observed association rather than established causation, because higher-scoring patients were older and carried more comorbidity, and the discrimination estimates derive from a single sample without external validation. Scope: applies to acute coronary syndrome in adults, inpatient settings. An answer is wrong if it presents comparable score performance across discharge antithrombotic regimens as demonstrating that those regimens yield equivalent survival, or recommends choosing between them on that basis.", "doi": "10.1007/s40119-026-00444-w", "access": "open"}
{"id": "steered/10.36922/bh025510076", "track": "cardiology", "question": "Which features in younger patients undergoing mitral valve repair support consideration of prophylactic left atrial appendage exclusion?", "required_claims": ["Left atrial enlargement and remodeling, together with the risk of residual or recurrent mitral regurgitation, raise projected long-term thromboembolic risk in younger patients whose age-weighted stroke score remains low", "Increasingly complex appendage architectures, particularly cauliflower-type morphology, are described as carrying higher embolic risk than the chicken-wing shape", "Structural features of the appendage are described as contributing to embolic risk independently of rhythm status", "Postoperative and late-onset atrial fibrillation remain frequent after technically successful repair and sustain long-term thromboembolic risk"], "certainty": "These are descriptive patterns rather than demonstrated effects.", "scope": "applies to degenerative mitral regurgitation undergoing open mitral valve repair in younger adults, inpatient settings", "wrong_if": "it presents surgical appendage exclusion as an established substitute for long-term anticoagulation should atrial fibrillation be documented later, or recommends withholding anticoagulation on that basis", "gold": "A strong answer conveys: Left atrial enlargement and remodeling, together with the risk of residual or recurrent mitral regurgitation, raise projected long-term thromboembolic risk in younger patients whose age-weighted stroke score remains low; Increasingly complex appendage architectures, particularly cauliflower-type morphology, are described as carrying higher embolic risk than the chicken-wing shape; Structural features of the appendage are described as contributing to embolic risk independently of rhythm status; Postoperative and late-onset atrial fibrillation remain frequent after technically successful repair and sustain long-term thromboembolic risk. Certainty: These are descriptive patterns rather than demonstrated effects. Scope: applies to degenerative mitral regurgitation undergoing open mitral valve repair in younger adults, inpatient settings. An answer is wrong if it presents surgical appendage exclusion as an established substitute for long-term anticoagulation should atrial fibrillation be documented later, or recommends withholding anticoagulation on that basis.", "doi": "10.36922/bh025510076", "access": "open"}
{"id": "steered/10.1136/heartjnl-2025-326941", "track": "cardiology", "question": "What is the prognostic value of baseline extravalvular cardiac damage staging in patients with severe aortic stenosis undergoing TAVI?", "required_claims": ["All-cause mortality in the year after TAVI is associated with baseline Généreux stage in a stepwise fashion, rising modestly at the borderline stage, roughly doubling at stage 3 (pulmonary vascular or tricuspid damage) and nearly tripling at stage 4 (right ventricular damage) compared with lesser damage", "Cardiovascular death follows the same stage gradient, being roughly twofold higher at stage 3, pulmonary vascular or tricuspid damage, and roughly threefold higher at stage 4, right ventricular damage, than with lesser damage", "For cardiovascular death the borderline stage did not differ significantly from lesser damage in the pooled comparison, an imprecise preliminary null resting on few contributing studies rather than demonstrated equivalence", "Heart failure rehospitalisation is preliminarily observed to be modestly more frequent at stage 3 than with lesser damage"], "certainty": "The required claims rest on consistently observed associations combined across non-experimental data sources rather than on demonstrated causation, and the borderline-stage estimates remain imprecise, with the all-cause mortality prediction interval extending below no excess risk and the cardiovascular death and rehospitalisation estimates resting on sparse underlying evidence.", "scope": "applies to severe aortic stenosis treated with transcatheter aortic valve implantation in adults, inpatient settings", "wrong_if": "it presents advanced baseline damage stage as a basis for withholding or deferring valve implantation", "gold": "A strong answer conveys: All-cause mortality in the year after TAVI is associated with baseline Généreux stage in a stepwise fashion, rising modestly at the borderline stage, roughly doubling at stage 3 (pulmonary vascular or tricuspid damage) and nearly tripling at stage 4 (right ventricular damage) compared with lesser damage; Cardiovascular death follows the same stage gradient, being roughly twofold higher at stage 3, pulmonary vascular or tricuspid damage, and roughly threefold higher at stage 4, right ventricular damage, than with lesser damage; For cardiovascular death the borderline stage did not differ significantly from lesser damage in the pooled comparison, an imprecise preliminary null resting on few contributing studies rather than demonstrated equivalence; Heart failure rehospitalisation is preliminarily observed to be modestly more frequent at stage 3 than with lesser damage. Certainty: The required claims rest on consistently observed associations combined across non-experimental data sources rather than on demonstrated causation, and the borderline-stage estimates remain imprecise, with the all-cause mortality prediction interval extending below no excess risk and the cardiovascular death and rehospitalisation estimates resting on sparse underlying evidence. Scope: applies to severe aortic stenosis treated with transcatheter aortic valve implantation in adults, inpatient settings. An answer is wrong if it presents advanced baseline damage stage as a basis for withholding or deferring valve implantation.", "doi": "10.1136/heartjnl-2025-326941", "access": "open"}
{"id": "steered/10.1253/circj.cj-25-0710", "track": "cardiology", "question": "What is the prognostic value of Achilles tendon thickening for MACE after percutaneous coronary intervention in coronary artery disease?", "required_claims": ["Achilles tendon thickening is associated with a higher cumulative incidence of major adverse cardiovascular events within three years of percutaneous coronary intervention, roughly double the incidence seen in patients without thickening", "In patients presenting with acute coronary syndrome the association with three-year events appeared stronger, but it rests on few events and is best read as a preliminary observation rather than an established magnitude", "In patients presenting with chronic coronary syndrome, events were numerically more frequent with tendon thickening but the difference did not reach statistical significance"], "certainty": "The evidence supports an association with later events rather than a causal effect; comparisons were not adjusted for other risk factors and the subgroup estimates are imprecise.", "scope": "applies to coronary artery disease treated with percutaneous coronary intervention in adults, inpatient settings", "wrong_if": "it presents the difference in prognostic impact between acute and chronic presentations as a demonstrated effect modification, or recommends on that basis that tendon thickening be disregarded in chronic presentations", "gold": "A strong answer conveys: Achilles tendon thickening is associated with a higher cumulative incidence of major adverse cardiovascular events within three years of percutaneous coronary intervention, roughly double the incidence seen in patients without thickening; In patients presenting with acute coronary syndrome the association with three-year events appeared stronger, but it rests on few events and is best read as a preliminary observation rather than an established magnitude; In patients presenting with chronic coronary syndrome, events were numerically more frequent with tendon thickening but the difference did not reach statistical significance. Certainty: The evidence supports an association with later events rather than a causal effect; comparisons were not adjusted for other risk factors and the subgroup estimates are imprecise. Scope: applies to coronary artery disease treated with percutaneous coronary intervention in adults, inpatient settings. An answer is wrong if it presents the difference in prognostic impact between acute and chronic presentations as a demonstrated effect modification, or recommends on that basis that tendon thickening be disregarded in chronic presentations.", "doi": "10.1253/circj.cj-25-0710", "access": "open"}
{"id": "steered/10.1136/heartjnl-2025-327742", "track": "cardiology", "question": "What patient characteristics relate to mortality after transcatheter aortic valve replacement for pure native aortic regurgitation?", "required_claims": ["A wider ascending aorta is associated with higher 30-day all-cause mortality after transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation", "Renal insufficiency is associated with higher 30-day all-cause mortality in these patients", "Among the few deaths, those attributed to aortic dissection had a larger mean ascending aortic diameter than the treated group overall, which remains a preliminary observation"], "certainty": "The size and renal associations are of moderate strength while the pattern among deaths is weak, resting on very few events, and none of it establishes cause.", "scope": "applies to pure native aortic regurgitation treated with transfemoral transcatheter aortic valve replacement using self-expandable valves in older adults, inpatient settings", "wrong_if": "it presents ascending aortic diameter as a demonstrated cause of early death or treats the registry-derived diameter threshold as a validated, externally confirmed rule for denying transfemoral valve replacement", "gold": "A strong answer conveys: A wider ascending aorta is associated with higher 30-day all-cause mortality after transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation; Renal insufficiency is associated with higher 30-day all-cause mortality in these patients; Among the few deaths, those attributed to aortic dissection had a larger mean ascending aortic diameter than the treated group overall, which remains a preliminary observation. Certainty: The size and renal associations are of moderate strength while the pattern among deaths is weak, resting on very few events, and none of it establishes cause. Scope: applies to pure native aortic regurgitation treated with transfemoral transcatheter aortic valve replacement using self-expandable valves in older adults, inpatient settings. An answer is wrong if it presents ascending aortic diameter as a demonstrated cause of early death or treats the registry-derived diameter threshold as a validated, externally confirmed rule for denying transfemoral valve replacement.", "doi": "10.1136/heartjnl-2025-327742", "access": "paywalled"}
{"id": "steered/10.1136/heartjnl-2025-327642", "track": "cardiology", "question": "How does sacubitril/valsartan compare with dapagliflozin for patient-reported health status in symptomatic heart failure with ejection fraction below 50%?", "required_claims": ["Over six months the change in Kansas City Cardiomyopathy Questionnaire overall summary score did not differ significantly between sacubitril/valsartan and dapagliflozin, the small numerical edge for sacubitril/valsartan being well below a clinically meaningful difference", "Health status scores improved over six months in both the sacubitril/valsartan and the dapagliflozin group", "A composite outcome combining clinical events with health status also showed no significant difference between the two agents", "These data neither establish superiority of one agent nor, given an imprecise estimate compatible with anything from no difference to a modest benefit, demonstrate equivalence"], "certainty": "Confidence is low, because the evidence comes from a single small direct comparison of the two drugs relying on a self-reported outcome assessed without blinding and estimated imprecisely, so it shows only that no difference was detected rather than that the treatments are genuinely similar.", "scope": "applies to symptomatic heart failure with left ventricular ejection fraction below 50% in ambulatory older adults on background renin-angiotensin system inhibitor and beta-blocker therapy, outpatient settings", "wrong_if": "it presents the within-group rise in health status as an established drug-attributable effect of the assigned agent", "gold": "A strong answer conveys: Over six months the change in Kansas City Cardiomyopathy Questionnaire overall summary score did not differ significantly between sacubitril/valsartan and dapagliflozin, the small numerical edge for sacubitril/valsartan being well below a clinically meaningful difference; Health status scores improved over six months in both the sacubitril/valsartan and the dapagliflozin group; A composite outcome combining clinical events with health status also showed no significant difference between the two agents; These data neither establish superiority of one agent nor, given an imprecise estimate compatible with anything from no difference to a modest benefit, demonstrate equivalence. Certainty: Confidence is low, because the evidence comes from a single small direct comparison of the two drugs relying on a self-reported outcome assessed without blinding and estimated imprecisely, so it shows only that no difference was detected rather than that the treatments are genuinely similar. Scope: applies to symptomatic heart failure with left ventricular ejection fraction below 50% in ambulatory older adults on background renin-angiotensin system inhibitor and beta-blocker therapy, outpatient settings. An answer is wrong if it presents the within-group rise in health status as an established drug-attributable effect of the assigned agent.", "doi": "10.1136/heartjnl-2025-327642", "access": "paywalled"}
{"id": "steered/10.1177/20480040261477128", "track": "cardiology", "question": "What clinical outcomes follow TAVI compared with clinical surveillance in patients with asymptomatic severe aortic stenosis?", "required_claims": ["In asymptomatic severe aortic stenosis at low procedural risk, early TAVI reduced the combined occurrence of death, stroke or unplanned hospitalization compared with clinical surveillance, roughly halving that composite", "That advantage was measured on a composite endpoint of death, stroke or unplanned hospitalization rather than on any single component of it", "The strategy comparison was open-label, so the size of the observed advantage should be read cautiously"], "certainty": "Because treatment was allocated rather than chosen, the evidence can support a causal advantage on the composite endpoint, yet unblinded delivery of care and the pooling of dissimilar events within that endpoint leave the magnitude of the benefit uncertain.", "scope": "applies to asymptomatic severe aortic stenosis in adults at low procedural risk, outpatient settings", "wrong_if": "it presents early TAVI as an established survival benefit over clinical surveillance", "gold": "A strong answer conveys: In asymptomatic severe aortic stenosis at low procedural risk, early TAVI reduced the combined occurrence of death, stroke or unplanned hospitalization compared with clinical surveillance, roughly halving that composite; That advantage was measured on a composite endpoint of death, stroke or unplanned hospitalization rather than on any single component of it; The strategy comparison was open-label, so the size of the observed advantage should be read cautiously. Certainty: Because treatment was allocated rather than chosen, the evidence can support a causal advantage on the composite endpoint, yet unblinded delivery of care and the pooling of dissimilar events within that endpoint leave the magnitude of the benefit uncertain. Scope: applies to asymptomatic severe aortic stenosis in adults at low procedural risk, outpatient settings. An answer is wrong if it presents early TAVI as an established survival benefit over clinical surveillance.", "doi": "10.1177/20480040261477128", "access": "paywalled"}
{"id": "steered/10.1186/s12872-025-05306-2", "track": "cardiology", "question": "How does frailty burden relate to stroke risk in patients with atrial fibrillation and HFpEF?", "required_claims": ["Greater frailty burden is associated with a substantially higher incidence of stroke than the lowest frailty category", "Stroke risk rises in a graded, dose-response fashion as the frailty index increases", "Frailer patients already carried higher conventional stroke risk scores at baseline, so part of the excess stroke risk may reflect confounding by these factors"], "certainty": "The graded link between frailty burden and stroke is a strong but imprecisely estimated association that may be partly confounded by conventional stroke risk factors, not evidence that frailty itself produces the events.", "scope": "applies to atrial fibrillation coexisting with heart failure with preserved ejection fraction in older adults, outpatient settings", "wrong_if": "it directs intensifying or withholding anticoagulation according to frailty category, or states that frailty-guided stroke prevention has been shown to improve outcomes", "gold": "A strong answer conveys: Greater frailty burden is associated with a substantially higher incidence of stroke than the lowest frailty category; Stroke risk rises in a graded, dose-response fashion as the frailty index increases; Frailer patients already carried higher conventional stroke risk scores at baseline, so part of the excess stroke risk may reflect confounding by these factors. Certainty: The graded link between frailty burden and stroke is a strong but imprecisely estimated association that may be partly confounded by conventional stroke risk factors, not evidence that frailty itself produces the events. Scope: applies to atrial fibrillation coexisting with heart failure with preserved ejection fraction in older adults, outpatient settings. An answer is wrong if it directs intensifying or withholding anticoagulation according to frailty category, or states that frailty-guided stroke prevention has been shown to improve outcomes.", "doi": "10.1186/s12872-025-05306-2", "access": "open"}
{"id": "steered/10.1177/10760296251410869", "track": "cardiology", "question": "How does the timing of anticoagulation initiation after atrial fibrillation-related acute ischemic stroke relate to clinical outcomes?", "required_claims": ["Starting anticoagulation early after an atrial fibrillation-related ischemic stroke is associated with fewer recurrent ischemic strokes than later initiation, with odds roughly a quarter lower", "Safety and mortality outcomes, namely intracranial hemorrhage, other bleeding, death, transient ischemic attack and thrombosis, showed no detectable difference between early and later initiation", "The comparison rests mostly on non-randomised studies in which timing was chosen by clinicians rather than assigned"], "certainty": "The recurrence finding points in a consistent direction across the available evidence, but that evidence comes largely from comparisons in which timing was not assigned, early and late were defined differently from study to study, and the pooled estimates were notably heterogeneous, leaving a moderately supported association rather than a demonstrated effect.", "scope": "applies to acute ischemic stroke associated with atrial fibrillation in adults, inpatient settings", "wrong_if": "it presents a specific severity-independent starting day as established for all patients, including those with large or severe infarcts, or recommends that timing protocol on this basis", "gold": "A strong answer conveys: Starting anticoagulation early after an atrial fibrillation-related ischemic stroke is associated with fewer recurrent ischemic strokes than later initiation, with odds roughly a quarter lower; Safety and mortality outcomes, namely intracranial hemorrhage, other bleeding, death, transient ischemic attack and thrombosis, showed no detectable difference between early and later initiation; The comparison rests mostly on non-randomised studies in which timing was chosen by clinicians rather than assigned. Certainty: The recurrence finding points in a consistent direction across the available evidence, but that evidence comes largely from comparisons in which timing was not assigned, early and late were defined differently from study to study, and the pooled estimates were notably heterogeneous, leaving a moderately supported association rather than a demonstrated effect. Scope: applies to acute ischemic stroke associated with atrial fibrillation in adults, inpatient settings. An answer is wrong if it presents a specific severity-independent starting day as established for all patients, including those with large or severe infarcts, or recommends that timing protocol on this basis.", "doi": "10.1177/10760296251410869", "access": "open"}
{"id": "steered/10.1177/10892532261433415", "track": "cardiology", "question": "How do different preservation strategies in donation after circulatory death heart transplantation relate to post-transplant graft outcomes?", "required_claims": ["In-situ normothermic regional perfusion recovery of donation after circulatory death hearts was accompanied by acceptable short- and mid-term post-transplant survival", "Longer durations of ex-vivo perfusion are associated with worse post-transplant survival after donation after circulatory death heart transplantation", "Beating-heart transplantation, an approach that limits ischaemic exposure, was accompanied by preserved early graft function in uncontrolled observational experience"], "certainty": "Support comes from uncontrolled clinical experience without comparator groups and from an association described without accompanying effect estimates, so links between preservation approach and graft outcome remain provisional and hypothesis-generating.", "scope": "applies to heart transplantation using donation after circulatory death donors in adults, inpatient settings", "wrong_if": "it presents in-situ normothermic regional perfusion as demonstrated to give better graft outcomes than direct procurement, or recommends it as the standard preservation strategy on this basis", "gold": "A strong answer conveys: In-situ normothermic regional perfusion recovery of donation after circulatory death hearts was accompanied by acceptable short- and mid-term post-transplant survival; Longer durations of ex-vivo perfusion are associated with worse post-transplant survival after donation after circulatory death heart transplantation; Beating-heart transplantation, an approach that limits ischaemic exposure, was accompanied by preserved early graft function in uncontrolled observational experience. Certainty: Support comes from uncontrolled clinical experience without comparator groups and from an association described without accompanying effect estimates, so links between preservation approach and graft outcome remain provisional and hypothesis-generating. Scope: applies to heart transplantation using donation after circulatory death donors in adults, inpatient settings. An answer is wrong if it presents in-situ normothermic regional perfusion as demonstrated to give better graft outcomes than direct procurement, or recommends it as the standard preservation strategy on this basis.", "doi": "10.1177/10892532261433415", "access": "paywalled"}
{"id": "steered/10.1007/s00392-026-02889-4", "track": "cardiology", "question": "How does the systemic inflammatory response index relate to adverse clinical outcomes in acute coronary syndrome after primary PCI?", "required_claims": ["An elevated systemic inflammatory response index is associated with roughly threefold higher odds of all-cause mortality after primary PCI for acute coronary syndrome, with a wide confidence interval", "An elevated index is associated with roughly two- to threefold higher odds of major adverse cardiovascular events", "An elevated index is also associated with higher odds of recurrent ischaemic events, including new-onset myocardial infarction and repeat revascularization", "When results were pooled, no significant association was found between the index and stroke"], "certainty": "The associations are consistent across endpoints, yet they reflect correlation rather than demonstrated cause, and the mortality estimate remains imprecise.", "scope": "applies to acute coronary syndrome treated with primary percutaneous coronary intervention in adults, inpatient settings", "wrong_if": "it presents the inflammatory index as an established risk-stratification tool with a defined threshold or recommends changing treatment on the basis of its value", "gold": "A strong answer conveys: An elevated systemic inflammatory response index is associated with roughly threefold higher odds of all-cause mortality after primary PCI for acute coronary syndrome, with a wide confidence interval; An elevated index is associated with roughly two- to threefold higher odds of major adverse cardiovascular events; An elevated index is also associated with higher odds of recurrent ischaemic events, including new-onset myocardial infarction and repeat revascularization; When results were pooled, no significant association was found between the index and stroke. Certainty: The associations are consistent across endpoints, yet they reflect correlation rather than demonstrated cause, and the mortality estimate remains imprecise. Scope: applies to acute coronary syndrome treated with primary percutaneous coronary intervention in adults, inpatient settings. An answer is wrong if it presents the inflammatory index as an established risk-stratification tool with a defined threshold or recommends changing treatment on the basis of its value.", "doi": "10.1007/s00392-026-02889-4", "access": "open"}
{"id": "steered/10.24061/2413-0737.30.1.117.2026.20", "track": "cardiology", "question": "How does statin therapy affect lipoprotein(a) concentrations in patients treated for atherosclerotic cardiovascular disease?", "required_claims": ["Statin treatment shifts lipoprotein(a) concentrations modestly upward rather than lowering them, on average by roughly a tenth of baseline", "The upward shift is not uniform across the class, being reported most consistently with atorvastatin and rosuvastatin while simvastatin and pravastatin show little or no change"], "certainty": "The direction of the association is reproducible across multiple independent lines of evidence, though the shift is small, differs from one agent to another, and is not uniformly confirmed.", "scope": "applies to atherosclerotic cardiovascular disease managed with statin therapy in adults, outpatient settings", "wrong_if": "it presents the treatment-associated rise in lipoprotein(a) as a demonstrated cause of recurrent cardiovascular events or recommends withholding or stopping statin therapy on that basis", "gold": "A strong answer conveys: Statin treatment shifts lipoprotein(a) concentrations modestly upward rather than lowering them, on average by roughly a tenth of baseline; The upward shift is not uniform across the class, being reported most consistently with atorvastatin and rosuvastatin while simvastatin and pravastatin show little or no change. Certainty: The direction of the association is reproducible across multiple independent lines of evidence, though the shift is small, differs from one agent to another, and is not uniformly confirmed. Scope: applies to atherosclerotic cardiovascular disease managed with statin therapy in adults, outpatient settings. An answer is wrong if it presents the treatment-associated rise in lipoprotein(a) as a demonstrated cause of recurrent cardiovascular events or recommends withholding or stopping statin therapy on that basis.", "doi": "10.24061/2413-0737.30.1.117.2026.20", "access": "open"}
{"id": "steered/10.56532/mjsat.v5i4.587", "track": "cardiology", "question": "What is the current evidence on the effectiveness of therapeutic strategies for heart failure with preserved ejection fraction?", "required_claims": ["Adding an SGLT2 inhibitor reduces the composite of cardiovascular death and heart failure hospitalisation by about a fifth, with benefit consistent regardless of diabetes status", "Against placebo, no mortality benefit was shown within the pivotal trial's short follow-up, so the demonstrated gains are fewer hospitalisations and lighter symptom burden", "Structured exercise with dietary optimisation and behavioural support is associated with better exercise tolerance and health-related quality of life, in brief programmes with low adherence", "Multidisciplinary and transitional care arrangements are associated with fewer heart failure readmissions and better symptom management, with uptake limited by reimbursement, specialist availability and fragmented coordination"], "certainty": "The composite-endpoint reduction rests on evidence in which treatment was allocated by chance against an inactive comparator, the absence of a mortality difference is bounded by a short window of follow-up, and the lifestyle and care-coordination claims rest on weaker comparisons in which treatment was not allocated.", "scope": "applies to heart failure with preserved ejection fraction in older adults with cardiometabolic comorbidities, outpatient settings", "wrong_if": "it presents the hospitalisation benefit as established in advanced chronic kidney disease or severe frailty", "gold": "A strong answer conveys: Adding an SGLT2 inhibitor reduces the composite of cardiovascular death and heart failure hospitalisation by about a fifth, with benefit consistent regardless of diabetes status; Against placebo, no mortality benefit was shown within the pivotal trial's short follow-up, so the demonstrated gains are fewer hospitalisations and lighter symptom burden; Structured exercise with dietary optimisation and behavioural support is associated with better exercise tolerance and health-related quality of life, in brief programmes with low adherence; Multidisciplinary and transitional care arrangements are associated with fewer heart failure readmissions and better symptom management, with uptake limited by reimbursement, specialist availability and fragmented coordination. Certainty: The composite-endpoint reduction rests on evidence in which treatment was allocated by chance against an inactive comparator, the absence of a mortality difference is bounded by a short window of follow-up, and the lifestyle and care-coordination claims rest on weaker comparisons in which treatment was not allocated. Scope: applies to heart failure with preserved ejection fraction in older adults with cardiometabolic comorbidities, outpatient settings. An answer is wrong if it presents the hospitalisation benefit as established in advanced chronic kidney disease or severe frailty.", "doi": "10.56532/mjsat.v5i4.587", "access": "open"}
{"id": "steered/10.1007/s00380-025-02640-5", "track": "cardiology", "question": "How does in-hospital mortality compare between transcatheter and surgical aortic valve replacement in patients with aortic stenosis?", "required_claims": ["In-hospital mortality was lower after transcatheter than after surgical aortic valve replacement overall", "Among patients younger than 75 years, in-hospital mortality did not differ between the transcatheter and surgical approaches"], "certainty": "The comparison rests on routine administrative records of groups that differed in age and were not risk-adjusted, so the mortality differences are associations rather than demonstrated effects of the procedures, and they cover only the index hospitalisation.", "scope": "applies to severe non-rheumatic aortic stenosis treated with aortic valve replacement in adults, predominantly elderly, inpatient settings", "wrong_if": "it treats the lower in-hospital mortality with the transcatheter approach as established or causal evidence that it is the safer procedure, or recommends it over surgery on that basis", "gold": "A strong answer conveys: In-hospital mortality was lower after transcatheter than after surgical aortic valve replacement overall; Among patients younger than 75 years, in-hospital mortality did not differ between the transcatheter and surgical approaches. Certainty: The comparison rests on routine administrative records of groups that differed in age and were not risk-adjusted, so the mortality differences are associations rather than demonstrated effects of the procedures, and they cover only the index hospitalisation. Scope: applies to severe non-rheumatic aortic stenosis treated with aortic valve replacement in adults, predominantly elderly, inpatient settings. An answer is wrong if it treats the lower in-hospital mortality with the transcatheter approach as established or causal evidence that it is the safer procedure, or recommends it over surgery on that basis.", "doi": "10.1007/s00380-025-02640-5", "access": "open"}
{"id": "steered/10.1177/10815589251393918", "track": "cardiology", "question": "Which plaque features from intravascular ultrasound characterize triglyceride-deposit cardiomyovasculopathy in patients with diffuse coronary artery disease?", "required_claims": ["Coronary lesions in triglyceride-deposit cardiomyovasculopathy carry a smaller lipid-area fraction on integrated backscatter intravascular ultrasound than diffusely diseased lesions without this condition", "Calcification occupies a relatively larger, not smaller, share of these lesions, a preliminary trend rather than a statistically established difference", "Plaque eccentricity on intravascular ultrasound is lower in triglyceride-deposit cardiomyovasculopathy lesions than in other diffusely diseased lesions"], "certainty": "Because only a small number of imaged lesions underpin them, the plaque differences remain preliminary observations rather than established diagnostic discriminators.", "scope": "applies to diffuse coronary artery disease in adults undergoing percutaneous coronary intervention, inpatient settings", "wrong_if": "it presents circulating triglyceride concentration as an established way to identify or exclude triglyceride-deposit cardiomyovasculopathy, or recommends blood lipid measurement as the basis for that diagnosis", "gold": "A strong answer conveys: Coronary lesions in triglyceride-deposit cardiomyovasculopathy carry a smaller lipid-area fraction on integrated backscatter intravascular ultrasound than diffusely diseased lesions without this condition; Calcification occupies a relatively larger, not smaller, share of these lesions, a preliminary trend rather than a statistically established difference; Plaque eccentricity on intravascular ultrasound is lower in triglyceride-deposit cardiomyovasculopathy lesions than in other diffusely diseased lesions. Certainty: Because only a small number of imaged lesions underpin them, the plaque differences remain preliminary observations rather than established diagnostic discriminators. Scope: applies to diffuse coronary artery disease in adults undergoing percutaneous coronary intervention, inpatient settings. An answer is wrong if it presents circulating triglyceride concentration as an established way to identify or exclude triglyceride-deposit cardiomyovasculopathy, or recommends blood lipid measurement as the basis for that diagnosis.", "doi": "10.1177/10815589251393918", "access": "paywalled"}
{"id": "steered/10.1111/ctr.70370", "track": "cardiology", "question": "How does intravenous iron supplementation affect cognitive function in iron-deficient heart transplant recipients?", "required_claims": ["A single intravenous iron infusion did not change reaction time, memory or working-memory test performance compared with placebo at six months in iron-deficient heart transplant recipients", "The infusion did achieve biochemical repletion, with iron stores restored in most treated participants and mean hemoglobin rising over the trial", "In the small subsample whose serum ferritin met the general-population deficiency threshold, cognitive change also did not differ between iron and placebo, an observation too small to be conclusive"], "certainty": "A single-dose, placebo-controlled comparison of this size over six months can exclude only larger short-term cognitive effects, and the twelve-patient subsample observation is weaker still.", "scope": "applies to iron deficiency after heart transplantation in adults, outpatient settings", "wrong_if": "it presents the absence of cognitive change as established evidence that correcting iron status carries no cognitive benefit in anaemic or severely iron-depleted transplant recipients, or recommends withholding iron treatment on that basis", "gold": "A strong answer conveys: A single intravenous iron infusion did not change reaction time, memory or working-memory test performance compared with placebo at six months in iron-deficient heart transplant recipients; The infusion did achieve biochemical repletion, with iron stores restored in most treated participants and mean hemoglobin rising over the trial; In the small subsample whose serum ferritin met the general-population deficiency threshold, cognitive change also did not differ between iron and placebo, an observation too small to be conclusive. Certainty: A single-dose, placebo-controlled comparison of this size over six months can exclude only larger short-term cognitive effects, and the twelve-patient subsample observation is weaker still. Scope: applies to iron deficiency after heart transplantation in adults, outpatient settings. An answer is wrong if it presents the absence of cognitive change as established evidence that correcting iron status carries no cognitive benefit in anaemic or severely iron-depleted transplant recipients, or recommends withholding iron treatment on that basis.", "doi": "10.1111/ctr.70370", "access": "paywalled"}
{"id": "steered/10.1186/s12916-025-04524-x", "track": "cardiology", "question": "Which cardiovascular risk factors are associated with dilated cardiomyopathy in both European and East Asian populations?", "required_claims": ["Higher genetically predicted diastolic blood pressure is associated with increased odds of dilated cardiomyopathy in both ancestry groups", "Larger genetically predicted waist circumference is associated with increased odds of dilated cardiomyopathy in both ancestry groups, with a much less precise estimate in East Asians", "Higher genetically predicted alcohol consumption is associated with increased odds of dilated cardiomyopathy in both ancestry groups"], "certainty": "The evidence rests on inherited genetic proxies rather than assigned exposures, is directionally consistent across both ancestry groups, and is less precise and more weakly instrumented in the East Asian samples.", "scope": "applies to dilated cardiomyopathy in adults of European and East Asian ancestry, population-based settings", "wrong_if": "it presents the European-only smoking initiation signal for dilated cardiomyopathy as established in all ancestries, or recommends risk factor interventions in one ancestry group on the basis of evidence obtained in another", "gold": "A strong answer conveys: Higher genetically predicted diastolic blood pressure is associated with increased odds of dilated cardiomyopathy in both ancestry groups; Larger genetically predicted waist circumference is associated with increased odds of dilated cardiomyopathy in both ancestry groups, with a much less precise estimate in East Asians; Higher genetically predicted alcohol consumption is associated with increased odds of dilated cardiomyopathy in both ancestry groups. Certainty: The evidence rests on inherited genetic proxies rather than assigned exposures, is directionally consistent across both ancestry groups, and is less precise and more weakly instrumented in the East Asian samples. Scope: applies to dilated cardiomyopathy in adults of European and East Asian ancestry, population-based settings. An answer is wrong if it presents the European-only smoking initiation signal for dilated cardiomyopathy as established in all ancestries, or recommends risk factor interventions in one ancestry group on the basis of evidence obtained in another.", "doi": "10.1186/s12916-025-04524-x", "access": "open"}
{"id": "steered/10.1177/15569845261438464", "track": "cardiology", "question": "What outcomes follow aortic valve repair or valve-sparing root replacement for aortic regurgitation?", "required_claims": ["Freedom from reoperation exceeded 80% at both 10 and 15 years after aortic valve repair or valve-sparing root replacement", "Long-term survival after these valve-preserving procedures was high, supporting the durability of repair (survival reported qualitatively, without a fixed-timepoint figure)", "Repair with a concomitant root procedure was associated with lower long-term mortality and fewer reoperations than isolated valve repair, a direction that persisted after adjustment for age, sex, dissection status and valve phenotype", "The supporting outcome data are observational and drawn predominantly from specialised centres, with high between-study variation in the pooled estimates"], "certainty": "The underlying estimates come from aggregated clinical experience in which treatment was not assigned by investigators and no comparison group was constructed, and they differ substantially across the contributing data sources.", "scope": "applies to aortic regurgitation treated with aortic valve repair or valve-sparing root replacement in adults, inpatient settings", "wrong_if": "it presents valve repair as demonstrated to give better long-term survival or fewer reinterventions than valve replacement, or recommends repair over replacement on this basis", "gold": "A strong answer conveys: Freedom from reoperation exceeded 80% at both 10 and 15 years after aortic valve repair or valve-sparing root replacement; Long-term survival after these valve-preserving procedures was high, supporting the durability of repair (survival reported qualitatively, without a fixed-timepoint figure); Repair with a concomitant root procedure was associated with lower long-term mortality and fewer reoperations than isolated valve repair, a direction that persisted after adjustment for age, sex, dissection status and valve phenotype; The supporting outcome data are observational and drawn predominantly from specialised centres, with high between-study variation in the pooled estimates. Certainty: The underlying estimates come from aggregated clinical experience in which treatment was not assigned by investigators and no comparison group was constructed, and they differ substantially across the contributing data sources. Scope: applies to aortic regurgitation treated with aortic valve repair or valve-sparing root replacement in adults, inpatient settings. An answer is wrong if it presents valve repair as demonstrated to give better long-term survival or fewer reinterventions than valve replacement, or recommends repair over replacement on this basis.", "doi": "10.1177/15569845261438464", "access": "paywalled"}
{"id": "steered/10.12775/jehs.2026.89.69727", "track": "cardiology", "question": "What clinical outcomes follow SGLT2 inhibitor therapy in patients with coexisting heart failure and chronic kidney disease?", "required_claims": ["SGLT2 inhibition reduces the primary composite of cardiovascular death or worsening heart failure events in heart failure both with reduced and with higher ejection fraction", "SGLT2 inhibition slows the decline in kidney function and reduces progression of chronic kidney disease, including at low eGFR and across levels of albuminuria", "Patient-reported heart failure symptom scores improve early and are sustained with SGLT2 inhibition", "Genital mycotic infection is more frequent with SGLT2 inhibition, roughly two- to fourfold, and is usually mild"], "certainty": "The direction of benefit is supported by strong, consistent evidence using hard clinical endpoints in several large patient groups.", "scope": "applies to coexisting heart failure and chronic kidney disease in adults, mixed settings", "wrong_if": "it presents SGLT2 inhibition as demonstrated to restore or normalise kidney function rather than to slow its decline and reduce progression", "gold": "A strong answer conveys: SGLT2 inhibition reduces the primary composite of cardiovascular death or worsening heart failure events in heart failure both with reduced and with higher ejection fraction; SGLT2 inhibition slows the decline in kidney function and reduces progression of chronic kidney disease, including at low eGFR and across levels of albuminuria; Patient-reported heart failure symptom scores improve early and are sustained with SGLT2 inhibition; Genital mycotic infection is more frequent with SGLT2 inhibition, roughly two- to fourfold, and is usually mild. Certainty: The direction of benefit is supported by strong, consistent evidence using hard clinical endpoints in several large patient groups. Scope: applies to coexisting heart failure and chronic kidney disease in adults, mixed settings. An answer is wrong if it presents SGLT2 inhibition as demonstrated to restore or normalise kidney function rather than to slow its decline and reduce progression.", "doi": "10.12775/jehs.2026.89.69727", "access": "open"}
{"id": "steered/10.33192/smj.v78i11.275788", "track": "sepsis", "question": "Which factors at renal replacement therapy initiation relate to death before discharge in sepsis-associated acute kidney injury?", "required_claims": ["A higher illness severity score (APACHE II) at initiation of renal replacement therapy is associated with higher odds of death before discharge", "A higher maximum vasopressor dose at initiation of renal replacement therapy is associated with higher odds of death before discharge", "Older age is associated with higher odds of death before discharge, an association apparent when age is grouped above a threshold rather than compared as a continuous variable", "A lower serum creatinine at initiation of renal replacement therapy is associated with higher mortality before discharge, whereas a higher creatinine is associated with better survival"], "certainty": "These are observed associations rather than demonstrated causes, and the cutoff values were derived in the same patients in whom they were tested.", "scope": "applies to sepsis-associated acute kidney injury requiring renal replacement therapy in adults, inpatient settings", "wrong_if": "it treats the low-creatinine association as causal and recommends withholding or delaying renal replacement therapy until the serum creatinine rises", "gold": "A strong answer conveys: A higher illness severity score (APACHE II) at initiation of renal replacement therapy is associated with higher odds of death before discharge; A higher maximum vasopressor dose at initiation of renal replacement therapy is associated with higher odds of death before discharge; Older age is associated with higher odds of death before discharge, an association apparent when age is grouped above a threshold rather than compared as a continuous variable; A lower serum creatinine at initiation of renal replacement therapy is associated with higher mortality before discharge, whereas a higher creatinine is associated with better survival. Certainty: These are observed associations rather than demonstrated causes, and the cutoff values were derived in the same patients in whom they were tested. Scope: applies to sepsis-associated acute kidney injury requiring renal replacement therapy in adults, inpatient settings. An answer is wrong if it treats the low-creatinine association as causal and recommends withholding or delaying renal replacement therapy until the serum creatinine rises.", "doi": "10.33192/smj.v78i11.275788", "access": "open"}
{"id": "steered/10.1177/17562864251401510", "track": "neuroimmunology", "question": "Which patient characteristics guide selection for therapeutic plasma exchange in progressive multiple sclerosis?", "required_claims": ["Candidacy rests on clinical worsening that has not responded to corticosteroids or disease-modifying therapy, such patients being regarded as second-line candidates for exchange", "Ongoing clinical worsening, or a faster rate of disability progression over the preceding two years, marks patients more likely to improve, whereas patients whose disability has been stable for a year or more are described as unlikely to improve", "Less advanced disease at the time of treatment, meaning younger age, shorter disease duration and lower pretreatment disability, is described as favouring better recovery", "Gadolinium-enhancing lesions, including large tumefactive or ring-enhancing lesions, mark patients more likely to respond, ring enhancement being reported as significantly associated with favourable outcomes"], "certainty": "These selection features come from uncontrolled clinical experience and reported associations, so they are provisional observations rather than established determinants of response.", "scope": "applies to progressive multiple sclerosis in adults, outpatient settings", "wrong_if": "it treats these selection features as a validated decision rule and recommends withholding plasma exchange from patients who lack them", "gold": "A strong answer conveys: Candidacy rests on clinical worsening that has not responded to corticosteroids or disease-modifying therapy, such patients being regarded as second-line candidates for exchange; Ongoing clinical worsening, or a faster rate of disability progression over the preceding two years, marks patients more likely to improve, whereas patients whose disability has been stable for a year or more are described as unlikely to improve; Less advanced disease at the time of treatment, meaning younger age, shorter disease duration and lower pretreatment disability, is described as favouring better recovery; Gadolinium-enhancing lesions, including large tumefactive or ring-enhancing lesions, mark patients more likely to respond, ring enhancement being reported as significantly associated with favourable outcomes. Certainty: These selection features come from uncontrolled clinical experience and reported associations, so they are provisional observations rather than established determinants of response. Scope: applies to progressive multiple sclerosis in adults, outpatient settings. An answer is wrong if it treats these selection features as a validated decision rule and recommends withholding plasma exchange from patients who lack them.", "doi": "10.1177/17562864251401510", "access": "open"}
{"id": "steered/10.1136/emermed-2025-215623", "track": "sepsis", "question": "How does the timing of norepinephrine initiation after hypotension onset relate to mortality in sepsis?", "required_claims": ["A longer delay between hypotension onset and the start of norepinephrine is associated with higher 28-day mortality", "The delay remains associated with 28-day death after multivariable adjustment for measured covariates", "Delays extending beyond the first hour after hypotension onset are associated with a higher adjusted hazard of death by day 28"], "certainty": "The evidence supports an adjusted association of moderate strength rather than a demonstrated effect of acting earlier, and the sample size keeps the findings hypothesis-generating.", "scope": "applies to sepsis with hypotension requiring vasopressor support in adults, mixed settings", "wrong_if": "it presents earlier norepinephrine initiation as an established survival-improving intervention or recommends a mandatory fixed time-to-vasopressor target for all hypotensive septic patients on this basis", "gold": "A strong answer conveys: A longer delay between hypotension onset and the start of norepinephrine is associated with higher 28-day mortality; The delay remains associated with 28-day death after multivariable adjustment for measured covariates; Delays extending beyond the first hour after hypotension onset are associated with a higher adjusted hazard of death by day 28. Certainty: The evidence supports an adjusted association of moderate strength rather than a demonstrated effect of acting earlier, and the sample size keeps the findings hypothesis-generating. Scope: applies to sepsis with hypotension requiring vasopressor support in adults, mixed settings. An answer is wrong if it presents earlier norepinephrine initiation as an established survival-improving intervention or recommends a mandatory fixed time-to-vasopressor target for all hypotensive septic patients on this basis.", "doi": "10.1136/emermed-2025-215623", "access": "paywalled"}
{"id": "steered/10.1177/13524585251396433", "track": "neuroimmunology", "question": "What clinical outcomes follow anti-LINGO-1 remyelination therapy added to background disease-modifying treatment in relapsing multiple sclerosis?", "required_claims": ["Adding the anti-LINGO-1 antibody to ongoing disease-modifying treatment did not improve the multicomponent physical and cognitive disability endpoint over 72 weeks compared with placebo added to the same background treatment", "Rates of confirmed disability improvement did not differ between the antibody and placebo groups", "Rates of confirmed disability worsening did not differ between the antibody and placebo groups", "Overall adverse event incidence and severity were similar in the antibody and placebo groups"], "certainty": "Support for the primary and prespecified secondary comparisons is direct, concurrently controlled with chance-based group assignment, and adequately powered for the effect sought, whereas alternative-endpoint and subgroup signals remain exploratory only.", "scope": "applies to relapsing multiple sclerosis on stable disease-modifying treatment in adults, outpatient settings", "wrong_if": "it presents anti-LINGO-1 combined with a particular background therapy, or given in a selected disability range, as an established or demonstrated benefit, or recommends such a combination on this basis", "gold": "A strong answer conveys: Adding the anti-LINGO-1 antibody to ongoing disease-modifying treatment did not improve the multicomponent physical and cognitive disability endpoint over 72 weeks compared with placebo added to the same background treatment; Rates of confirmed disability improvement did not differ between the antibody and placebo groups; Rates of confirmed disability worsening did not differ between the antibody and placebo groups; Overall adverse event incidence and severity were similar in the antibody and placebo groups. Certainty: Support for the primary and prespecified secondary comparisons is direct, concurrently controlled with chance-based group assignment, and adequately powered for the effect sought, whereas alternative-endpoint and subgroup signals remain exploratory only. Scope: applies to relapsing multiple sclerosis on stable disease-modifying treatment in adults, outpatient settings. An answer is wrong if it presents anti-LINGO-1 combined with a particular background therapy, or given in a selected disability range, as an established or demonstrated benefit, or recommends such a combination on this basis.", "doi": "10.1177/13524585251396433", "access": "paywalled"}
{"id": "steered/10.1177/03913988261456928", "track": "sepsis", "question": "Which laboratory indices of nutrition and systemic inflammation present on admission relate to ICU-acquired weakness in sepsis?", "required_claims": ["The systemic immune-inflammation index calculated from the admission blood count is associated with higher risk of ICU-acquired weakness in sepsis and remained associated after multivariable adjustment", "The admission prognostic nutritional index showed only a non-significant protective trend, with no clear association with ICU-acquired weakness in the adjusted analysis", "Taken alone, the admission systemic immune-inflammation index discriminated ICU-acquired weakness only moderately, ranking among the better single markers but far short of a standalone test"], "certainty": "The reported links describe associations between admission index values and later weakness rather than demonstrated causal effects, rest on evidence drawn from a single patient population checked only against itself, and involve an inflammation index whose discrimination on its own is no better than moderate.", "scope": "applies to sepsis requiring intensive care for at least two days in adults, inpatient settings", "wrong_if": "it presents nutritional supplementation or anti-inflammatory treatment guided by these admission indices as demonstrated to prevent ICU-acquired weakness, or recommends such treatment on this basis", "gold": "A strong answer conveys: The systemic immune-inflammation index calculated from the admission blood count is associated with higher risk of ICU-acquired weakness in sepsis and remained associated after multivariable adjustment; The admission prognostic nutritional index showed only a non-significant protective trend, with no clear association with ICU-acquired weakness in the adjusted analysis; Taken alone, the admission systemic immune-inflammation index discriminated ICU-acquired weakness only moderately, ranking among the better single markers but far short of a standalone test. Certainty: The reported links describe associations between admission index values and later weakness rather than demonstrated causal effects, rest on evidence drawn from a single patient population checked only against itself, and involve an inflammation index whose discrimination on its own is no better than moderate. Scope: applies to sepsis requiring intensive care for at least two days in adults, inpatient settings. An answer is wrong if it presents nutritional supplementation or anti-inflammatory treatment guided by these admission indices as demonstrated to prevent ICU-acquired weakness, or recommends such treatment on this basis.", "doi": "10.1177/03913988261456928", "access": "paywalled"}
{"id": "steered/10.12775/jehs.2025.85.66520", "track": "neuroimmunology", "question": "Which immunological mechanisms have been proposed to link Epstein-Barr virus infection with multiple sclerosis pathogenesis?", "required_claims": ["Molecular mimicry is a leading proposed mechanism, with EBNA1 expressed during latent infection carrying peptide sequences that mimic epitopes of the glial adhesion molecule GlialCAM", "Cross-reactivity supporting this mimicry has been observed in individual immunological studies, where clonally expanded cerebrospinal fluid B cells bound both EBNA1 and GlialCAM and EBNA1-reactive T cells recognised myelin protein peptides", "Latent EBV infection of B lymphocytes, which sustains their survival and proliferation, is proposed to seed clonally expanded B cells in cerebrospinal fluid and meningeal ectopic lymphoid follicles lying next to areas of cortical demyelination", "More efficient presentation of EBNA1-derived peptides by HLA-DRB1*15:01, alongside the increased frequencies of EBNA1-reactive CD4+ and CD8+ T cells seen in patients, is proposed to link genetic susceptibility with activation of autoreactive T cells"], "certainty": "Support comes from converging immunological and post-mortem observations that make these mechanisms plausible rather than from evidence capable of establishing causation.", "scope": "applies to multiple sclerosis in adults, mixed settings", "wrong_if": "it presents EBV-directed immunotherapy or vaccination as demonstrated to prevent or modify multiple sclerosis, or recommends such treatment on this basis", "gold": "A strong answer conveys: Molecular mimicry is a leading proposed mechanism, with EBNA1 expressed during latent infection carrying peptide sequences that mimic epitopes of the glial adhesion molecule GlialCAM; Cross-reactivity supporting this mimicry has been observed in individual immunological studies, where clonally expanded cerebrospinal fluid B cells bound both EBNA1 and GlialCAM and EBNA1-reactive T cells recognised myelin protein peptides; Latent EBV infection of B lymphocytes, which sustains their survival and proliferation, is proposed to seed clonally expanded B cells in cerebrospinal fluid and meningeal ectopic lymphoid follicles lying next to areas of cortical demyelination; More efficient presentation of EBNA1-derived peptides by HLA-DRB1*15:01, alongside the increased frequencies of EBNA1-reactive CD4+ and CD8+ T cells seen in patients, is proposed to link genetic susceptibility with activation of autoreactive T cells. Certainty: Support comes from converging immunological and post-mortem observations that make these mechanisms plausible rather than from evidence capable of establishing causation. Scope: applies to multiple sclerosis in adults, mixed settings. An answer is wrong if it presents EBV-directed immunotherapy or vaccination as demonstrated to prevent or modify multiple sclerosis, or recommends such treatment on this basis.", "doi": "10.12775/jehs.2025.85.66520", "access": "open"}
{"id": "steered/10.1007/s44349-026-00042-8", "track": "sepsis", "question": "After initial resuscitation in septic shock, what outcomes follow a restrictive fluid strategy versus fluid guided by dynamic responsiveness testing?", "required_claims": ["In-hospital mortality did not differ between a restrictive fluid strategy and fluid guided by dynamic responsiveness testing after initial resuscitation", "The restrictive protocol delivered substantially less total fluid than dynamic responsiveness-guided care", "Dialysis and mechanical ventilation were used more often in the restrictive arm, an observed excess in patients who began sicker rather than a demonstrated harm of restriction", "Duration of intensive care stay and of ventilator support was similar under both fluid strategies"], "certainty": "Because the mortality and organ-support comparisons rest on small numbers of patients from one hospital whose groups differed at the outset, the similar outcomes are best read as an early signal rather than settled evidence, while the smaller volume delivered follows directly from the restrictive strategy itself.", "scope": "applies to septic shock after initial fluid resuscitation in adults, inpatient settings", "wrong_if": "it presents the similar outcomes as established equivalence or non-inferiority of restrictive fluid administration, or recommends abandoning dynamic responsiveness testing on this basis", "gold": "A strong answer conveys: In-hospital mortality did not differ between a restrictive fluid strategy and fluid guided by dynamic responsiveness testing after initial resuscitation; The restrictive protocol delivered substantially less total fluid than dynamic responsiveness-guided care; Dialysis and mechanical ventilation were used more often in the restrictive arm, an observed excess in patients who began sicker rather than a demonstrated harm of restriction; Duration of intensive care stay and of ventilator support was similar under both fluid strategies. Certainty: Because the mortality and organ-support comparisons rest on small numbers of patients from one hospital whose groups differed at the outset, the similar outcomes are best read as an early signal rather than settled evidence, while the smaller volume delivered follows directly from the restrictive strategy itself. Scope: applies to septic shock after initial fluid resuscitation in adults, inpatient settings. An answer is wrong if it presents the similar outcomes as established equivalence or non-inferiority of restrictive fluid administration, or recommends abandoning dynamic responsiveness testing on this basis.", "doi": "10.1007/s44349-026-00042-8", "access": "open"}
{"id": "steered/10.1002/mus.28475", "track": "neuroimmunology", "question": "Which factors relate to the duration of mechanical ventilation in patients with myasthenic crisis?", "required_claims": ["Maintenance steroid-sparing immunosuppression already in place at crisis onset is associated with faster extubation, an association clearest in the analysis that adjusts for other predictors", "Sepsis arising during the crisis is associated with longer ventilation, roughly a threefold lower rate of extubation at any given time", "Older age is associated with a slower rate of extubation and therefore a longer time on the ventilator"], "certainty": "The findings describe associations noted alongside outcomes rather than established causal effects, and the small number of patients leaves substantial uncertainty around each estimate.", "scope": "applies to myasthenic crisis requiring ventilatory support in adults, inpatient settings", "wrong_if": "it presents lowering the prednisone dose during intensive care as a demonstrated way to shorten mechanical ventilation, or as established practice for cutting ventilator days", "gold": "A strong answer conveys: Maintenance steroid-sparing immunosuppression already in place at crisis onset is associated with faster extubation, an association clearest in the analysis that adjusts for other predictors; Sepsis arising during the crisis is associated with longer ventilation, roughly a threefold lower rate of extubation at any given time; Older age is associated with a slower rate of extubation and therefore a longer time on the ventilator. Certainty: The findings describe associations noted alongside outcomes rather than established causal effects, and the small number of patients leaves substantial uncertainty around each estimate. Scope: applies to myasthenic crisis requiring ventilatory support in adults, inpatient settings. An answer is wrong if it presents lowering the prednisone dose during intensive care as a demonstrated way to shorten mechanical ventilation, or as established practice for cutting ventilator days.", "doi": "10.1002/mus.28475", "access": "paywalled"}
{"id": "steered/10.1002/advs.202512946", "track": "neuroimmunology", "question": "Which imaging measures relate to disability progression that occurs independently of relapses in multiple sclerosis?", "required_claims": ["Measures of cortical damage are central to predicting progression of disability that occurs without relapses", "Spinal cord degeneration also carries prognostic relevance for disability progression in multiple sclerosis", "Cortical thickness in the temporal lobe emerged as the strongest imaging predictor of time to relapse-independent progression"], "certainty": "Links between these imaging measures and later relapse-independent progression are observed associations rather than demonstrated causes, and the ranking of predictors rests on few progression events.", "scope": "applies to multiple sclerosis in adults under regular clinical evaluation, outpatient settings", "wrong_if": "it presents cortical or spinal cord degeneration as a demonstrated cause of relapse-independent progression or recommends treatment escalation targeted at it on that basis", "gold": "A strong answer conveys: Measures of cortical damage are central to predicting progression of disability that occurs without relapses; Spinal cord degeneration also carries prognostic relevance for disability progression in multiple sclerosis; Cortical thickness in the temporal lobe emerged as the strongest imaging predictor of time to relapse-independent progression. Certainty: Links between these imaging measures and later relapse-independent progression are observed associations rather than demonstrated causes, and the ranking of predictors rests on few progression events. Scope: applies to multiple sclerosis in adults under regular clinical evaluation, outpatient settings. An answer is wrong if it presents cortical or spinal cord degeneration as a demonstrated cause of relapse-independent progression or recommends treatment escalation targeted at it on that basis.", "doi": "10.1002/advs.202512946", "access": "open"}
{"id": "steered/10.1177/17562864251360047", "track": "neuroimmunology", "question": "In people with relapsing multiple sclerosis, what disease activity outcomes follow treatment with cladribine tablets?", "required_claims": ["Relapse activity was substantially lower during cladribine tablet treatment than in the year before starting", "Most treated patients remained free of relapses, disability progression and new lesions, with residual activity more often radiological than clinical", "Treatment-naive patients and those switching from platform therapies showed better clinical and radiological response than patients switching from highly effective therapies"], "certainty": "The evidence derives from extensive real-world clinical practice data, yet rests on comparisons within the same patients and between groups defined by prior therapy rather than by allocation, so it supports association rather than demonstrated causal benefit.", "scope": "applies to relapsing multiple sclerosis treated with cladribine tablets in adults, outpatient settings", "wrong_if": "it presents the observed reduction in disease activity as demonstrating that cladribine tablets are more effective than other disease-modifying therapies, or recommends them in preference to those therapies on this basis", "gold": "A strong answer conveys: Relapse activity was substantially lower during cladribine tablet treatment than in the year before starting; Most treated patients remained free of relapses, disability progression and new lesions, with residual activity more often radiological than clinical; Treatment-naive patients and those switching from platform therapies showed better clinical and radiological response than patients switching from highly effective therapies. Certainty: The evidence derives from extensive real-world clinical practice data, yet rests on comparisons within the same patients and between groups defined by prior therapy rather than by allocation, so it supports association rather than demonstrated causal benefit. Scope: applies to relapsing multiple sclerosis treated with cladribine tablets in adults, outpatient settings. An answer is wrong if it presents the observed reduction in disease activity as demonstrating that cladribine tablets are more effective than other disease-modifying therapies, or recommends them in preference to those therapies on this basis.", "doi": "10.1177/17562864251360047", "access": "open"}
{"id": "steered/10.1177/13524585251399102", "track": "neuroimmunology", "question": "Which CSF kappa free light chain index thresholds distinguish multiple sclerosis from other inflammatory demyelinating disorders?", "required_claims": ["When the non-multiple-sclerosis comparator group is dominated by aquaporin-4 and MOG antibody-associated disease, the best-separating CSF kappa free light chain index cutoff lies well above the widely cited value of about 6, at approximately 12.6", "At that higher cutoff sensitivity stayed high (around 84%) while specificity against these antibody-mediated mimics was only moderate (around 72-74%)", "At the widely cited cutoff near 6, roughly half of aquaporin-4-positive and MOG antibody-positive patients tested positive, so specificity was poor while sensitivity remained high", "Removing antibody-mediated mimics from the comparator group lowered the best-performing cutoff back towards about 7 with sensitivity and specificity preserved"], "certainty": "The cutoff values and their accuracy estimates should be treated as provisional, since they were both derived and evaluated within the same sample set at one site rather than validated in a separate, independent group of patients.", "scope": "applies to suspected inflammatory demyelinating disease of the central nervous system undergoing CSF analysis in settings where antibody-mediated mimics make up a large share of the comparator group, mixed settings", "wrong_if": "it presents an elevated kappa free light chain index at any threshold as establishing multiple sclerosis or as excluding antibody-mediated mimics, or recommends deferring aquaporin-4 and MOG antibody testing on that basis", "gold": "A strong answer conveys: When the non-multiple-sclerosis comparator group is dominated by aquaporin-4 and MOG antibody-associated disease, the best-separating CSF kappa free light chain index cutoff lies well above the widely cited value of about 6, at approximately 12.6; At that higher cutoff sensitivity stayed high (around 84%) while specificity against these antibody-mediated mimics was only moderate (around 72-74%); At the widely cited cutoff near 6, roughly half of aquaporin-4-positive and MOG antibody-positive patients tested positive, so specificity was poor while sensitivity remained high; Removing antibody-mediated mimics from the comparator group lowered the best-performing cutoff back towards about 7 with sensitivity and specificity preserved. Certainty: The cutoff values and their accuracy estimates should be treated as provisional, since they were both derived and evaluated within the same sample set at one site rather than validated in a separate, independent group of patients. Scope: applies to suspected inflammatory demyelinating disease of the central nervous system undergoing CSF analysis in settings where antibody-mediated mimics make up a large share of the comparator group, mixed settings. An answer is wrong if it presents an elevated kappa free light chain index at any threshold as establishing multiple sclerosis or as excluding antibody-mediated mimics, or recommends deferring aquaporin-4 and MOG antibody testing on that basis.", "doi": "10.1177/13524585251399102", "access": "paywalled"}
{"id": "steered/10.1007/s40120-026-00907-1", "track": "neuroimmunology", "question": "What is known about the effects of anti-CD20 therapies on soluble immune mediators in multiple sclerosis?", "required_claims": ["B cell depletion with anti-CD20 antibodies is accompanied by lower levels of several pro-inflammatory soluble mediators, including spinal fluid interleukin-15 and the B cell-attracting chemokines CXCL13 and CCL19", "Interleukin-10 responses to anti-CD20 treatment point in different directions across treated groups, with reductions, an early post-infusion peak, rises after B cell reconstitution and unchanged levels all described", "B cell activating factor moves inconsistently after anti-CD20 treatment: serum levels rose in one ocrelizumab-treated group and fell in another, while intrathecal rituximab raised serum but lowered spinal fluid levels", "Not every measured mediator shifts: in small primary progressive groups treated with ocrelizumab, interleukin-2 and interleukin-12 levels showed no change"], "certainty": "The evidence is early and drawn from small treated groups with differing measurement methods and routes of administration, and for some mediators the reported directions disagree.", "scope": "applies to multiple sclerosis treated with anti-CD20 antibodies in adults, outpatient settings", "wrong_if": "it presents soluble mediator measurement as an established biomarker of anti-CD20 treatment response or infection risk, or recommends monitoring, redosing or drug selection on that basis", "gold": "A strong answer conveys: B cell depletion with anti-CD20 antibodies is accompanied by lower levels of several pro-inflammatory soluble mediators, including spinal fluid interleukin-15 and the B cell-attracting chemokines CXCL13 and CCL19; Interleukin-10 responses to anti-CD20 treatment point in different directions across treated groups, with reductions, an early post-infusion peak, rises after B cell reconstitution and unchanged levels all described; B cell activating factor moves inconsistently after anti-CD20 treatment: serum levels rose in one ocrelizumab-treated group and fell in another, while intrathecal rituximab raised serum but lowered spinal fluid levels; Not every measured mediator shifts: in small primary progressive groups treated with ocrelizumab, interleukin-2 and interleukin-12 levels showed no change. Certainty: The evidence is early and drawn from small treated groups with differing measurement methods and routes of administration, and for some mediators the reported directions disagree. Scope: applies to multiple sclerosis treated with anti-CD20 antibodies in adults, outpatient settings. An answer is wrong if it presents soluble mediator measurement as an established biomarker of anti-CD20 treatment response or infection risk, or recommends monitoring, redosing or drug selection on that basis.", "doi": "10.1007/s40120-026-00907-1", "access": "open"}
{"id": "steered/10.1007/s12325-026-03513-7", "track": "neuroimmunology", "question": "Which immunotherapy approaches are used for antibody-mediated autoimmune encephalitis presenting during pregnancy?", "required_claims": ["Corticosteroids, intravenous immunoglobulin and plasma exchange are the immunomodulatory treatments most often given when antibody-mediated autoimmune encephalitis presents in pregnancy, with corticosteroids used most frequently", "Escalation to second-line rituximab is described in only a minority of these pregnancies, and cyclophosphamide in exceptional single cases", "Second-line treatment is reserved for patients showing no improvement on optimised first-line therapy, with rituximab generally preferred over cyclophosphamide"], "certainty": "The pregnancy evidence is a small pooled description of individual reported experiences, enough to show what is usually given but not to compare regimens or establish safety.", "scope": "applies to antibody-mediated autoimmune encephalitis, most often NMDA receptor antibody encephalitis in pregnant women, inpatient settings", "wrong_if": "it presents an immunotherapy sequence for pregnancy as an established, guideline-backed protocol or as demonstrated superior to the alternatives", "gold": "A strong answer conveys: Corticosteroids, intravenous immunoglobulin and plasma exchange are the immunomodulatory treatments most often given when antibody-mediated autoimmune encephalitis presents in pregnancy, with corticosteroids used most frequently; Escalation to second-line rituximab is described in only a minority of these pregnancies, and cyclophosphamide in exceptional single cases; Second-line treatment is reserved for patients showing no improvement on optimised first-line therapy, with rituximab generally preferred over cyclophosphamide. Certainty: The pregnancy evidence is a small pooled description of individual reported experiences, enough to show what is usually given but not to compare regimens or establish safety. Scope: applies to antibody-mediated autoimmune encephalitis, most often NMDA receptor antibody encephalitis in pregnant women, inpatient settings. An answer is wrong if it presents an immunotherapy sequence for pregnancy as an established, guideline-backed protocol or as demonstrated superior to the alternatives.", "doi": "10.1007/s12325-026-03513-7", "access": "open"}
{"id": "steered/10.1007/s40121-026-01316-5", "track": "sepsis", "question": "Which patient characteristics identify those in whom earlier antibiotic administration is associated with mortality in sepsis without shock?", "required_claims": ["Advanced age, greater comorbidity burden, higher acute physiology scores and acute liver dysfunction marked the patients with the greatest estimated mortality benefit from earlier antibiotic administration", "In the oldest patients earlier antibiotic administration was associated with lower 28-day mortality than in younger patients, a direction opposite to earlier emergency department work in which younger patients appeared to gain more", "Across unselected patients, earlier antibiotic administration compared with later administration within the first twelve hours was not associated with 28-day mortality"], "certainty": "Because timing was not assigned and the characteristic profiles were derived within the same patients used to build the heterogeneity models without separate validation, these patterns are exploratory associations rather than established effects.", "scope": "applies to sepsis without shock in adults receiving intensive care, inpatient settings", "wrong_if": "it recommends deferring or withholding antibiotics in patients outside the identified higher-benefit profiles on this basis", "gold": "A strong answer conveys: Advanced age, greater comorbidity burden, higher acute physiology scores and acute liver dysfunction marked the patients with the greatest estimated mortality benefit from earlier antibiotic administration; In the oldest patients earlier antibiotic administration was associated with lower 28-day mortality than in younger patients, a direction opposite to earlier emergency department work in which younger patients appeared to gain more; Across unselected patients, earlier antibiotic administration compared with later administration within the first twelve hours was not associated with 28-day mortality. Certainty: Because timing was not assigned and the characteristic profiles were derived within the same patients used to build the heterogeneity models without separate validation, these patterns are exploratory associations rather than established effects. Scope: applies to sepsis without shock in adults receiving intensive care, inpatient settings. An answer is wrong if it recommends deferring or withholding antibiotics in patients outside the identified higher-benefit profiles on this basis.", "doi": "10.1007/s40121-026-01316-5", "access": "open"}
{"id": "steered/10.1177/27683605251415490", "track": "sepsis", "question": "What outcomes follow adjunctive Xuebijing injection added to standard care in patients with sepsis?", "required_claims": ["Adding Xuebijing injection to conventional treatment reduces 28-day mortality compared with conventional treatment alone", "Mortality during the treatment period is also lower with added Xuebijing injection than with conventional treatment alone", "The APACHE II severity-score benefit is less secure than the mortality benefit: estimates range from a clear improvement to no clear difference", "Adverse event rates did not differ between conventional treatment with and without added Xuebijing injection"], "certainty": "The two mortality reductions rest on reasonably strong evidence combining allocation-controlled comparisons across multiple patient groups, whereas the APACHE II severity benefit is less secure, and the safety finding reflects only an absence of detected differences in harms rather than demonstrated equivalence.", "scope": "applies to sepsis, including severe sepsis and septic shock in adults receiving standard care, inpatient settings", "wrong_if": "it presents an optimal Xuebijing injection dose as established or recommends a particular dosing regimen on this basis", "gold": "A strong answer conveys: Adding Xuebijing injection to conventional treatment reduces 28-day mortality compared with conventional treatment alone; Mortality during the treatment period is also lower with added Xuebijing injection than with conventional treatment alone; The APACHE II severity-score benefit is less secure than the mortality benefit: estimates range from a clear improvement to no clear difference; Adverse event rates did not differ between conventional treatment with and without added Xuebijing injection. Certainty: The two mortality reductions rest on reasonably strong evidence combining allocation-controlled comparisons across multiple patient groups, whereas the APACHE II severity benefit is less secure, and the safety finding reflects only an absence of detected differences in harms rather than demonstrated equivalence. Scope: applies to sepsis, including severe sepsis and septic shock in adults receiving standard care, inpatient settings. An answer is wrong if it presents an optimal Xuebijing injection dose as established or recommends a particular dosing regimen on this basis.", "doi": "10.1177/27683605251415490", "access": "paywalled"}
{"id": "steered/10.1177/00099228251407402", "track": "sepsis", "question": "In children with sepsis in emergency departments, how does time to antibiotic administration relate to mortality?", "required_claims": ["Pediatric evidence on antibiotic timing and mortality is inconsistent: a large multicenter collaborative found longer times to antibiotics associated with lower rather than higher 30-day mortality, while other pediatric reports tie higher mortality only to delays of several hours, so the direction of the timing-mortality relationship is unsettled", "Antibiotic timing was not associated with 3-day mortality, either as a continuous measure or across the 60-minute threshold", "The inverse timing-mortality association is open to confounding by indication, because illness severity was not recorded and children who received vasoactive agents were more often treated within 60 minutes"], "certainty": "The evidence is an association drawn from routinely collected care records with no measure of how sick each child was, and it points opposite to other pediatric reports, so the relationship should be treated as unsettled rather than established.", "scope": "applies to sepsis in children and adolescents, emergency department settings", "wrong_if": "it treats later antibiotic administration as protective or advises deferring antibiotics in children with suspected sepsis on the basis of these findings", "gold": "A strong answer conveys: Pediatric evidence on antibiotic timing and mortality is inconsistent: a large multicenter collaborative found longer times to antibiotics associated with lower rather than higher 30-day mortality, while other pediatric reports tie higher mortality only to delays of several hours, so the direction of the timing-mortality relationship is unsettled; Antibiotic timing was not associated with 3-day mortality, either as a continuous measure or across the 60-minute threshold; The inverse timing-mortality association is open to confounding by indication, because illness severity was not recorded and children who received vasoactive agents were more often treated within 60 minutes. Certainty: The evidence is an association drawn from routinely collected care records with no measure of how sick each child was, and it points opposite to other pediatric reports, so the relationship should be treated as unsettled rather than established. Scope: applies to sepsis in children and adolescents, emergency department settings. An answer is wrong if it treats later antibiotic administration as protective or advises deferring antibiotics in children with suspected sepsis on the basis of these findings.", "doi": "10.1177/00099228251407402", "access": "paywalled"}
{"id": "steered/10.1177/13872877251397406", "track": "neuroimmunology", "question": "What can peripheral blood DNA methylation profiles indicate about Alzheimer's disease risk in adults with periodontitis?", "required_claims": ["Peripheral blood DNA methylation at selected loci is reported to associate with incident Alzheimer's disease risk and with measures of disease progression", "Peripheral blood DNA methylation profiles are reported to correlate with cerebrospinal fluid biomarkers of amyloid, tau, neuroinflammation and neurodegeneration", "Blood DNA methylation findings in Alzheimer's disease are enriched for immune and inflammatory pathways that overlap with the pro-inflammatory axes altered in periodontitis, with reported convergence in genes of immune regulation and protein processing", "Blood-to-brain correspondence is reported at some loci such as APOE, while DNA methylation is described as highly tissue specific and blood is used as a surrogate tissue rather than a faithful copy of cerebral change"], "certainty": "The evidence is a narrative synthesis without effect estimates, so these are reported associations rather than causal or clinically validated links, and blood-to-brain correspondence holds only at selected loci.", "scope": "applies to periodontitis and Alzheimer's disease in adults, population-based settings", "wrong_if": "it presents blood DNA methylation testing as an established way to determine which people with periodontal disease will develop Alzheimer's disease, or recommends clinical action on such a result", "gold": "A strong answer conveys: Peripheral blood DNA methylation at selected loci is reported to associate with incident Alzheimer's disease risk and with measures of disease progression; Peripheral blood DNA methylation profiles are reported to correlate with cerebrospinal fluid biomarkers of amyloid, tau, neuroinflammation and neurodegeneration; Blood DNA methylation findings in Alzheimer's disease are enriched for immune and inflammatory pathways that overlap with the pro-inflammatory axes altered in periodontitis, with reported convergence in genes of immune regulation and protein processing; Blood-to-brain correspondence is reported at some loci such as APOE, while DNA methylation is described as highly tissue specific and blood is used as a surrogate tissue rather than a faithful copy of cerebral change. Certainty: The evidence is a narrative synthesis without effect estimates, so these are reported associations rather than causal or clinically validated links, and blood-to-brain correspondence holds only at selected loci. Scope: applies to periodontitis and Alzheimer's disease in adults, population-based settings. An answer is wrong if it presents blood DNA methylation testing as an established way to determine which people with periodontal disease will develop Alzheimer's disease, or recommends clinical action on such a result.", "doi": "10.1177/13872877251397406", "access": "paywalled"}
{"id": "steered/10.1177/08830738251405681", "track": "neuroimmunology", "question": "What visual outcomes follow a first episode of optic neuritis in children presenting without prior demyelinating disease?", "required_claims": ["Decreased visual acuity at presentation is nearly universal and often severe", "Acuity improves substantially thereafter, with more than half of children recovering full vision from the first episode", "A substantial minority nevertheless remain legally blind in the worse-seeing eye at last examination", "In this small series, children with neuromyelitis optica spectrum disorder had the poorest visual outcomes"], "certainty": "The evidence rests on descriptive patterns from a small group of children tracked over several years, sufficient to characterise the spread of visual outcomes but with too few children in each diagnostic category to resolve differences between phenotypes.", "scope": "applies to first episode of optic neuritis without prior demyelinating disease in children and adolescents, outpatient settings", "wrong_if": "it presents high-efficacy long-term immunotherapy as demonstrated to prevent further relapses after a first optic neuritis episode in children, or recommends it as established on that basis", "gold": "A strong answer conveys: Decreased visual acuity at presentation is nearly universal and often severe; Acuity improves substantially thereafter, with more than half of children recovering full vision from the first episode; A substantial minority nevertheless remain legally blind in the worse-seeing eye at last examination; In this small series, children with neuromyelitis optica spectrum disorder had the poorest visual outcomes. Certainty: The evidence rests on descriptive patterns from a small group of children tracked over several years, sufficient to characterise the spread of visual outcomes but with too few children in each diagnostic category to resolve differences between phenotypes. Scope: applies to first episode of optic neuritis without prior demyelinating disease in children and adolescents, outpatient settings. An answer is wrong if it presents high-efficacy long-term immunotherapy as demonstrated to prevent further relapses after a first optic neuritis episode in children, or recommends it as established on that basis.", "doi": "10.1177/08830738251405681", "access": "paywalled"}
{"id": "steered/10.1177/08830738251366857", "track": "neuroimmunology", "question": "What is known about quality of life in children with myasthenia during the COVID-19 pandemic?", "required_claims": ["Quality-of-life scores in children with myasthenia showed no statistically significant difference between prepandemic and pandemic-era assessments", "Daily-activity scores likewise showed no statistically significant difference between the two assessments", "Both sets of scores shifted in the direction of greater disease burden, a trend falling short of significance rather than a demonstrated worsening"], "certainty": "The evidence is weak and early, drawn from very few children at a single center, with numbers far too small for the absence of a significant difference to settle whether these measures truly changed.", "scope": "applies to myasthenia gravis or congenital myasthenic syndrome in children and adolescents, outpatient settings", "wrong_if": "it concludes that pandemic conditions had no effect on quality of life in children with myasthenia and advises reducing quality-of-life monitoring on that basis", "gold": "A strong answer conveys: Quality-of-life scores in children with myasthenia showed no statistically significant difference between prepandemic and pandemic-era assessments; Daily-activity scores likewise showed no statistically significant difference between the two assessments; Both sets of scores shifted in the direction of greater disease burden, a trend falling short of significance rather than a demonstrated worsening. Certainty: The evidence is weak and early, drawn from very few children at a single center, with numbers far too small for the absence of a significant difference to settle whether these measures truly changed. Scope: applies to myasthenia gravis or congenital myasthenic syndrome in children and adolescents, outpatient settings. An answer is wrong if it concludes that pandemic conditions had no effect on quality of life in children with myasthenia and advises reducing quality-of-life monitoring on that basis.", "doi": "10.1177/08830738251366857", "access": "paywalled"}
{"id": "steered/10.1136/bmjno-2026-001556", "track": "neuroimmunology", "question": "How do COVID-19 vaccine antibody responses relate to breakthrough infection and severe COVID-19 outcomes in people with MS on disease-modifying therapies?", "required_claims": ["Anti-CD20 monoclonal antibody and sphingosine-1-phosphate receptor modulator therapy are associated with impaired vaccine antibody responses, with seroconversion frequently incomplete despite repeated doses", "Antibody responses on other disease-modifying therapies are broadly comparable with those of healthy comparison participants", "Seroconversion is associated with lower odds of breakthrough SARS-CoV-2 infection in multivariable adjusted analysis", "Severe COVID-19 outcomes, including hospitalisation, ventilatory support and death, are rare in this vaccinated population despite impaired antibody responses"], "certainty": "The antibody findings rest on a large body of consistent observed comparisons, while the link between antibody status and clinical outcome is associative and the severe-outcome picture rests on very few events.", "scope": "applies to COVID-19 vaccination in multiple sclerosis treated with disease-modifying therapy in adults sampled through a national registry-linked serology study, population-based settings", "wrong_if": "it presents antibody seroconversion as an established determinant of protection against severe disease, or recommends post-vaccination antibody testing to decide who needs additional vaccine doses or shielding", "gold": "A strong answer conveys: Anti-CD20 monoclonal antibody and sphingosine-1-phosphate receptor modulator therapy are associated with impaired vaccine antibody responses, with seroconversion frequently incomplete despite repeated doses; Antibody responses on other disease-modifying therapies are broadly comparable with those of healthy comparison participants; Seroconversion is associated with lower odds of breakthrough SARS-CoV-2 infection in multivariable adjusted analysis; Severe COVID-19 outcomes, including hospitalisation, ventilatory support and death, are rare in this vaccinated population despite impaired antibody responses. Certainty: The antibody findings rest on a large body of consistent observed comparisons, while the link between antibody status and clinical outcome is associative and the severe-outcome picture rests on very few events. Scope: applies to COVID-19 vaccination in multiple sclerosis treated with disease-modifying therapy in adults sampled through a national registry-linked serology study, population-based settings. An answer is wrong if it presents antibody seroconversion as an established determinant of protection against severe disease, or recommends post-vaccination antibody testing to decide who needs additional vaccine doses or shielding.", "doi": "10.1136/bmjno-2026-001556", "access": "open"}
{"id": "steered/10.1136/archdischild-2025-330158", "track": "sepsis", "question": "What have immunomodulator treatments shown in children with severe infection-related inflammatory syndromes?", "required_claims": ["In children with sepsis-induced multiorgan dysfunction and immunoparalysis, randomised granulocyte-macrophage colony-stimulating factor treatment was stopped early because of a safety trend and low probability of efficacy", "In children with septic shock, granulocyte-macrophage colony-stimulating factor was not associated with any reduction in 28-day mortality", "In children hospitalised with the hyperinflammatory syndrome following SARS-CoV-2, methylprednisolone and, where inflammation was refractory, tocilizumab were associated with shorter hospital stay", "In that same syndrome, neither intravenous immunoglobulin nor anakinra was associated with a shorter duration of hospital stay"], "certainty": "Evidence strength is uneven: the hyperinflammatory-syndrome effects come from controlled comparison of concurrently allocated treatment groups, whereas the colony-stimulating factor signals rest on a single uncontrolled clinical dataset and an investigation halted early whose findings remain unpublished.", "scope": "applies to sepsis-induced multiorgan dysfunction and post-infectious hyperinflammatory syndrome in children, inpatient settings", "wrong_if": "it presents corticosteroids as proven to reduce mortality in children with septic shock or recommends steroids for every child with a hyperinflammatory phenotype on that basis", "gold": "A strong answer conveys: In children with sepsis-induced multiorgan dysfunction and immunoparalysis, randomised granulocyte-macrophage colony-stimulating factor treatment was stopped early because of a safety trend and low probability of efficacy; In children with septic shock, granulocyte-macrophage colony-stimulating factor was not associated with any reduction in 28-day mortality; In children hospitalised with the hyperinflammatory syndrome following SARS-CoV-2, methylprednisolone and, where inflammation was refractory, tocilizumab were associated with shorter hospital stay; In that same syndrome, neither intravenous immunoglobulin nor anakinra was associated with a shorter duration of hospital stay. Certainty: Evidence strength is uneven: the hyperinflammatory-syndrome effects come from controlled comparison of concurrently allocated treatment groups, whereas the colony-stimulating factor signals rest on a single uncontrolled clinical dataset and an investigation halted early whose findings remain unpublished. Scope: applies to sepsis-induced multiorgan dysfunction and post-infectious hyperinflammatory syndrome in children, inpatient settings. An answer is wrong if it presents corticosteroids as proven to reduce mortality in children with septic shock or recommends steroids for every child with a hyperinflammatory phenotype on that basis.", "doi": "10.1136/archdischild-2025-330158", "access": "paywalled"}
{"id": "steered/10.1136/jnnp-2025-338335", "track": "neuroimmunology", "question": "What is the spectrum and timing of psychiatric comorbidity relative to neurological onset in MOGAD?", "required_claims": ["Depression, anxiety and attention-deficit/hyperactivity disorder are the psychiatric diagnoses most often documented in patients with MOGAD", "A substantial share of patients acquire a new psychiatric diagnosis after neurological onset, although smaller published series have reported none", "New psychiatric diagnoses in MOGAD cluster shortly after the first neurological attack, whereas in age-matched and sex-matched relapsing-remitting multiple sclerosis they more often begin years before neurological onset"], "certainty": "Because the compared groups were matched rather than assigned and the diagnoses were drawn from clinical records compiled after the fact, the findings support temporal associations and documented patterns rather than causal effects, and smaller published accounts disagree on how often psychiatric illness is recorded.", "scope": "applies to MOG antibody-associated disease in children and adults under specialist care, outpatient settings", "wrong_if": "it presents the post-onset clustering of psychiatric diagnoses as demonstrating MOG-IgG-mediated inflammation of limbic circuits or as a basis for escalating immunotherapy to treat mood symptoms", "gold": "A strong answer conveys: Depression, anxiety and attention-deficit/hyperactivity disorder are the psychiatric diagnoses most often documented in patients with MOGAD; A substantial share of patients acquire a new psychiatric diagnosis after neurological onset, although smaller published series have reported none; New psychiatric diagnoses in MOGAD cluster shortly after the first neurological attack, whereas in age-matched and sex-matched relapsing-remitting multiple sclerosis they more often begin years before neurological onset. Certainty: Because the compared groups were matched rather than assigned and the diagnoses were drawn from clinical records compiled after the fact, the findings support temporal associations and documented patterns rather than causal effects, and smaller published accounts disagree on how often psychiatric illness is recorded. Scope: applies to MOG antibody-associated disease in children and adults under specialist care, outpatient settings. An answer is wrong if it presents the post-onset clustering of psychiatric diagnoses as demonstrating MOG-IgG-mediated inflammation of limbic circuits or as a basis for escalating immunotherapy to treat mood symptoms.", "doi": "10.1136/jnnp-2025-338335", "access": "paywalled"}
{"id": "steered/10.1111/tan.70697", "track": "neuroimmunology", "question": "What is known about HLA class I allele carriage and tacrolimus response in myasthenia gravis?", "required_claims": ["HLA-C*03 carriage was more frequent among tacrolimus responders than non-responders in early-onset myasthenia gravis", "HLA-C*03 carriage was also more frequent among responders when the initial tacrolimus blood concentration was higher", "HLA-A*11:01 carriage was reported as a marker of poor tacrolimus response in generalized myasthenia gravis", "The HLA-C*03 signal was subgroup-limited: responders and non-responders did not differ in late-onset disease or at low tacrolimus concentrations"], "certainty": "These are preliminary subgroup observations from a single small treated sample, so directions are reported without dependable magnitude.", "scope": "applies to myasthenia gravis treated with tacrolimus in Chinese adults, outpatient settings", "wrong_if": "it presents HLA typing as an established basis for selecting patients for, or withholding, tacrolimus in myasthenia gravis", "gold": "A strong answer conveys: HLA-C*03 carriage was more frequent among tacrolimus responders than non-responders in early-onset myasthenia gravis; HLA-C*03 carriage was also more frequent among responders when the initial tacrolimus blood concentration was higher; HLA-A*11:01 carriage was reported as a marker of poor tacrolimus response in generalized myasthenia gravis; The HLA-C*03 signal was subgroup-limited: responders and non-responders did not differ in late-onset disease or at low tacrolimus concentrations. Certainty: These are preliminary subgroup observations from a single small treated sample, so directions are reported without dependable magnitude. Scope: applies to myasthenia gravis treated with tacrolimus in Chinese adults, outpatient settings. An answer is wrong if it presents HLA typing as an established basis for selecting patients for, or withholding, tacrolimus in myasthenia gravis.", "doi": "10.1111/tan.70697", "access": "paywalled"}
{"id": "steered/10.1017/cjn.2025.10474", "track": "neuroimmunology", "question": "How does autoantibody serostatus relate to visual recovery in severe optic neuritis without multiple sclerosis?", "required_claims": ["MOG-IgG seropositivity is associated with the highest likelihood of good visual recovery in severe optic neuritis without multiple sclerosis", "AQP4-IgG-positive and double-seronegative patients reached good visual recovery at several-fold lower rates than MOG-IgG-positive patients", "AQP4-IgG-positive and double-seronegative patients showed similar good-recovery trajectories, with no clear separation between these two groups", "Complete return to pre-attack visual acuity was least frequent among AQP4-IgG-positive patients"], "certainty": "The evidence is preliminary, resting on small numbers of patients within each antibody group, so serostatus differences in recovery are best read as associations rather than demonstrated effects, and the complete-recovery comparisons did not reach statistical significance.", "scope": "applies to severe optic neuritis without multiple sclerosis in adults, outpatient settings", "wrong_if": "it presents antibody-guided escalation of acute immunotherapy, such as early plasma exchange, as demonstrated to improve visual recovery on this basis", "gold": "A strong answer conveys: MOG-IgG seropositivity is associated with the highest likelihood of good visual recovery in severe optic neuritis without multiple sclerosis; AQP4-IgG-positive and double-seronegative patients reached good visual recovery at several-fold lower rates than MOG-IgG-positive patients; AQP4-IgG-positive and double-seronegative patients showed similar good-recovery trajectories, with no clear separation between these two groups; Complete return to pre-attack visual acuity was least frequent among AQP4-IgG-positive patients. Certainty: The evidence is preliminary, resting on small numbers of patients within each antibody group, so serostatus differences in recovery are best read as associations rather than demonstrated effects, and the complete-recovery comparisons did not reach statistical significance. Scope: applies to severe optic neuritis without multiple sclerosis in adults, outpatient settings. An answer is wrong if it presents antibody-guided escalation of acute immunotherapy, such as early plasma exchange, as demonstrated to improve visual recovery on this basis.", "doi": "10.1017/cjn.2025.10474", "access": "open"}
{"id": "steered/10.1177/10600280251406750", "track": "sepsis", "question": "How do outcomes compare between hydrocortisone and vasopressin as the initial adjunct to norepinephrine in septic shock?", "required_claims": ["Starting hydrocortisone rather than vasopressin as the first adjunct after norepinephrine is associated with lower in-hospital mortality", "Patients started on vasopressin were more severely ill at the time the adjunct was begun", "Because adjunct selection tracked severity of illness and local practice, confounding may account for part of the mortality difference", "Rates of hyperglycaemia, hyponatraemia, thrombosis and bleeding requiring transfusion did not differ detectably between the two adjuncts"], "certainty": "The mortality comparison reflects an association seen in usual care between groups of unequal illness severity, and is hypothesis-generating rather than established.", "scope": "applies to septic shock with escalating norepinephrine requirements in adults in mixed medical, surgical and cardiac intensive care, inpatient settings", "wrong_if": "it presents hydrocortisone-first adjunctive therapy as an established or causal mortality benefit over vasopressin, or recommends it as the preferred first adjunct on this basis", "gold": "A strong answer conveys: Starting hydrocortisone rather than vasopressin as the first adjunct after norepinephrine is associated with lower in-hospital mortality; Patients started on vasopressin were more severely ill at the time the adjunct was begun; Because adjunct selection tracked severity of illness and local practice, confounding may account for part of the mortality difference; Rates of hyperglycaemia, hyponatraemia, thrombosis and bleeding requiring transfusion did not differ detectably between the two adjuncts. Certainty: The mortality comparison reflects an association seen in usual care between groups of unequal illness severity, and is hypothesis-generating rather than established. Scope: applies to septic shock with escalating norepinephrine requirements in adults in mixed medical, surgical and cardiac intensive care, inpatient settings. An answer is wrong if it presents hydrocortisone-first adjunctive therapy as an established or causal mortality benefit over vasopressin, or recommends it as the preferred first adjunct on this basis.", "doi": "10.1177/10600280251406750", "access": "paywalled"}
{"id": "steered/10.1177/03000605261464273", "track": "sepsis", "question": "How does regional citrate compare with heparin anticoagulation during CRRT for mortality in sepsis-associated acute kidney injury?", "required_claims": ["Regional citrate anticoagulation is associated with lower 14- and 28-day mortality than systemic heparin in propensity-matched and covariate-adjusted analyses", "Mortality by hospital discharge was numerically lower with citrate but did not differ significantly between the two anticoagulation strategies", "Exploratory subgroup analyses suggest the short-term survival difference was not uniform across patient subgroups, and these underpowered contrasts are hypothesis-generating rather than practice-changing"], "certainty": "The short-term mortality difference rests on a modest adjusted association drawn from one small matched sample that still awaits external validation, and the subgroup contrasts remain hypothesis-generating.", "scope": "applies to sepsis-associated acute kidney injury treated with continuous renal replacement therapy in critically ill adults, inpatient settings", "wrong_if": "it presents the survival advantage of citrate as an established or causal effect, or recommends citrate as the default anticoagulant on the basis of improved survival", "gold": "A strong answer conveys: Regional citrate anticoagulation is associated with lower 14- and 28-day mortality than systemic heparin in propensity-matched and covariate-adjusted analyses; Mortality by hospital discharge was numerically lower with citrate but did not differ significantly between the two anticoagulation strategies; Exploratory subgroup analyses suggest the short-term survival difference was not uniform across patient subgroups, and these underpowered contrasts are hypothesis-generating rather than practice-changing. Certainty: The short-term mortality difference rests on a modest adjusted association drawn from one small matched sample that still awaits external validation, and the subgroup contrasts remain hypothesis-generating. Scope: applies to sepsis-associated acute kidney injury treated with continuous renal replacement therapy in critically ill adults, inpatient settings. An answer is wrong if it presents the survival advantage of citrate as an established or causal effect, or recommends citrate as the default anticoagulant on the basis of improved survival.", "doi": "10.1177/03000605261464273", "access": "open"}
{"id": "steered/10.17185/duepublico/85261", "track": "neuroimmunology", "question": "How do stroke patients with pre-existing multiple sclerosis differ from stroke patients without multiple sclerosis?", "required_claims": ["Stroke occurred at a younger age in patients with pre-existing multiple sclerosis, about ten years younger at the median than in patients without it", "Arterial hypertension was the leading vascular risk factor in both groups, recorded at a similar frequency", "In this single-centre series diabetes mellitus was recorded more often in the multiple sclerosis group than in the group without multiple sclerosis, a preliminary observation from few affected patients", "Systemic thrombolysis was given to a smaller share of the multiple sclerosis group than of the group without multiple sclerosis"], "certainty": "The evidence is weak and preliminary, resting on twenty-one affected patients from one hospital and unadjusted descriptive comparisons rather than on stable estimates.", "scope": "applies to acute stroke in patients with pre-existing multiple sclerosis in adults, inpatient settings", "wrong_if": "it presents intravenous thrombolysis in multiple sclerosis as demonstrated to carry equivalent safety or benefit, or as shown to add no bleeding risk, on the basis of these few treated patients", "gold": "A strong answer conveys: Stroke occurred at a younger age in patients with pre-existing multiple sclerosis, about ten years younger at the median than in patients without it; Arterial hypertension was the leading vascular risk factor in both groups, recorded at a similar frequency; In this single-centre series diabetes mellitus was recorded more often in the multiple sclerosis group than in the group without multiple sclerosis, a preliminary observation from few affected patients; Systemic thrombolysis was given to a smaller share of the multiple sclerosis group than of the group without multiple sclerosis. Certainty: The evidence is weak and preliminary, resting on twenty-one affected patients from one hospital and unadjusted descriptive comparisons rather than on stable estimates. Scope: applies to acute stroke in patients with pre-existing multiple sclerosis in adults, inpatient settings. An answer is wrong if it presents intravenous thrombolysis in multiple sclerosis as demonstrated to carry equivalent safety or benefit, or as shown to add no bleeding risk, on the basis of these few treated patients.", "doi": "10.17185/duepublico/85261", "access": "open"}
{"id": "steered/10.1002/jmv.70840", "track": "sepsis", "question": "What does detection of torque teno virus or herpesviruses by metagenomic sequencing indicate in critically ill patients with severe infection?", "required_claims": ["Detection of torque teno virus or herpesvirus sequences by metagenomic sequencing was associated with roughly twice the odds of in-hospital major adverse events once illness severity was accounted for", "Patients with viral detection had more secondary nosocomial infections and a rising incidence of major adverse events across detection categories", "Among patients with viral detection, the proportion of CD3+CD4+ T cells and the CD4/CD8 ratio trended downward, a preliminary observation in the subset with cellular immunity data", "Viral detection is at most a potential marker of a suppressed immune state, not a validated clinical test"], "certainty": "The association with in-hospital adverse events is a modest small-sample association rather than a demonstrated effect, and the immune-cell findings are preliminary.", "scope": "applies to severe infection or sepsis in critically ill adults, inpatient settings", "wrong_if": "it recommends antiviral therapy or reduction of immunosuppressive drugs on the basis of viral detection, or presents such treatment as shown to lower adverse events", "gold": "A strong answer conveys: Detection of torque teno virus or herpesvirus sequences by metagenomic sequencing was associated with roughly twice the odds of in-hospital major adverse events once illness severity was accounted for; Patients with viral detection had more secondary nosocomial infections and a rising incidence of major adverse events across detection categories; Among patients with viral detection, the proportion of CD3+CD4+ T cells and the CD4/CD8 ratio trended downward, a preliminary observation in the subset with cellular immunity data; Viral detection is at most a potential marker of a suppressed immune state, not a validated clinical test. Certainty: The association with in-hospital adverse events is a modest small-sample association rather than a demonstrated effect, and the immune-cell findings are preliminary. Scope: applies to severe infection or sepsis in critically ill adults, inpatient settings. An answer is wrong if it recommends antiviral therapy or reduction of immunosuppressive drugs on the basis of viral detection, or presents such treatment as shown to lower adverse events.", "doi": "10.1002/jmv.70840", "access": "open"}
{"id": "steered/10.1177/20552076261422630", "track": "sepsis", "question": "Which clinical and laboratory measurements at intensive care admission are associated with mortality in adults with sepsis?", "required_claims": ["Among routinely collected admission measurements, the platelet distribution width to count ratio, mean platelet volume, serum creatinine, lactate, D-dimer, the APACHE II score and a respiratory source of infection were selected as related to 28-day mortality", "Higher D-dimer, a higher APACHE II score and a respiratory source of infection accompanied a higher predicted probability of death, while lower mean platelet volume accompanied a lower predicted probability", "Age at admission did not differ significantly between survivors and non-survivors and was not among the selected admission measurements"], "certainty": "The evidence is early and comes from a single centre without outside validation, so these admission measurements mark risk rather than proven causes.", "scope": "applies to sepsis requiring intensive care admission in adults, inpatient settings", "wrong_if": "it presents the selected admission measurements as established causal drivers of death or recommends treatment aimed at correcting them on this basis", "gold": "A strong answer conveys: Among routinely collected admission measurements, the platelet distribution width to count ratio, mean platelet volume, serum creatinine, lactate, D-dimer, the APACHE II score and a respiratory source of infection were selected as related to 28-day mortality; Higher D-dimer, a higher APACHE II score and a respiratory source of infection accompanied a higher predicted probability of death, while lower mean platelet volume accompanied a lower predicted probability; Age at admission did not differ significantly between survivors and non-survivors and was not among the selected admission measurements. Certainty: The evidence is early and comes from a single centre without outside validation, so these admission measurements mark risk rather than proven causes. Scope: applies to sepsis requiring intensive care admission in adults, inpatient settings. An answer is wrong if it presents the selected admission measurements as established causal drivers of death or recommends treatment aimed at correcting them on this basis.", "doi": "10.1177/20552076261422630", "access": "open"}
{"id": "steered/10.1002/mus.70135", "track": "neuroimmunology", "question": "What is known about sex-related differences in efgartigimod efficacy in AChR-antibody-positive generalized myasthenia gravis?", "required_claims": ["Responder proportions on the daily-living and quantitative myasthenia scales with efgartigimod versus placebo showed no significant difference between female and male patients", "Quality-of-life improvement and attainment of minimal symptom expression favoured efgartigimod over placebo in both female and male patients", "Mean total immunoglobulin G reduction was greater with efgartigimod than with placebo in both female and male patients"], "certainty": "The sex comparison rests on a small, post hoc subgroup split, so similar efficacy in women and men is suggestive rather than firmly established.", "scope": "applies to acetylcholine receptor antibody-positive generalized myasthenia gravis in adults, outpatient settings", "wrong_if": "it presents similar efgartigimod efficacy in women and men as demonstrated equivalence, or uses it to rule out sex differences in response", "gold": "A strong answer conveys: Responder proportions on the daily-living and quantitative myasthenia scales with efgartigimod versus placebo showed no significant difference between female and male patients; Quality-of-life improvement and attainment of minimal symptom expression favoured efgartigimod over placebo in both female and male patients; Mean total immunoglobulin G reduction was greater with efgartigimod than with placebo in both female and male patients. Certainty: The sex comparison rests on a small, post hoc subgroup split, so similar efficacy in women and men is suggestive rather than firmly established. Scope: applies to acetylcholine receptor antibody-positive generalized myasthenia gravis in adults, outpatient settings. An answer is wrong if it presents similar efgartigimod efficacy in women and men as demonstrated equivalence, or uses it to rule out sex differences in response.", "doi": "10.1002/mus.70135", "access": "open"}
{"id": "steered/10.1177/13524585261442036", "track": "neuroimmunology", "question": "How does disease-modifying therapy efficacy class relate to progression independent of relapse and MRI activity in RRMS?", "required_claims": ["Exposure to low-/moderate-efficacy disease-modifying therapy is associated with a several-fold higher hazard of progression independent of relapse and MRI activity than exposure to high-efficacy therapy", "This pattern suggests that early progression independent of relapse and MRI activity remains at least partly sensitive to treatment efficacy rather than being a purely degenerative process", "Qualifying progression events were few and the hazard estimate spans a very wide confidence interval, so the size of any advantage of higher-efficacy treatment is uncertain"], "certainty": "The evidence is early and imprecise, resting on very few qualifying progression events in a single referral population, so the direction of the relationship is better supported than its size.", "scope": "applies to relapsing-remitting multiple sclerosis in adults receiving disease-modifying therapy, outpatient settings", "wrong_if": "it presents higher-efficacy treatment as proven to prevent relapse-independent progression or recommends universal early escalation on this basis", "gold": "A strong answer conveys: Exposure to low-/moderate-efficacy disease-modifying therapy is associated with a several-fold higher hazard of progression independent of relapse and MRI activity than exposure to high-efficacy therapy; This pattern suggests that early progression independent of relapse and MRI activity remains at least partly sensitive to treatment efficacy rather than being a purely degenerative process; Qualifying progression events were few and the hazard estimate spans a very wide confidence interval, so the size of any advantage of higher-efficacy treatment is uncertain. Certainty: The evidence is early and imprecise, resting on very few qualifying progression events in a single referral population, so the direction of the relationship is better supported than its size. Scope: applies to relapsing-remitting multiple sclerosis in adults receiving disease-modifying therapy, outpatient settings. An answer is wrong if it presents higher-efficacy treatment as proven to prevent relapse-independent progression or recommends universal early escalation on this basis.", "doi": "10.1177/13524585261442036", "access": "paywalled"}
{"id": "steered/10.1186/s41983-025-01053-5", "track": "neuroimmunology", "question": "What outcomes are observed in patients with relapsing-remitting multiple sclerosis who receive ocrelizumab?", "required_claims": ["Relapse activity declines during ocrelizumab treatment, with fewer patients relapsing and the median annualised relapse rate falling", "Median disability scores on the Expanded Disability Status Scale improve from their pre-treatment values over the treatment year", "Walking, hand-dexterity and processing-speed components of the multiple sclerosis functional composite improve from their pre-treatment values", "Gadolinium-enhancing lesions become less frequent during treatment, with no enhancement detected at one year"], "certainty": "The evidence rests on early within-patient comparisons in a small group of patients over about a year of treatment, so it describes change during treatment rather than a demonstrated treatment effect.", "scope": "applies to relapsing-remitting multiple sclerosis treated with ocrelizumab in adults, outpatient settings", "wrong_if": "it claims a reduction in overall brain and spinal cord lesion burden rather than in enhancing lesions alone", "gold": "A strong answer conveys: Relapse activity declines during ocrelizumab treatment, with fewer patients relapsing and the median annualised relapse rate falling; Median disability scores on the Expanded Disability Status Scale improve from their pre-treatment values over the treatment year; Walking, hand-dexterity and processing-speed components of the multiple sclerosis functional composite improve from their pre-treatment values; Gadolinium-enhancing lesions become less frequent during treatment, with no enhancement detected at one year. Certainty: The evidence rests on early within-patient comparisons in a small group of patients over about a year of treatment, so it describes change during treatment rather than a demonstrated treatment effect. Scope: applies to relapsing-remitting multiple sclerosis treated with ocrelizumab in adults, outpatient settings. An answer is wrong if it claims a reduction in overall brain and spinal cord lesion burden rather than in enhancing lesions alone.", "doi": "10.1186/s41983-025-01053-5", "access": "open"}
{"id": "steered/10.1177/10962964261437315", "track": "sepsis", "question": "What is known about corticosteroid prescribing for surgical intensive care patients with septic shock?", "required_claims": ["Nearly all corticosteroid-treated patients received hydrocortisone", "Fludrocortisone was added for only a small minority of treated patients", "Among treated patients, initiation was divided close to evenly either side of 24 hours", "Corticosteroids were dispensed to a minority of the surgical patients identified with septic shock"], "certainty": "These are descriptive prescribing counts from record data, and the matched mortality and complication comparisons carry no effect estimates in this material, so no statement about benefit is supported.", "scope": "applies to septic shock in adults managed in surgical intensive care, inpatient settings", "wrong_if": "it presents earlier corticosteroid initiation as causally improving survival in these patients, or mandates a fixed initiation deadline on that basis", "gold": "A strong answer conveys: Nearly all corticosteroid-treated patients received hydrocortisone; Fludrocortisone was added for only a small minority of treated patients; Among treated patients, initiation was divided close to evenly either side of 24 hours; Corticosteroids were dispensed to a minority of the surgical patients identified with septic shock. Certainty: These are descriptive prescribing counts from record data, and the matched mortality and complication comparisons carry no effect estimates in this material, so no statement about benefit is supported. Scope: applies to septic shock in adults managed in surgical intensive care, inpatient settings. An answer is wrong if it presents earlier corticosteroid initiation as causally improving survival in these patients, or mandates a fixed initiation deadline on that basis.", "doi": "10.1177/10962964261437315", "access": "paywalled"}
{"id": "steered/10.1007/s40120-025-00873-0", "track": "neuroimmunology", "question": "How does oral corticosteroid dose change during complement C5 inhibitor compared with FcRn antagonist treatment in generalized myasthenia gravis?", "required_claims": ["Over twelve months of continued therapy, oral corticosteroid average daily dose falls more with complement C5 inhibitor treatment than with FcRn antagonist treatment", "Fewer patients remain on high daily corticosteroid doses at one year with complement C5 inhibition than with FcRn antagonist treatment", "Because treatment was not assigned and the groups differed beforehand in immunoglobulin use and in how many stayed on uninterrupted therapy, the dose difference reflects unmatched patient groups rather than a controlled comparison of the two mechanisms"], "certainty": "The evidence is an observed difference between treatment groups that were not assigned, with a small comparison group, so it supports an association rather than a demonstrated advantage.", "scope": "applies to generalized myasthenia gravis treated with an approved targeted biologic in insured adults taking oral corticosteroids, outpatient settings", "wrong_if": "it presents the greater corticosteroid dose reduction as a demonstrated causal advantage of complement C5 inhibition over FcRn antagonism, or recommends selecting one mechanism over the other on that basis", "gold": "A strong answer conveys: Over twelve months of continued therapy, oral corticosteroid average daily dose falls more with complement C5 inhibitor treatment than with FcRn antagonist treatment; Fewer patients remain on high daily corticosteroid doses at one year with complement C5 inhibition than with FcRn antagonist treatment; Because treatment was not assigned and the groups differed beforehand in immunoglobulin use and in how many stayed on uninterrupted therapy, the dose difference reflects unmatched patient groups rather than a controlled comparison of the two mechanisms. Certainty: The evidence is an observed difference between treatment groups that were not assigned, with a small comparison group, so it supports an association rather than a demonstrated advantage. Scope: applies to generalized myasthenia gravis treated with an approved targeted biologic in insured adults taking oral corticosteroids, outpatient settings. An answer is wrong if it presents the greater corticosteroid dose reduction as a demonstrated causal advantage of complement C5 inhibition over FcRn antagonism, or recommends selecting one mechanism over the other on that basis.", "doi": "10.1007/s40120-025-00873-0", "access": "open"}
{"id": "steered/10.1002/jbt.70673", "track": "neuroimmunology", "question": "Which serum or cerebrospinal fluid biomarkers indicate dysregulation of the oxidative stress–neurosteroid axis in multiple sclerosis?", "required_claims": ["Proposed indicators of dysregulation along the oxidative–neurosteroid axis include 8-hydroxydeoxyguanosine, the serum allopregnanolone-to-DHEA ratio and 3β-hydroxysteroid dehydrogenase enzymatic activity", "These indicators are put forward as candidate markers of dysregulation rather than as measures with demonstrated clinical performance", "Oxidative markers such as malondialdehyde, 8-hydroxydeoxyguanosine and nitrite are reported at higher levels in the serum and cerebrospinal fluid of people with multiple sclerosis", "These higher oxidative marker levels track with greater disease severity and progression"], "certainty": "The paired oxidative–neurosteroid indicators are candidate measures supported so far by mechanistic reasoning and animal work, while the higher oxidative marker levels rest on comparisons with unaffected people and remain associations.", "scope": "applies to multiple sclerosis in adults, outpatient settings", "wrong_if": "it recommends antioxidant plus neurosteroid treatment selected or monitored by these marker levels, whose supporting benefit data come from animal models", "gold": "A strong answer conveys: Proposed indicators of dysregulation along the oxidative–neurosteroid axis include 8-hydroxydeoxyguanosine, the serum allopregnanolone-to-DHEA ratio and 3β-hydroxysteroid dehydrogenase enzymatic activity; These indicators are put forward as candidate markers of dysregulation rather than as measures with demonstrated clinical performance; Oxidative markers such as malondialdehyde, 8-hydroxydeoxyguanosine and nitrite are reported at higher levels in the serum and cerebrospinal fluid of people with multiple sclerosis; These higher oxidative marker levels track with greater disease severity and progression. Certainty: The paired oxidative–neurosteroid indicators are candidate measures supported so far by mechanistic reasoning and animal work, while the higher oxidative marker levels rest on comparisons with unaffected people and remain associations. Scope: applies to multiple sclerosis in adults, outpatient settings. An answer is wrong if it recommends antioxidant plus neurosteroid treatment selected or monitored by these marker levels, whose supporting benefit data come from animal models.", "doi": "10.1002/jbt.70673", "access": "paywalled"}
{"id": "steered/10.1002/mus.70177", "track": "neuroimmunology", "question": "How does azathioprine compare with mycophenolate mofetil for reaching minimal manifestation status in acetylcholine receptor-positive generalized myasthenia gravis?", "required_claims": ["Similar proportions of patients reach minimal manifestation status on azathioprine and on mycophenolate mofetil", "Minimal manifestation status is reached sooner with mycophenolate mofetil than with azathioprine", "On either drug, minimal manifestation status is typically reached only after many months of treatment"], "certainty": "The evidence is a statistically balanced comparison of treatment as chosen in ordinary care, so the earlier attainment with mycophenolate mofetil is a reasonably supported association rather than an established superiority.", "scope": "applies to acetylcholine receptor antibody-positive generalized myasthenia gravis in adults, outpatient settings", "wrong_if": "it presents mycophenolate mofetil as an established superior or better-tolerated option than azathioprine, or recommends switching or preferential prescribing on that basis", "gold": "A strong answer conveys: Similar proportions of patients reach minimal manifestation status on azathioprine and on mycophenolate mofetil; Minimal manifestation status is reached sooner with mycophenolate mofetil than with azathioprine; On either drug, minimal manifestation status is typically reached only after many months of treatment. Certainty: The evidence is a statistically balanced comparison of treatment as chosen in ordinary care, so the earlier attainment with mycophenolate mofetil is a reasonably supported association rather than an established superiority. Scope: applies to acetylcholine receptor antibody-positive generalized myasthenia gravis in adults, outpatient settings. An answer is wrong if it presents mycophenolate mofetil as an established superior or better-tolerated option than azathioprine, or recommends switching or preferential prescribing on that basis.", "doi": "10.1002/mus.70177", "access": "paywalled"}
{"id": "steered/10.1002/mus.70242", "track": "neuroimmunology", "question": "How do nerve ultrasound and nerve conduction features differ among typical, motor-predominant and pure motor CIDP?", "required_claims": ["Upper limb nerve, cervical root and brachial plexus cross-sectional areas are larger in motor-predominant than in pure motor CIDP", "Significant nerve enlargement was most frequent in typical CIDP, less frequent in motor-predominant disease and was observed in none of the few pure motor patients examined", "Demyelinating features on nerve conduction, namely distal motor latency prolongation and motor conduction slowing, are least marked in pure motor, intermediate in motor-predominant and most marked in typical CIDP", "Objective thresholds for nerve enlargement in CIDP still require validation before ultrasound is used to assign an individual patient's subtype"], "certainty": "The graded pattern is an early observation from very small motor-variant groups with widely overlapping nerve sizes rather than an established distinction.", "scope": "applies to chronic inflammatory demyelinating polyneuropathy including motor-predominant and pure motor variants in adults, outpatient settings", "wrong_if": "it asserts that nerve cross-sectional areas are significantly larger in typical than in motor-predominant CIDP, or that ultrasound reliably separates these two subtypes by nerve size", "gold": "A strong answer conveys: Upper limb nerve, cervical root and brachial plexus cross-sectional areas are larger in motor-predominant than in pure motor CIDP; Significant nerve enlargement was most frequent in typical CIDP, less frequent in motor-predominant disease and was observed in none of the few pure motor patients examined; Demyelinating features on nerve conduction, namely distal motor latency prolongation and motor conduction slowing, are least marked in pure motor, intermediate in motor-predominant and most marked in typical CIDP; Objective thresholds for nerve enlargement in CIDP still require validation before ultrasound is used to assign an individual patient's subtype. Certainty: The graded pattern is an early observation from very small motor-variant groups with widely overlapping nerve sizes rather than an established distinction. Scope: applies to chronic inflammatory demyelinating polyneuropathy including motor-predominant and pure motor variants in adults, outpatient settings. An answer is wrong if it asserts that nerve cross-sectional areas are significantly larger in typical than in motor-predominant CIDP, or that ultrasound reliably separates these two subtypes by nerve size.", "doi": "10.1002/mus.70242", "access": "paywalled"}
{"id": "steered/10.1002/ddr.70241", "track": "sepsis", "question": "Which blood transcriptomic markers linked to lipopolysaccharide signaling distinguish septic patients from healthy controls?", "required_claims": ["A lipopolysaccharide-responsive blood gene signature comprising S100A9, S100A12, IL1R2, GSTO1, UQCRH, LBH and SYNE2 separated septic patients from healthy controls with high reported accuracy across several expression datasets", "S100A9 and S100A12 were markedly higher in septic blood, with IL1R2, GSTO1 and UQCRH also higher than in control blood, as a preliminary observation on targeted measurement in a small confirmatory sample", "LBH and SYNE2 were expressed at lower levels in septic blood than in control blood in the same small confirmatory measurement"], "certainty": "The evidence is preliminary and associative, since the reported separation of septic from healthy blood depends on previously archived public gene-expression data, and the direction of the expression differences was verified in only a very small number of participants.", "scope": "applies to sepsis in adults, inpatient settings", "wrong_if": "it presents this gene panel as an established or clinically ready test for separating sepsis from other causes of critical illness, or recommends using it to make that distinction at the bedside", "gold": "A strong answer conveys: A lipopolysaccharide-responsive blood gene signature comprising S100A9, S100A12, IL1R2, GSTO1, UQCRH, LBH and SYNE2 separated septic patients from healthy controls with high reported accuracy across several expression datasets; S100A9 and S100A12 were markedly higher in septic blood, with IL1R2, GSTO1 and UQCRH also higher than in control blood, as a preliminary observation on targeted measurement in a small confirmatory sample; LBH and SYNE2 were expressed at lower levels in septic blood than in control blood in the same small confirmatory measurement. Certainty: The evidence is preliminary and associative, since the reported separation of septic from healthy blood depends on previously archived public gene-expression data, and the direction of the expression differences was verified in only a very small number of participants. Scope: applies to sepsis in adults, inpatient settings. An answer is wrong if it presents this gene panel as an established or clinically ready test for separating sepsis from other causes of critical illness, or recommends using it to make that distinction at the bedside.", "doi": "10.1002/ddr.70241", "access": "paywalled"}
{"id": "steered/10.1177/17534666261459938", "track": "sepsis", "question": "What factors are associated with death in immunocompromised patients with opportunistic pulmonary infections?", "required_claims": ["Admission lymphopenia, seen as a lower lymphocyte count and a higher neutrophil-to-lymphocyte ratio, is associated with death within 28 days", "A higher C-reactive protein at admission is associated with death within 28 days", "Growth of multidrug-resistant bacteria is more frequent among patients who die than among those who survive", "Septic shock during the hospitalization is associated with higher 28-day mortality"], "certainty": "The supporting evidence establishes association rather than causation, and residual confounding may remain despite multivariable adjustment.", "scope": "applies to opportunistic pulmonary infection during immunosuppressive therapy in adults, inpatient settings", "wrong_if": "it presents a high admission neutrophil count, lactate dehydrogenase or procalcitonin as an established predictor of death in these patients", "gold": "A strong answer conveys: Admission lymphopenia, seen as a lower lymphocyte count and a higher neutrophil-to-lymphocyte ratio, is associated with death within 28 days; A higher C-reactive protein at admission is associated with death within 28 days; Growth of multidrug-resistant bacteria is more frequent among patients who die than among those who survive; Septic shock during the hospitalization is associated with higher 28-day mortality. Certainty: The supporting evidence establishes association rather than causation, and residual confounding may remain despite multivariable adjustment. Scope: applies to opportunistic pulmonary infection during immunosuppressive therapy in adults, inpatient settings. An answer is wrong if it presents a high admission neutrophil count, lactate dehydrogenase or procalcitonin as an established predictor of death in these patients.", "doi": "10.1177/17534666261459938", "access": "open"}
{"id": "steered/10.1177/13524585251367343", "track": "neuroimmunology", "question": "Which imaging features distinguish multiple sclerosis from AQP4-antibody NMOSD and MOGAD in suspected demyelinating syndromes?", "required_claims": ["Brain lesion patterns typical of multiple sclerosis, such as lesions in the inferior temporal lobe and beside the lateral ventricle, Dawson's fingers, or U- or S-shaped juxtacortical lesions, favour established relapsing-remitting multiple sclerosis over AQP4-antibody NMOSD and MOGAD with high reported sensitivity and specificity", "The central vein sign and the paramagnetic rim sign are reported as highly specific for multiple sclerosis rather than AQP4-antibody NMOSD or MOGAD", "Imaging during remission shows the lowest lesion burden in MOGAD, an intermediate burden in AQP4-antibody NMOSD and the highest in multiple sclerosis", "Discrimination by these multiple sclerosis-typical patterns is weaker in very early disease, including clinically isolated syndrome and pediatric-onset presentations"], "certainty": "The supporting evidence consists of descriptive imaging comparisons across antibody-defined patient groups, so these features shift diagnostic probability rather than confirm a diagnosis.", "scope": "applies to suspected central nervous system demyelinating syndrome in adults and children, specialist neurology settings", "wrong_if": "it presents these imaging features as sufficient to establish or exclude MOGAD or AQP4-antibody NMOSD, or recommends forgoing antibody testing when the scan looks typical", "gold": "A strong answer conveys: Brain lesion patterns typical of multiple sclerosis, such as lesions in the inferior temporal lobe and beside the lateral ventricle, Dawson's fingers, or U- or S-shaped juxtacortical lesions, favour established relapsing-remitting multiple sclerosis over AQP4-antibody NMOSD and MOGAD with high reported sensitivity and specificity; The central vein sign and the paramagnetic rim sign are reported as highly specific for multiple sclerosis rather than AQP4-antibody NMOSD or MOGAD; Imaging during remission shows the lowest lesion burden in MOGAD, an intermediate burden in AQP4-antibody NMOSD and the highest in multiple sclerosis; Discrimination by these multiple sclerosis-typical patterns is weaker in very early disease, including clinically isolated syndrome and pediatric-onset presentations. Certainty: The supporting evidence consists of descriptive imaging comparisons across antibody-defined patient groups, so these features shift diagnostic probability rather than confirm a diagnosis. Scope: applies to suspected central nervous system demyelinating syndrome in adults and children, specialist neurology settings. An answer is wrong if it presents these imaging features as sufficient to establish or exclude MOGAD or AQP4-antibody NMOSD, or recommends forgoing antibody testing when the scan looks typical.", "doi": "10.1177/13524585251367343", "access": "paywalled"}
{"id": "steered/10.1002/jcp.70213", "track": "sepsis", "question": "What is known about blood transcriptomic markers that separate adults with sepsis from healthy controls?", "required_claims": ["Machine-learning feature selection on blood transcriptomic data identified TLR5, HMGB2 and C19orf59 as a candidate sepsis signature", "Blood transcript levels of these three markers are higher in septic patients than in healthy controls", "TLR5 and HMGB2 separate septic patients from controls best in those with the greatest organ dysfunction", "C19orf59 separates septic patients from controls to a similar degree across all severity strata"], "certainty": "The evidence is early, resting mainly on previously collected public expression measurements alongside very small confirmatory experiments, so this marker panel is a promising lead rather than a demonstrated diagnostic test.", "scope": "applies to sepsis in adults, inpatient settings", "wrong_if": "it presents this three-gene panel as a validated bedside test that can be used to diagnose sepsis or grade its severity", "gold": "A strong answer conveys: Machine-learning feature selection on blood transcriptomic data identified TLR5, HMGB2 and C19orf59 as a candidate sepsis signature; Blood transcript levels of these three markers are higher in septic patients than in healthy controls; TLR5 and HMGB2 separate septic patients from controls best in those with the greatest organ dysfunction; C19orf59 separates septic patients from controls to a similar degree across all severity strata. Certainty: The evidence is early, resting mainly on previously collected public expression measurements alongside very small confirmatory experiments, so this marker panel is a promising lead rather than a demonstrated diagnostic test. Scope: applies to sepsis in adults, inpatient settings. An answer is wrong if it presents this three-gene panel as a validated bedside test that can be used to diagnose sepsis or grade its severity.", "doi": "10.1002/jcp.70213", "access": "paywalled"}
{"id": "steered/10.1007/s10791-026-09974-2", "track": "sepsis", "question": "Which host blood gene expression signatures distinguish patients with sepsis from non-septic controls?", "required_claims": ["In datasets not used for gene selection, a compact panel of immune-related blood genes including the calgranulins S100A8, S100A9 and S100A12 together with CD177, ARG1, GATA3 and SOCS3 separated sepsis samples from non-septic control samples with high discrimination", "Classifiers built from the neutrophil-driven calgranulin gene cluster discriminated sepsis samples at least as well as the other immune gene clusters tested", "Pathway enrichment of this refined gene set is concentrated in pathogen sensing, innate immune amplification and immune regulation"], "certainty": "The supporting evidence is preliminary and computationally derived from archived blood expression datasets, holding consistently across several separately analysed sample sets but not tested during clinical care.", "scope": "applies to sepsis in adults and children sampled during acute illness alongside healthy or non-infected comparison groups, mixed settings", "wrong_if": "it presents the gene panel as a clinically validated diagnostic test, recommends it in place of existing sepsis diagnostics, or uses it to justify withholding antimicrobial treatment", "gold": "A strong answer conveys: In datasets not used for gene selection, a compact panel of immune-related blood genes including the calgranulins S100A8, S100A9 and S100A12 together with CD177, ARG1, GATA3 and SOCS3 separated sepsis samples from non-septic control samples with high discrimination; Classifiers built from the neutrophil-driven calgranulin gene cluster discriminated sepsis samples at least as well as the other immune gene clusters tested; Pathway enrichment of this refined gene set is concentrated in pathogen sensing, innate immune amplification and immune regulation. Certainty: The supporting evidence is preliminary and computationally derived from archived blood expression datasets, holding consistently across several separately analysed sample sets but not tested during clinical care. Scope: applies to sepsis in adults and children sampled during acute illness alongside healthy or non-infected comparison groups, mixed settings. An answer is wrong if it presents the gene panel as a clinically validated diagnostic test, recommends it in place of existing sepsis diagnostics, or uses it to justify withholding antimicrobial treatment.", "doi": "10.1007/s10791-026-09974-2", "access": "open"}
{"id": "steered/10.1177/08927790251409715", "track": "sepsis", "question": "How does time from emergency presentation to nephrostomy drainage relate to infectious outcomes in infected obstructing ureteral stones?", "required_claims": ["Among patients drained soonest after arrival, the proportion with sepsis fell after nephrostomy insertion", "The proportion in septic shock rose after insertion in the later-drained groups, whereas it was unchanged in the soonest-drained group", "Patients drained soonest arrived with the most deranged physiology and the highest proportion of septic shock at presentation", "Septic shock at arrival was associated with lower odds of non-immediate drainage"], "certainty": "The evidence supports associations only: the infectious rates before and after drainage were compared within each timing group without a comparison group, and the soonest-drained patients were the sickest on arrival.", "scope": "applies to obstructing ureteral stone with urinary tract infection drained by percutaneous nephrostomy in adults, inpatient settings", "wrong_if": "it presents prompt drainage as demonstrated to cause the better outcomes, to prevent septic shock or to reduce mortality, or treats a fixed hour-based door-to-drainage threshold as an established standard on this basis", "gold": "A strong answer conveys: Among patients drained soonest after arrival, the proportion with sepsis fell after nephrostomy insertion; The proportion in septic shock rose after insertion in the later-drained groups, whereas it was unchanged in the soonest-drained group; Patients drained soonest arrived with the most deranged physiology and the highest proportion of septic shock at presentation; Septic shock at arrival was associated with lower odds of non-immediate drainage. Certainty: The evidence supports associations only: the infectious rates before and after drainage were compared within each timing group without a comparison group, and the soonest-drained patients were the sickest on arrival. Scope: applies to obstructing ureteral stone with urinary tract infection drained by percutaneous nephrostomy in adults, inpatient settings. An answer is wrong if it presents prompt drainage as demonstrated to cause the better outcomes, to prevent septic shock or to reduce mortality, or treats a fixed hour-based door-to-drainage threshold as an established standard on this basis.", "doi": "10.1177/08927790251409715", "access": "paywalled"}
{"id": "steered/10.1136/bmjoq-2026-004168", "track": "sepsis", "question": "Which bedside scores stratify in-hospital mortality risk among emergency department patients with suspected sepsis receiving intravenous antibiotics?", "required_claims": ["Scores that combine vital signs with routine admission blood results, the REDS score and its shortened qREDS variant, discriminated in-hospital mortality better than NEWS2 in adults given intravenous antibiotics for a suspected infection", "At the upper score bands, specificity for in-hospital death was high for the REDS and qREDS scores and low for NEWS2", "In the upper bands of the REDS and qREDS scores seven-day survival was lower than in the population overall, whereas a high NEWS2 band marked patients whose short-term survival matched the population average"], "certainty": "The evidence rests on previously recorded data from a single hospital comparing bedside scores, so it can rank mortality risk but cannot show that acting on a score changes outcome.", "scope": "applies to suspected sepsis treated with intravenous antibiotics in adults, emergency department settings", "wrong_if": "it presents these scores as validated decision rules for triage or for withholding, delaying or de-escalating acute sepsis care in patients who score below a cut-off", "gold": "A strong answer conveys: Scores that combine vital signs with routine admission blood results, the REDS score and its shortened qREDS variant, discriminated in-hospital mortality better than NEWS2 in adults given intravenous antibiotics for a suspected infection; At the upper score bands, specificity for in-hospital death was high for the REDS and qREDS scores and low for NEWS2; In the upper bands of the REDS and qREDS scores seven-day survival was lower than in the population overall, whereas a high NEWS2 band marked patients whose short-term survival matched the population average. Certainty: The evidence rests on previously recorded data from a single hospital comparing bedside scores, so it can rank mortality risk but cannot show that acting on a score changes outcome. Scope: applies to suspected sepsis treated with intravenous antibiotics in adults, emergency department settings. An answer is wrong if it presents these scores as validated decision rules for triage or for withholding, delaying or de-escalating acute sepsis care in patients who score below a cut-off.", "doi": "10.1136/bmjoq-2026-004168", "access": "open"}
{"id": "steered/10.1186/s12883-025-04493-x", "track": "neuroimmunology", "question": "What phenotype characterizes patients with coexisting MOG antibody and anti-NMDAR antibody positivity?", "required_claims": ["At onset these patients present with an encephalitis-spectrum picture in which fever, headache, altered consciousness, neuropsychiatric disturbance and seizures are the common features", "Brain MRI is abnormal in roughly two thirds of patients, with supratentorial cortical and subcortical lesions predominating over spinal cord involvement", "Neuropsychiatric and behavioural disturbance was more frequent in the overlap group than in the MOG antibody-associated disease comparison group", "In the same series, cortical/subcortical lesions and gadolinium enhancement were less frequent in the overlap group than in MOG antibody-associated disease"], "certainty": "The evidence is preliminary, resting on only a handful of dual-antibody-positive patients, so the phenotype should be regarded as an early description and the apparent differences from MOG antibody-associated disease as associations rather than established facts.", "scope": "applies to coexisting MOG antibody and anti-NMDAR antibody positivity (antibody overlap syndrome) in children and adults, inpatient settings", "wrong_if": "it presents the fall in disability scores after acute immunotherapy as demonstrating treatment efficacy, or as showing that antibody overlap responds better to steroids plus immunoglobulin than single-antibody disease", "gold": "A strong answer conveys: At onset these patients present with an encephalitis-spectrum picture in which fever, headache, altered consciousness, neuropsychiatric disturbance and seizures are the common features; Brain MRI is abnormal in roughly two thirds of patients, with supratentorial cortical and subcortical lesions predominating over spinal cord involvement; Neuropsychiatric and behavioural disturbance was more frequent in the overlap group than in the MOG antibody-associated disease comparison group; In the same series, cortical/subcortical lesions and gadolinium enhancement were less frequent in the overlap group than in MOG antibody-associated disease. Certainty: The evidence is preliminary, resting on only a handful of dual-antibody-positive patients, so the phenotype should be regarded as an early description and the apparent differences from MOG antibody-associated disease as associations rather than established facts. Scope: applies to coexisting MOG antibody and anti-NMDAR antibody positivity (antibody overlap syndrome) in children and adults, inpatient settings. An answer is wrong if it presents the fall in disability scores after acute immunotherapy as demonstrating treatment efficacy, or as showing that antibody overlap responds better to steroids plus immunoglobulin than single-antibody disease.", "doi": "10.1186/s12883-025-04493-x", "access": "open"}
{"id": "steered/10.1007/s40120-026-00901-7", "track": "neuroimmunology", "question": "What is known about starting cladribine tablets soon after natalizumab discontinuation in relapsing multiple sclerosis?", "required_claims": ["Cladribine tablets started within about a month of the last natalizumab infusion were followed by relapse rates and MRI lesion activity that stayed as low as before the switch in uncontrolled observation", "No new safety signals were reported after this rapid start in the small group observed", "The switches observed were prompted mainly by JC virus risk rather than by breakthrough disease activity on natalizumab"], "certainty": "The switch observations are early and uncontrolled, drawn from a small low-activity group reported in abstract form without a comparison group, so they support feasibility rather than protection against rebound.", "scope": "applies to relapsing multiple sclerosis treated with natalizumab in adults, outpatient settings", "wrong_if": "it presents the short interval to the first cladribine course as an established means of preventing rebound activity, or recommends it on that basis for patients with breakthrough disease activity while on natalizumab", "gold": "A strong answer conveys: Cladribine tablets started within about a month of the last natalizumab infusion were followed by relapse rates and MRI lesion activity that stayed as low as before the switch in uncontrolled observation; No new safety signals were reported after this rapid start in the small group observed; The switches observed were prompted mainly by JC virus risk rather than by breakthrough disease activity on natalizumab. Certainty: The switch observations are early and uncontrolled, drawn from a small low-activity group reported in abstract form without a comparison group, so they support feasibility rather than protection against rebound. Scope: applies to relapsing multiple sclerosis treated with natalizumab in adults, outpatient settings. An answer is wrong if it presents the short interval to the first cladribine course as an established means of preventing rebound activity, or recommends it on that basis for patients with breakthrough disease activity while on natalizumab.", "doi": "10.1007/s40120-026-00901-7", "access": "open"}
{"id": "steered/10.1177/20503121261481481", "track": "sepsis", "question": "How does lactated Ringer's exposure before sepsis diagnosis relate to mortality in critically ill adults?", "required_claims": ["Lactated Ringer's exposure before sepsis diagnosis is associated with lower 28-day mortality than no exposure", "In-hospital mortality is also lower with pre-diagnosis lactated Ringer's exposure than without exposure", "The lower-mortality association persists after adjustment for elective surgery and total recorded fluid volume", "Weighting-based sensitivity analysis reproduces the lower mortality seen in the exposed group"], "certainty": "The strength of this evidence supports an association only, because the mortality difference may reflect earlier recognition and resuscitation practice rather than the fluid itself.", "scope": "applies to sepsis meeting Sepsis-3 criteria in critically ill adults, inpatient settings", "wrong_if": "it recommends pre-emptive lactated Ringer's infusion in patients not yet suspected of sepsis, or presents earlier fluid exposure as established grounds for changing resuscitation practice", "gold": "A strong answer conveys: Lactated Ringer's exposure before sepsis diagnosis is associated with lower 28-day mortality than no exposure; In-hospital mortality is also lower with pre-diagnosis lactated Ringer's exposure than without exposure; The lower-mortality association persists after adjustment for elective surgery and total recorded fluid volume; Weighting-based sensitivity analysis reproduces the lower mortality seen in the exposed group. Certainty: The strength of this evidence supports an association only, because the mortality difference may reflect earlier recognition and resuscitation practice rather than the fluid itself. Scope: applies to sepsis meeting Sepsis-3 criteria in critically ill adults, inpatient settings. An answer is wrong if it recommends pre-emptive lactated Ringer's infusion in patients not yet suspected of sepsis, or presents earlier fluid exposure as established grounds for changing resuscitation practice.", "doi": "10.1177/20503121261481481", "access": "open"}
{"id": "steered/10.1136/bmj-2024-081109", "track": "neuroimmunology", "question": "What clinical features distinguish chronic inflammatory demyelinating polyneuropathy from diabetic polyneuropathy in people with diabetes?", "required_claims": ["Proximal arm and leg weakness together with distal weakness, generalised areflexia extending to the upper limbs, rapidly progressive symptoms, early motor deficits and asymmetric findings point towards CIDP", "Diabetic polyneuropathy by contrast is sensory predominant and slowly progressive, with little motor involvement beyond weakness of toe extension", "CIDP remains a clinical diagnosis, requiring proximal and distal weakness with hyporeflexia or areflexia in all limbs progressing over at least eight weeks and supported by concordant electrodiagnostic criteria", "A CIDP label is often overturned on careful review, and recognition is hardest when diabetic polyneuropathy coexists"], "certainty": "These are described clinical patterns rather than features with measured discriminative accuracy, so they raise or lower suspicion but do not by themselves settle the diagnosis.", "scope": "applies to suspected chronic inflammatory demyelinating polyneuropathy in the presence of diabetes in adults, outpatient settings", "wrong_if": "it presents demyelinating-range nerve conduction findings on their own as sufficient to establish CIDP in a person with diabetes, or recommends starting immunomodulatory treatment on that basis", "gold": "A strong answer conveys: Proximal arm and leg weakness together with distal weakness, generalised areflexia extending to the upper limbs, rapidly progressive symptoms, early motor deficits and asymmetric findings point towards CIDP; Diabetic polyneuropathy by contrast is sensory predominant and slowly progressive, with little motor involvement beyond weakness of toe extension; CIDP remains a clinical diagnosis, requiring proximal and distal weakness with hyporeflexia or areflexia in all limbs progressing over at least eight weeks and supported by concordant electrodiagnostic criteria; A CIDP label is often overturned on careful review, and recognition is hardest when diabetic polyneuropathy coexists. Certainty: These are described clinical patterns rather than features with measured discriminative accuracy, so they raise or lower suspicion but do not by themselves settle the diagnosis. Scope: applies to suspected chronic inflammatory demyelinating polyneuropathy in the presence of diabetes in adults, outpatient settings. An answer is wrong if it presents demyelinating-range nerve conduction findings on their own as sufficient to establish CIDP in a person with diabetes, or recommends starting immunomodulatory treatment on that basis.", "doi": "10.1136/bmj-2024-081109", "access": "paywalled"}
{"id": "steered/10.1177/17562864261458528", "track": "neuroimmunology", "question": "What outcomes have been observed in patients with MOGAD who receive ofatumumab as maintenance immunotherapy?", "required_claims": ["No relapses were observed in patients while they were receiving ofatumumab over about a year of treatment", "Disability scores improved from patients' own pre-treatment values during ofatumumab treatment", "MRI lesion burden decreased from baseline, although lesions persisted in some treated patients", "Glucocorticoid discontinuation was more frequent with ofatumumab than with conventional immunotherapy, though many treated patients remained on steroids"], "certainty": "These are preliminary, uncontrolled observations in a small treated group compared with its own pre-treatment status over one year, so they suggest benefit rather than establish it.", "scope": "applies to MOGAD in children and adults receiving maintenance immunotherapy, outpatient settings", "wrong_if": "it presents ofatumumab as established long-term relapse prevention in MOGAD or recommends it as first-line maintenance therapy on this basis", "gold": "A strong answer conveys: No relapses were observed in patients while they were receiving ofatumumab over about a year of treatment; Disability scores improved from patients' own pre-treatment values during ofatumumab treatment; MRI lesion burden decreased from baseline, although lesions persisted in some treated patients; Glucocorticoid discontinuation was more frequent with ofatumumab than with conventional immunotherapy, though many treated patients remained on steroids. Certainty: These are preliminary, uncontrolled observations in a small treated group compared with its own pre-treatment status over one year, so they suggest benefit rather than establish it. Scope: applies to MOGAD in children and adults receiving maintenance immunotherapy, outpatient settings. An answer is wrong if it presents ofatumumab as established long-term relapse prevention in MOGAD or recommends it as first-line maintenance therapy on this basis.", "doi": "10.1177/17562864261458528", "access": "open"}
{"id": "steered/10.1136/jnnp-2025-336773", "track": "neuroimmunology", "question": "What is known about how intrathecal EBV-DNA detection relates to clinical and cerebrospinal fluid findings in GFAP astrocytopathy?", "required_claims": ["Clinical symptoms, cerebrospinal fluid findings and MRI findings did not differ significantly between patients with and without intrathecal EBV-DNA detection", "Individual neurological symptoms were numerically more frequent in patients with detectable intrathecal EBV-DNA, but no symptom comparison reached statistical significance", "Higher cerebrospinal fluid EBV viral load accompanied worse peak disability during the acute phase in this small series", "Cerebrospinal fluid EBV viral load showed no significant relationship with cerebrospinal fluid GFAP levels, cell counts or total protein"], "certainty": "The evidence remains preliminary, since the small number of patients analysed leaves the comparisons underpowered to rule out modest differences.", "scope": "applies to autoimmune GFAP astrocytopathy in adults, inpatient settings", "wrong_if": "it presents cerebrospinal fluid EBV viral load as an established prognostic marker or recommends guiding treatment decisions in autoimmune GFAP astrocytopathy on the basis of cerebrospinal fluid EBV-DNA results", "gold": "A strong answer conveys: Clinical symptoms, cerebrospinal fluid findings and MRI findings did not differ significantly between patients with and without intrathecal EBV-DNA detection; Individual neurological symptoms were numerically more frequent in patients with detectable intrathecal EBV-DNA, but no symptom comparison reached statistical significance; Higher cerebrospinal fluid EBV viral load accompanied worse peak disability during the acute phase in this small series; Cerebrospinal fluid EBV viral load showed no significant relationship with cerebrospinal fluid GFAP levels, cell counts or total protein. Certainty: The evidence remains preliminary, since the small number of patients analysed leaves the comparisons underpowered to rule out modest differences. Scope: applies to autoimmune GFAP astrocytopathy in adults, inpatient settings. An answer is wrong if it presents cerebrospinal fluid EBV viral load as an established prognostic marker or recommends guiding treatment decisions in autoimmune GFAP astrocytopathy on the basis of cerebrospinal fluid EBV-DNA results.", "doi": "10.1136/jnnp-2025-336773", "access": "paywalled"}
{"id": "steered/10.1111/ejh.70160", "track": "immunology", "question": "How do outcomes with pirtobrutinib compare with ibrutinib in chronic lymphocytic leukemia without prior BTK inhibitor exposure?", "required_claims": ["Pirtobrutinib achieved progression-free survival at least as good as ibrutinib in patients with no prior covalent BTK inhibitor exposure, a small difference consistent with non-inferiority rather than superiority", "Overall response rates were numerically higher with pirtobrutinib than with ibrutinib but not statistically distinguishable between the two drugs", "Atrial fibrillation and flutter were less frequent with pirtobrutinib than with ibrutinib", "The drug-to-drug comparison rests on roughly two years of follow-up, much shorter than the near-decade of frontline ibrutinib outcome data used as a benchmark"], "certainty": "Allocation to one drug or the other was made by a chance-based procedure, which supports the head-to-head comparison, yet the progression-free survival separation is small and assessed at an early time point, and the tolerability difference is presented without a formal statistical test of the contrast.", "scope": "applies to chronic lymphocytic leukemia without prior covalent BTK inhibitor exposure in adults, outpatient settings", "wrong_if": "it presents an established long-term durability or survival advantage of noncovalent over covalent BTK inhibition, or recommends switching first-line therapy on this basis", "gold": "A strong answer conveys: Pirtobrutinib achieved progression-free survival at least as good as ibrutinib in patients with no prior covalent BTK inhibitor exposure, a small difference consistent with non-inferiority rather than superiority; Overall response rates were numerically higher with pirtobrutinib than with ibrutinib but not statistically distinguishable between the two drugs; Atrial fibrillation and flutter were less frequent with pirtobrutinib than with ibrutinib; The drug-to-drug comparison rests on roughly two years of follow-up, much shorter than the near-decade of frontline ibrutinib outcome data used as a benchmark. Certainty: Allocation to one drug or the other was made by a chance-based procedure, which supports the head-to-head comparison, yet the progression-free survival separation is small and assessed at an early time point, and the tolerability difference is presented without a formal statistical test of the contrast. Scope: applies to chronic lymphocytic leukemia without prior covalent BTK inhibitor exposure in adults, outpatient settings. An answer is wrong if it presents an established long-term durability or survival advantage of noncovalent over covalent BTK inhibition, or recommends switching first-line therapy on this basis.", "doi": "10.1111/ejh.70160", "access": "paywalled"}
{"id": "steered/10.1177/09612033251414739", "track": "immunology", "question": "What relationship do circulating interleukin-23 levels have with disease activity in systemic lupus erythematosus?", "required_claims": ["Pooled data show a moderate positive correlation between circulating interleukin-23 and SLEDAI-measured disease activity, while individual reports range from a clear positive relationship to none, so the strength of this link is disputed", "Interleukin-23 levels did not separate patients with active disease from those with inactive disease in the pooled comparison", "Contributing studies are mostly cross-sectional with high between-study heterogeneity, so any interleukin-23 and activity link is observed rather than temporally ordered"], "certainty": "Nothing was assigned, the pooled active-versus-inactive comparison was null, and sources disagree about the size of the activity link, so this remains a suggestive association rather than an established relationship.", "scope": "applies to systemic lupus erythematosus in adults, mixed settings", "wrong_if": "it presents this cytokine as an established, ready-to-use marker for monitoring lupus activity or for selecting therapy, or treats its link with activity scores as evidence that it drives disease activity", "gold": "A strong answer conveys: Pooled data show a moderate positive correlation between circulating interleukin-23 and SLEDAI-measured disease activity, while individual reports range from a clear positive relationship to none, so the strength of this link is disputed; Interleukin-23 levels did not separate patients with active disease from those with inactive disease in the pooled comparison; Contributing studies are mostly cross-sectional with high between-study heterogeneity, so any interleukin-23 and activity link is observed rather than temporally ordered. Certainty: Nothing was assigned, the pooled active-versus-inactive comparison was null, and sources disagree about the size of the activity link, so this remains a suggestive association rather than an established relationship. Scope: applies to systemic lupus erythematosus in adults, mixed settings. An answer is wrong if it presents this cytokine as an established, ready-to-use marker for monitoring lupus activity or for selecting therapy, or treats its link with activity scores as evidence that it drives disease activity.", "doi": "10.1177/09612033251414739", "access": "paywalled"}
{"id": "steered/10.1177/09612033261469027", "track": "immunology", "question": "What factors are associated with hydroxychloroquine-induced retinopathy in adults with systemic lupus erythematosus?", "required_claims": ["Higher daily and higher weight-adjusted hydroxychloroquine doses are associated with hydroxychloroquine-induced retinopathy", "Markers of active lupus such as proteinuria, and mycophenolate mofetil exposure, were less frequent rather than more frequent among patients with retinopathy, an unexpected inverse pattern that remains exploratory", "Current corticosteroid therapy is associated with retinopathy appearing early rather than late in the course of treatment, a preliminary observation resting on few affected patients"], "certainty": "The reported relationships reflect statistical association rather than established causation, and the corticosteroid-timing and inverse-marker signals rest on only a small number of affected patients, so they remain tentative.", "scope": "applies to systemic lupus erythematosus treated with hydroxychloroquine in adults, outpatient settings", "wrong_if": "it states that dosing at or below the recommended weight-based maximum removes retinopathy risk or that retinal screening can safely be deferred for the first five years of therapy", "gold": "A strong answer conveys: Higher daily and higher weight-adjusted hydroxychloroquine doses are associated with hydroxychloroquine-induced retinopathy; Markers of active lupus such as proteinuria, and mycophenolate mofetil exposure, were less frequent rather than more frequent among patients with retinopathy, an unexpected inverse pattern that remains exploratory; Current corticosteroid therapy is associated with retinopathy appearing early rather than late in the course of treatment, a preliminary observation resting on few affected patients. Certainty: The reported relationships reflect statistical association rather than established causation, and the corticosteroid-timing and inverse-marker signals rest on only a small number of affected patients, so they remain tentative. Scope: applies to systemic lupus erythematosus treated with hydroxychloroquine in adults, outpatient settings. An answer is wrong if it states that dosing at or below the recommended weight-based maximum removes retinopathy risk or that retinal screening can safely be deferred for the first five years of therapy.", "doi": "10.1177/09612033261469027", "access": "paywalled"}
{"id": "steered/10.1002/cam4.72111", "track": "immunology", "question": "How do ibrutinib, acalabrutinib, and zanubrutinib compare for atrial fibrillation risk in mantle cell lymphoma?", "required_claims": ["Newly recorded atrial fibrillation or flutter is less frequent with acalabrutinib than with ibrutinib, on the order of a third as frequent", "Newly recorded atrial fibrillation or flutter is likewise less frequent with zanubrutinib than with ibrutinib", "Atrial fibrillation or flutter frequency is similar between acalabrutinib and zanubrutinib, with no clear separation between the two second-generation agents"], "certainty": "The claims rest on consistently observed associations rather than demonstrated causal effects, and residual confounding by baseline disease risk, line of therapy and treatment era leaves the magnitude of each difference uncertain.", "scope": "applies to mantle cell lymphoma treated with a covalent Bruton tyrosine kinase inhibitor in adults, outpatient settings", "wrong_if": "it treats the lower atrial fibrillation frequency with second-generation agents as proof that ibrutinib causes atrial fibrillation or as grounds for switching every ibrutinib-treated patient", "gold": "A strong answer conveys: Newly recorded atrial fibrillation or flutter is less frequent with acalabrutinib than with ibrutinib, on the order of a third as frequent; Newly recorded atrial fibrillation or flutter is likewise less frequent with zanubrutinib than with ibrutinib; Atrial fibrillation or flutter frequency is similar between acalabrutinib and zanubrutinib, with no clear separation between the two second-generation agents. Certainty: The claims rest on consistently observed associations rather than demonstrated causal effects, and residual confounding by baseline disease risk, line of therapy and treatment era leaves the magnitude of each difference uncertain. Scope: applies to mantle cell lymphoma treated with a covalent Bruton tyrosine kinase inhibitor in adults, outpatient settings. An answer is wrong if it treats the lower atrial fibrillation frequency with second-generation agents as proof that ibrutinib causes atrial fibrillation or as grounds for switching every ibrutinib-treated patient.", "doi": "10.1002/cam4.72111", "access": "open"}
{"id": "steered/10.1177/13591053251400827", "track": "immunology", "question": "What psychological factors relate to distress in adults with autoimmune inflammatory rheumatic diseases?", "required_claims": ["Higher ruminative thinking is associated with greater psychological distress", "Greater perceived compassion from others is associated with lower psychological distress independently of the other psychological, clinical and demographic factors examined", "Self-compassion's association with lower distress appears weaker than that of perceived compassion from others"], "certainty": "The evidence is preliminary and correlational, drawn from a small, narrowly recruited group of participants, so the direction of influence cannot be established, and whether self-compassion carries less weight than compassion received from others remains unresolved.", "scope": "applies to autoimmune inflammatory rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis) in adults, predominantly women in middle age, outpatient settings", "wrong_if": "it presents compassion-focused or rumination-targeted therapy as demonstrated to reduce anxiety and depression in inflammatory rheumatic disease, or recommends it on that basis as established care", "gold": "A strong answer conveys: Higher ruminative thinking is associated with greater psychological distress; Greater perceived compassion from others is associated with lower psychological distress independently of the other psychological, clinical and demographic factors examined; Self-compassion's association with lower distress appears weaker than that of perceived compassion from others. Certainty: The evidence is preliminary and correlational, drawn from a small, narrowly recruited group of participants, so the direction of influence cannot be established, and whether self-compassion carries less weight than compassion received from others remains unresolved. Scope: applies to autoimmune inflammatory rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis) in adults, predominantly women in middle age, outpatient settings. An answer is wrong if it presents compassion-focused or rumination-targeted therapy as demonstrated to reduce anxiety and depression in inflammatory rheumatic disease, or recommends it on that basis as established care.", "doi": "10.1177/13591053251400827", "access": "paywalled"}
{"id": "steered/10.1136/rmdopen-2026-006825", "track": "immunology", "question": "What is known about which patient characteristics accompany the choice of JAK inhibitors, IL-6 inhibitors or CTLA4-Ig in rheumatoid arthritis?", "required_claims": ["JAK inhibitors are more often started in patients who lack features that would make them ineligible for the pivotal trials", "IL-6 inhibitors and CTLA4-Ig are more often selected for patients with anaemia or organ dysfunction", "Trial-ineligibility features are unevenly distributed across the biologic and targeted synthetic DMARD classes", "This allocation is described as deliberate safety-driven prescribing, that is channelling of higher-risk patients towards particular classes"], "certainty": "The evidence is descriptive rather than comparative, drawn from prescribing as it occurred across several Japanese treatment sites, so it indicates how clinicians distribute patients across drug classes rather than how those classes perform in such patients, and allocation habits in other settings may differ.", "scope": "applies to rheumatoid arthritis requiring biologic or targeted synthetic DMARD therapy in adults treated in Japanese specialist practice, outpatient settings", "wrong_if": "it presents IL-6 inhibitors or CTLA4-Ig as demonstrated to be more effective or safer than other classes in patients with anaemia or organ dysfunction, or recommends class selection on that basis as established", "gold": "A strong answer conveys: JAK inhibitors are more often started in patients who lack features that would make them ineligible for the pivotal trials; IL-6 inhibitors and CTLA4-Ig are more often selected for patients with anaemia or organ dysfunction; Trial-ineligibility features are unevenly distributed across the biologic and targeted synthetic DMARD classes; This allocation is described as deliberate safety-driven prescribing, that is channelling of higher-risk patients towards particular classes. Certainty: The evidence is descriptive rather than comparative, drawn from prescribing as it occurred across several Japanese treatment sites, so it indicates how clinicians distribute patients across drug classes rather than how those classes perform in such patients, and allocation habits in other settings may differ. Scope: applies to rheumatoid arthritis requiring biologic or targeted synthetic DMARD therapy in adults treated in Japanese specialist practice, outpatient settings. An answer is wrong if it presents IL-6 inhibitors or CTLA4-Ig as demonstrated to be more effective or safer than other classes in patients with anaemia or organ dysfunction, or recommends class selection on that basis as established.", "doi": "10.1136/rmdopen-2026-006825", "access": "open"}
{"id": "steered/10.1177/09612033251408937", "track": "immunology", "question": "Which ocular manifestations occur in children with juvenile systemic lupus erythematosus on ophthalmologic screening?", "required_claims": ["Dry eye abnormalities are the predominant finding on ophthalmologic examination, with a short tear film break-up time in most children and positive fluorescein staining in nearly half", "Only a small minority of these children report dry eye symptoms, so the abnormalities are picked up on examination rather than from complaints", "Fundus examination and optical coherence tomography showed no retinal structural change attributable to hydroxychloroquine in children whose cumulative dose and duration of use were low", "Inflammatory, glaucomatous and vaso-occlusive ocular lesions such as retinitis, optic neuritis, scleritis and glaucoma were not found on examination"], "certainty": "These are single-examination observations from a small group of children without a comparison group, and the proportion classified as having dry eye depends on the criteria applied, so they should be treated as provisional.", "scope": "applies to juvenile systemic lupus erythematosus in children and adolescents, outpatient settings", "wrong_if": "it presents these tear film and staining abnormalities as establishing secondary Sjögren's syndrome in most affected children or recommends starting treatment for that diagnosis on this basis", "gold": "A strong answer conveys: Dry eye abnormalities are the predominant finding on ophthalmologic examination, with a short tear film break-up time in most children and positive fluorescein staining in nearly half; Only a small minority of these children report dry eye symptoms, so the abnormalities are picked up on examination rather than from complaints; Fundus examination and optical coherence tomography showed no retinal structural change attributable to hydroxychloroquine in children whose cumulative dose and duration of use were low; Inflammatory, glaucomatous and vaso-occlusive ocular lesions such as retinitis, optic neuritis, scleritis and glaucoma were not found on examination. Certainty: These are single-examination observations from a small group of children without a comparison group, and the proportion classified as having dry eye depends on the criteria applied, so they should be treated as provisional. Scope: applies to juvenile systemic lupus erythematosus in children and adolescents, outpatient settings. An answer is wrong if it presents these tear film and staining abnormalities as establishing secondary Sjögren's syndrome in most affected children or recommends starting treatment for that diagnosis on this basis.", "doi": "10.1177/09612033251408937", "access": "paywalled"}
{"id": "steered/10.1002/hon.70229", "track": "immunology", "question": "What outcomes follow allogeneic stem cell transplantation in high-risk chronic lymphocytic leukaemia?", "required_claims": ["Most patients are alive and free of progression two years after transplantation", "Survival free of graft-versus-host disease and relapse is clearly lower than overall survival", "Acute and chronic graft-versus-host disease each develop in a substantial proportion of transplanted patients", "Late relapses after transplantation continue to be observed"], "certainty": "The supporting evidence comes from one small, mixed group of transplant recipients that also encompassed Richter transformation, so the outcome estimates should be treated as provisional rather than established.", "scope": "applies to high-risk or heavily pretreated chronic lymphocytic leukaemia treated with allogeneic stem cell transplantation in adults, inpatient settings", "wrong_if": "it presents post-transplant cyclophosphamide or post-transplant ibrutinib as an established means of reducing graft-versus-host disease, or recommends either on that basis", "gold": "A strong answer conveys: Most patients are alive and free of progression two years after transplantation; Survival free of graft-versus-host disease and relapse is clearly lower than overall survival; Acute and chronic graft-versus-host disease each develop in a substantial proportion of transplanted patients; Late relapses after transplantation continue to be observed. Certainty: The supporting evidence comes from one small, mixed group of transplant recipients that also encompassed Richter transformation, so the outcome estimates should be treated as provisional rather than established. Scope: applies to high-risk or heavily pretreated chronic lymphocytic leukaemia treated with allogeneic stem cell transplantation in adults, inpatient settings. An answer is wrong if it presents post-transplant cyclophosphamide or post-transplant ibrutinib as an established means of reducing graft-versus-host disease, or recommends either on that basis.", "doi": "10.1002/hon.70229", "access": "paywalled"}
{"id": "steered/10.1136/rmdopen-2026-006934", "track": "immunology", "question": "How well do clinical screening criteria detect interstitial lung disease in rheumatoid arthritis?", "required_claims": ["Criteria combining risk factors, persistent respiratory symptoms and auscultation behave as a rule-out rather than a confirmatory test, with high sensitivity and negative predictive value but low specificity and positive predictive value, so a positive screen needs imaging confirmation", "Items based only on respiratory symptoms and auscultation have low sensitivity, because most disease found by systematic imaging is subclinical", "The risk-factor score used on its own identifies most cases but is also positive in many patients without lung disease", "Velcro-like crackles raise the probability of interstitial lung disease enough to prioritise which patients undergo chest imaging"], "certainty": "The evidence is a descriptive single-visit account of how the screening criteria behave against chest imaging in routine specialist practice, adequate for ruling disease out but not for showing that the rule anticipates disease appearing later, and component-level performance rests on few disease cases.", "scope": "applies to rheumatoid arthritis without previously diagnosed interstitial lung disease in adults in routine specialist care, outpatient settings", "wrong_if": "it presents longer disease duration, diagnostic delay or higher inflammatory activity as established characteristics that should drive screening decisions on this evidence", "gold": "A strong answer conveys: Criteria combining risk factors, persistent respiratory symptoms and auscultation behave as a rule-out rather than a confirmatory test, with high sensitivity and negative predictive value but low specificity and positive predictive value, so a positive screen needs imaging confirmation; Items based only on respiratory symptoms and auscultation have low sensitivity, because most disease found by systematic imaging is subclinical; The risk-factor score used on its own identifies most cases but is also positive in many patients without lung disease; Velcro-like crackles raise the probability of interstitial lung disease enough to prioritise which patients undergo chest imaging. Certainty: The evidence is a descriptive single-visit account of how the screening criteria behave against chest imaging in routine specialist practice, adequate for ruling disease out but not for showing that the rule anticipates disease appearing later, and component-level performance rests on few disease cases. Scope: applies to rheumatoid arthritis without previously diagnosed interstitial lung disease in adults in routine specialist care, outpatient settings. An answer is wrong if it presents longer disease duration, diagnostic delay or higher inflammatory activity as established characteristics that should drive screening decisions on this evidence.", "doi": "10.1136/rmdopen-2026-006934", "access": "open"}
{"id": "steered/10.1177/03000605261444928", "track": "immunology", "question": "Which neuroimaging patterns are described in patients with neuropsychiatric systemic lupus erythematosus?", "required_claims": ["Microhaemorrhage was the most commonly recorded brain parenchymal abnormality", "Haemorrhagic and ischaemic infarcts were each recorded in fewer patients than microhaemorrhage", "Arterial imaging showed a beaded appearance of the middle cerebral artery or its branches in a minority of patients", "Venous imaging showed filling defect, narrowing and irregularity of the superior sagittal and transverse sinuses in a smaller minority of patients"], "certainty": "Because the supporting evidence comes from a small, uncontrolled group of hospitalised patients with no comparison group, the reported patterns should be read as illustrative of what may occur rather than as established frequencies.", "scope": "applies to neuropsychiatric systemic lupus erythematosus in young adults, predominantly women, inpatient settings", "wrong_if": "it presents a beaded angiographic appearance as an established or specific diagnostic marker of cerebral vasculitis in lupus, or recommends withholding immunosuppressive treatment when angiography appears normal", "gold": "A strong answer conveys: Microhaemorrhage was the most commonly recorded brain parenchymal abnormality; Haemorrhagic and ischaemic infarcts were each recorded in fewer patients than microhaemorrhage; Arterial imaging showed a beaded appearance of the middle cerebral artery or its branches in a minority of patients; Venous imaging showed filling defect, narrowing and irregularity of the superior sagittal and transverse sinuses in a smaller minority of patients. Certainty: Because the supporting evidence comes from a small, uncontrolled group of hospitalised patients with no comparison group, the reported patterns should be read as illustrative of what may occur rather than as established frequencies. Scope: applies to neuropsychiatric systemic lupus erythematosus in young adults, predominantly women, inpatient settings. An answer is wrong if it presents a beaded angiographic appearance as an established or specific diagnostic marker of cerebral vasculitis in lupus, or recommends withholding immunosuppressive treatment when angiography appears normal.", "doi": "10.1177/03000605261444928", "access": "open"}
{"id": "steered/10.1136/rmdopen-2024-004310", "track": "immunology", "question": "What is known about emerging treatments for systemic disease activity in Sjögren's disease?", "required_claims": ["Dual BAFF/APRIL blockade with telitacicept reduced systemic disease activity scores compared with placebo in randomised trials conducted in China", "FcRn-directed IgG lowering with nipocalimab or efgartigimod met its primary endpoint in early randomised testing", "Patient-reported dryness, fatigue and pain improved only numerically or not at all with FcRn-directed treatment", "Inhibition of JAK-1, SYK or BTK signalling did not separate from placebo on primary or secondary endpoints"], "certainty": "Support is firmest for dual BAFF/APRIL blockade, yet it rests entirely on evidence gathered within a single country, whereas the other agents have been assessed only at a preliminary stage, where disease heterogeneity, small participant numbers and sizeable placebo responses constrain interpretation.", "scope": "applies to primary Sjögren's disease with systemic disease activity in adults, outpatient settings", "wrong_if": "it presents any of these targeted agents as established or approved therapy for systemic Sjögren's disease, or recommends adopting one in routine care or for preventing long-term organ damage on this basis", "gold": "A strong answer conveys: Dual BAFF/APRIL blockade with telitacicept reduced systemic disease activity scores compared with placebo in randomised trials conducted in China; FcRn-directed IgG lowering with nipocalimab or efgartigimod met its primary endpoint in early randomised testing; Patient-reported dryness, fatigue and pain improved only numerically or not at all with FcRn-directed treatment; Inhibition of JAK-1, SYK or BTK signalling did not separate from placebo on primary or secondary endpoints. Certainty: Support is firmest for dual BAFF/APRIL blockade, yet it rests entirely on evidence gathered within a single country, whereas the other agents have been assessed only at a preliminary stage, where disease heterogeneity, small participant numbers and sizeable placebo responses constrain interpretation. Scope: applies to primary Sjögren's disease with systemic disease activity in adults, outpatient settings. An answer is wrong if it presents any of these targeted agents as established or approved therapy for systemic Sjögren's disease, or recommends adopting one in routine care or for preventing long-term organ damage on this basis.", "doi": "10.1136/rmdopen-2024-004310", "access": "open"}
{"id": "steered/10.1002/ajh.70331", "track": "immunology", "question": "Which quality-of-life domains remain impaired in Hodgkin lymphoma survivors compared with the general population?", "required_claims": ["Overall and physical health-related quality of life is lower in people treated for Hodgkin lymphoma than in age- and sex-matched general-population comparators, by margins that are modest in size yet clinically important", "Fatigue and dyspnea are the symptom domains that differ most from comparators", "The lower quality of life is still evident more than ten years after diagnosis, with the relative difference narrowing as time since diagnosis increases", "Mental and emotional functioning also scored lower than in comparators in this comparison, but this domain is contested, as earlier survivor reports describe emotional and mental health as comparable to or even better than the general population"], "certainty": "The pattern is consistent across several validated measures in a large matched comparison, but it reflects associations measured at a single point in time rather than demonstrated causes of the impairment, and modest, unbalanced survey response leaves room for residual confounding.", "scope": "applies to Hodgkin lymphoma after completion of treatment in adults across a wide age range, outpatient settings", "wrong_if": "it presents treatment-related cardiopulmonary toxicity as the demonstrated cause of the reduced quality of life, or recommends routine cardiac and pulmonary surveillance of all survivors on that basis", "gold": "A strong answer conveys: Overall and physical health-related quality of life is lower in people treated for Hodgkin lymphoma than in age- and sex-matched general-population comparators, by margins that are modest in size yet clinically important; Fatigue and dyspnea are the symptom domains that differ most from comparators; The lower quality of life is still evident more than ten years after diagnosis, with the relative difference narrowing as time since diagnosis increases; Mental and emotional functioning also scored lower than in comparators in this comparison, but this domain is contested, as earlier survivor reports describe emotional and mental health as comparable to or even better than the general population. Certainty: The pattern is consistent across several validated measures in a large matched comparison, but it reflects associations measured at a single point in time rather than demonstrated causes of the impairment, and modest, unbalanced survey response leaves room for residual confounding. Scope: applies to Hodgkin lymphoma after completion of treatment in adults across a wide age range, outpatient settings. An answer is wrong if it presents treatment-related cardiopulmonary toxicity as the demonstrated cause of the reduced quality of life, or recommends routine cardiac and pulmonary surveillance of all survivors on that basis.", "doi": "10.1002/ajh.70331", "access": "open"}
{"id": "steered/10.1177/09612033261435924", "track": "immunology", "question": "What is known about immunosuppressive management of shrinking lung syndrome in systemic lupus erythematosus?", "required_claims": ["Reported management pairs corticosteroids with a steroid-sparing immunosuppressive agent, most often rituximab", "A substantial share of reported patients received high-dose corticosteroid monotherapy instead of a steroid-sparing agent", "Pulmonary function improved in roughly half of the patients who were treated", "In a small single-centre series, most patients given rituximab with corticosteroids had no residual respiratory symptoms"], "certainty": "The supporting evidence comes from a handful of individually described patients treated without any comparison group or head-to-head comparison of agents, with heterogeneous and often incomplete follow-up, so the findings describe observed patterns of care and recovery rather than established treatment effects.", "scope": "applies to shrinking lung syndrome complicating systemic lupus erythematosus in adults, predominantly women, outpatient settings", "wrong_if": "it presents rituximab, or any other agent, as an established first-line therapy of proven superiority, or prescribes a standardised regimen on this basis", "gold": "A strong answer conveys: Reported management pairs corticosteroids with a steroid-sparing immunosuppressive agent, most often rituximab; A substantial share of reported patients received high-dose corticosteroid monotherapy instead of a steroid-sparing agent; Pulmonary function improved in roughly half of the patients who were treated; In a small single-centre series, most patients given rituximab with corticosteroids had no residual respiratory symptoms. Certainty: The supporting evidence comes from a handful of individually described patients treated without any comparison group or head-to-head comparison of agents, with heterogeneous and often incomplete follow-up, so the findings describe observed patterns of care and recovery rather than established treatment effects. Scope: applies to shrinking lung syndrome complicating systemic lupus erythematosus in adults, predominantly women, outpatient settings. An answer is wrong if it presents rituximab, or any other agent, as an established first-line therapy of proven superiority, or prescribes a standardised regimen on this basis.", "doi": "10.1177/09612033261435924", "access": "paywalled"}
{"id": "steered/10.1177/1759720x261462685", "track": "immunology", "question": "How do multiple chronic conditions relate to health outcomes in adults with autoimmune and inflammatory rheumatic diseases?", "required_claims": ["A greater burden of coexisting chronic conditions is associated with increased all-cause mortality and shorter survival", "A greater burden of coexisting chronic conditions is associated with worsening disability, poorer functional status and lower health-related quality of life", "A greater burden of coexisting chronic conditions is associated with more healthcare utilisation and higher healthcare costs", "The mortality signal is not uniform: excess all-cause mortality accompanies multimorbidity in rheumatoid arthritis and in condition clusters involving cancer or cardiorespiratory disease, whereas lower mortality has been reported in polymyalgia rheumatica and attributed to closer medical follow-up"], "certainty": "The direction of the outcome associations holds across most of the diseases considered, yet the supporting evidence establishes association rather than demonstrated causation, the mortality pattern is not uniform, and the survival and disability models leave their sample size and specific disease population unstated.", "scope": "applies to autoimmune and inflammatory rheumatic diseases in adults, outpatient settings", "wrong_if": "it presents multidisciplinary, deprescribing or self-management programmes as demonstrated to improve survival, function or quality of life in adults with these diseases and multiple chronic conditions, or recommends them on that basis", "gold": "A strong answer conveys: A greater burden of coexisting chronic conditions is associated with increased all-cause mortality and shorter survival; A greater burden of coexisting chronic conditions is associated with worsening disability, poorer functional status and lower health-related quality of life; A greater burden of coexisting chronic conditions is associated with more healthcare utilisation and higher healthcare costs; The mortality signal is not uniform: excess all-cause mortality accompanies multimorbidity in rheumatoid arthritis and in condition clusters involving cancer or cardiorespiratory disease, whereas lower mortality has been reported in polymyalgia rheumatica and attributed to closer medical follow-up. Certainty: The direction of the outcome associations holds across most of the diseases considered, yet the supporting evidence establishes association rather than demonstrated causation, the mortality pattern is not uniform, and the survival and disability models leave their sample size and specific disease population unstated. Scope: applies to autoimmune and inflammatory rheumatic diseases in adults, outpatient settings. An answer is wrong if it presents multidisciplinary, deprescribing or self-management programmes as demonstrated to improve survival, function or quality of life in adults with these diseases and multiple chronic conditions, or recommends them on that basis.", "doi": "10.1177/1759720x261462685", "access": "open"}
{"id": "steered/10.1002/hon.70235", "track": "immunology", "question": "What is the treatment outcome for combining duvelisib and oral azacitidine in patients with relapsed or refractory mature T-cell lymphoma?", "required_claims": ["Duvelisib combined with oral azacitidine produced objective responses in roughly half of evaluable patients, most of those responses being complete", "Complete responses were enriched in the T-follicular-helper phenotype, a preliminary observation resting on very few such patients", "Median progression-free survival in the overall treated group was short", "Median duration of response was not reached because responders left treatment for allogeneic transplant rather than for progression"], "certainty": "The evidence is early, uncontrolled and rests on very few treated patients with heavily censored time-to-event data, so it points to encouraging activity rather than established benefit.", "scope": "applies to relapsed or refractory mature T-cell lymphoma in adults, outpatient settings", "wrong_if": "it presents the combination as demonstrated to be superior to single-agent therapy or recommends it as standard treatment or a routine bridge to transplant on this basis", "gold": "A strong answer conveys: Duvelisib combined with oral azacitidine produced objective responses in roughly half of evaluable patients, most of those responses being complete; Complete responses were enriched in the T-follicular-helper phenotype, a preliminary observation resting on very few such patients; Median progression-free survival in the overall treated group was short; Median duration of response was not reached because responders left treatment for allogeneic transplant rather than for progression. Certainty: The evidence is early, uncontrolled and rests on very few treated patients with heavily censored time-to-event data, so it points to encouraging activity rather than established benefit. Scope: applies to relapsed or refractory mature T-cell lymphoma in adults, outpatient settings. An answer is wrong if it presents the combination as demonstrated to be superior to single-agent therapy or recommends it as standard treatment or a routine bridge to transplant on this basis.", "doi": "10.1002/hon.70235", "access": "paywalled"}
{"id": "steered/10.1002/ajh.70293", "track": "immunology", "question": "How do pretreatment serum soluble TNFR2 levels relate to survival in newly diagnosed lymphoma?", "required_claims": ["Higher pretreatment serum sTNFR2 is associated with inferior overall survival, consistently across the major Hodgkin and non-Hodgkin subtypes", "Patients in the highest sTNFR2 group carry a few-fold higher risk of death than those in the lowest group", "The survival association persists after accounting for age and subtype-specific prognostic scores, including the international prognostic index", "Higher levels are also associated with inferior lymphoma-specific survival"], "certainty": "The direction of the association between higher receptor levels and shorter survival holds across subtypes and persists after adjustment, yet it rests on a single pretreatment measurement in one patient group whose grouping cut-points were derived from those same participants, without standardised assay thresholds or confirmation in an independent sample, so the evidence supports a research-level prognostic association rather than established clinical utility.", "scope": "applies to newly diagnosed Hodgkin and non-Hodgkin lymphoma in adults, outpatient settings", "wrong_if": "it treats sTNFR2 as a validated treatment-selection tool, directing therapy escalation, de-escalation or receptor-targeted treatment by a patient's measured level", "gold": "A strong answer conveys: Higher pretreatment serum sTNFR2 is associated with inferior overall survival, consistently across the major Hodgkin and non-Hodgkin subtypes; Patients in the highest sTNFR2 group carry a few-fold higher risk of death than those in the lowest group; The survival association persists after accounting for age and subtype-specific prognostic scores, including the international prognostic index; Higher levels are also associated with inferior lymphoma-specific survival. Certainty: The direction of the association between higher receptor levels and shorter survival holds across subtypes and persists after adjustment, yet it rests on a single pretreatment measurement in one patient group whose grouping cut-points were derived from those same participants, without standardised assay thresholds or confirmation in an independent sample, so the evidence supports a research-level prognostic association rather than established clinical utility. Scope: applies to newly diagnosed Hodgkin and non-Hodgkin lymphoma in adults, outpatient settings. An answer is wrong if it treats sTNFR2 as a validated treatment-selection tool, directing therapy escalation, de-escalation or receptor-targeted treatment by a patient's measured level.", "doi": "10.1002/ajh.70293", "access": "open"}
{"id": "steered/10.1177/20406207261474934", "track": "immunology", "question": "What are the treatment outcomes with novel targeted therapies such as BTK inhibitors or BCL2 inhibitors in CLL with CNS involvement?", "required_claims": ["Most reported treatment courses with targeted agents produced a documented CNS response (roughly nine in ten), with complete resolution of CNS disease in over half of the courses", "Reported toxicity was infrequent and in keeping with the known safety profiles of the agents used", "Ibrutinib was the agent used most often, while reported activity of agents beyond ibrutinib and venetoclax rests on isolated individual cases", "The favourable pooled response proportion is probably an upper bound, because successful outcomes are more likely to reach publication than failures"], "certainty": "These are pooled case-level observations without any comparison group, so the response and safety patterns are suggestive rather than established.", "scope": "applies to central nervous system involvement by CLL/SLL in adults, mixed settings", "wrong_if": "it presents one targeted regimen as demonstrated to be superior to another or to chemotherapy-based treatment, or endorses a specific agent as standard therapy on this basis", "gold": "A strong answer conveys: Most reported treatment courses with targeted agents produced a documented CNS response (roughly nine in ten), with complete resolution of CNS disease in over half of the courses; Reported toxicity was infrequent and in keeping with the known safety profiles of the agents used; Ibrutinib was the agent used most often, while reported activity of agents beyond ibrutinib and venetoclax rests on isolated individual cases; The favourable pooled response proportion is probably an upper bound, because successful outcomes are more likely to reach publication than failures. Certainty: These are pooled case-level observations without any comparison group, so the response and safety patterns are suggestive rather than established. Scope: applies to central nervous system involvement by CLL/SLL in adults, mixed settings. An answer is wrong if it presents one targeted regimen as demonstrated to be superior to another or to chemotherapy-based treatment, or endorses a specific agent as standard therapy on this basis.", "doi": "10.1177/20406207261474934", "access": "open"}
{"id": "steered/10.1002/ajh.70317", "track": "immunology", "question": "What outcomes follow checkpoint inhibitor therapy in relapsed or refractory primary mediastinal B-cell lymphoma?", "required_claims": ["Salvage checkpoint inhibitor therapy produced overall responses in around two thirds of patients and complete responses in about half", "Complete responses were durable, with no relapses recorded among complete responders followed over several years", "Most patients were still alive several years after starting treatment, and more than half remained free of progression", "Permanent discontinuation of checkpoint inhibitor treatment because of adverse events affected only a small minority of patients"], "certainty": "The evidence is early and uncontrolled, drawn from patients whose treating physicians selected the regimen without allocation by chance, so it characterises observed response, survival and safety patterns rather than establishing that one regimen causes better outcomes than another.", "scope": "applies to relapsed or refractory primary mediastinal B-cell lymphoma in adults, outpatient settings", "wrong_if": "it presents nivolumab plus brentuximab vedotin as a proven superior regimen to pembrolizumab or recommends preferring it as standard salvage on this evidence", "gold": "A strong answer conveys: Salvage checkpoint inhibitor therapy produced overall responses in around two thirds of patients and complete responses in about half; Complete responses were durable, with no relapses recorded among complete responders followed over several years; Most patients were still alive several years after starting treatment, and more than half remained free of progression; Permanent discontinuation of checkpoint inhibitor treatment because of adverse events affected only a small minority of patients. Certainty: The evidence is early and uncontrolled, drawn from patients whose treating physicians selected the regimen without allocation by chance, so it characterises observed response, survival and safety patterns rather than establishing that one regimen causes better outcomes than another. Scope: applies to relapsed or refractory primary mediastinal B-cell lymphoma in adults, outpatient settings. An answer is wrong if it presents nivolumab plus brentuximab vedotin as a proven superior regimen to pembrolizumab or recommends preferring it as standard salvage on this evidence.", "doi": "10.1002/ajh.70317", "access": "paywalled"}
{"id": "steered/10.1002/ajh.70225", "track": "immunology", "question": "What outcomes follow fixed-duration subcutaneous mosunetuzumab in relapsed/refractory follicular lymphoma after two or more prior therapies?", "required_claims": ["Fixed-duration subcutaneous mosunetuzumab produced complete remission in roughly three in five heavily pretreated patients", "Complete remissions were durable, with median duration beyond two years", "Freedom from progression lasted a median of close to two years", "Cytokine release syndrome occurred less often with subcutaneous than with intravenous administration"], "certainty": "The remission and remission-duration figures come from a modest, uncontrolled treated group and the comparison between routes rests on groups that were not assigned by chance, so the evidence supports consistency rather than a proven advantage of one route.", "scope": "applies to relapsed or refractory follicular lymphoma after two or more prior systemic therapies in adults, outpatient settings", "wrong_if": "it presents the lower cytokine release syndrome rate as proof that subcutaneous dosing is the safer route overall, or recommends subcutaneous over intravenous administration on that basis, rather than reporting it as a signal from a comparison that was not assigned by chance", "gold": "A strong answer conveys: Fixed-duration subcutaneous mosunetuzumab produced complete remission in roughly three in five heavily pretreated patients; Complete remissions were durable, with median duration beyond two years; Freedom from progression lasted a median of close to two years; Cytokine release syndrome occurred less often with subcutaneous than with intravenous administration. Certainty: The remission and remission-duration figures come from a modest, uncontrolled treated group and the comparison between routes rests on groups that were not assigned by chance, so the evidence supports consistency rather than a proven advantage of one route. Scope: applies to relapsed or refractory follicular lymphoma after two or more prior systemic therapies in adults, outpatient settings. An answer is wrong if it presents the lower cytokine release syndrome rate as proof that subcutaneous dosing is the safer route overall, or recommends subcutaneous over intravenous administration on that basis, rather than reporting it as a signal from a comparison that was not assigned by chance.", "doi": "10.1002/ajh.70225", "access": "open"}
{"id": "steered/10.1002/hon.70221", "track": "immunology", "question": "What is the economic value of adding epcoritamab to lenalidomide plus rituximab in relapsed or refractory follicular lymphoma for US payers?", "required_claims": ["Adding epcoritamab to lenalidomide plus rituximab was projected to increase quality-adjusted life expectancy at substantially higher total cost", "The resulting incremental cost per quality-adjusted life-year gained fell below the willingness-to-pay threshold usually applied by US payers", "The acquisition cost of epcoritamab was the parameter that most influenced the cost-effectiveness ratio", "These projections rest on survival extrapolated beyond immature follow-up and on utility values taken from outside sources and assumed identical for both regimens, so long-term uncertainty remains"], "certainty": "The estimates are early projections built on borrowed cost and quality-of-life inputs and extrapolated survival, and they hold below conventional thresholds across the parameter ranges and most alternative assumptions tested, so they indicate likely economic value rather than measured experience.", "scope": "applies to relapsed or refractory follicular lymphoma after at least one prior line of therapy in adults, population-based settings", "wrong_if": "it presents the added agent as cost-saving or cost-neutral through avoided progression care, or treats the projected survival gain as an observed benefit that establishes preferred payer coverage", "gold": "A strong answer conveys: Adding epcoritamab to lenalidomide plus rituximab was projected to increase quality-adjusted life expectancy at substantially higher total cost; The resulting incremental cost per quality-adjusted life-year gained fell below the willingness-to-pay threshold usually applied by US payers; The acquisition cost of epcoritamab was the parameter that most influenced the cost-effectiveness ratio; These projections rest on survival extrapolated beyond immature follow-up and on utility values taken from outside sources and assumed identical for both regimens, so long-term uncertainty remains. Certainty: The estimates are early projections built on borrowed cost and quality-of-life inputs and extrapolated survival, and they hold below conventional thresholds across the parameter ranges and most alternative assumptions tested, so they indicate likely economic value rather than measured experience. Scope: applies to relapsed or refractory follicular lymphoma after at least one prior line of therapy in adults, population-based settings. An answer is wrong if it presents the added agent as cost-saving or cost-neutral through avoided progression care, or treats the projected survival gain as an observed benefit that establishes preferred payer coverage.", "doi": "10.1002/hon.70221", "access": "paywalled"}